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(57) ABSTRACT 
Compounds of Formula I or II, and methods of making and 
using thereof, are described herein. 
D-A-B-ZBG 
I 
;°x:., 
M \-{_ 
R1s 
II 
R14 
R13Q, N-R16 
rnc-R-A-°' ;°J---\._R., 
E-M \-{_ 
R1s 
M represents a macrolide subunit, 
E is a C1_6 group, optionally containing one or more het-
eroatoms, 
Dis an alkyl or aryl group, 
A is a linking group connected to D, 
Bis an alkyl, alkylaryl or alkylheteroaryl spacer group, 
ZBG is a Zinc Binding Group, 
R1 , R2 and R4 are independently are selected from hydro-
gen, a Cl-6 alkyl group, a C2 _6 alkenyl group, a C2 _6 
alkynyl group, a cl-6 alkanoate group, a c2-6 carbamate 
group, a c2-6 carbonate group, a c2-6 carbamate group, 
or a c2-6 thiocarbamate group, 
R3 is hydrogen or -OR5 , 
R5 is selected from a group consisting of Hydrogen, a C1 _6 
alkyl group, a c2-6 alkenyl group, a c2-6 alkynyl group, 
cl-6 alkanoate group, c2-6 carbamate group, c2-6 car-
bonate group, C2 _6 carbamate group, orC2 _6 thiocarbam-
ate group. 
17 Claims, No Drawings 
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NON-PEPTIDE MACROCYCLIC HISTONE 
DEACETYLESE (HDAC) INHIBITORS AND 
METHODS OF MAKING AND USING 
THEREOF 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
2 
matory, anti-arthritic, anti-infective, anti-malarial, cytopro-
tective, neuroprotective, chemopreventive and/or cognitive 
enhancing effects. 
All HDAC inhibitors so far reported typically fit a three-
5 motif pharmacophoric model namely, a zinc-binding group 
(ZBG), a hydrophobic linker and a recognition cap-group 
(Miller, T. A.; Witter, D. J.; Belvedere, S., J. Med Chem., 46, 
5097-5116 (2003)). Structural modifications of the ZBG 
This application is a continuation-in-part of U.S. Ser. No. yielding hydroxamate isosteres such as benzamide, a-ke-
12/643,633 filed Dec. 21, 2009, now U.S. Pat. No. 8,188,054, 10 toesters, electrophilic ketones, mercaptoamide and phospho-
issued May 9, 2012, which is a continuation-in-part of PCT/ 
US2008/068787 filed Jun. 30, 2008, which claims priority to 
U.S. Ser. No. 60/947,036 filed Jun. 29, 2007. 
FIELD OF THE INVENTION 
The present invention generally relates to non-peptide 
macrocyclic histone deacetylase (HDAC) inhibitors and 
methods of making and using thereof. 
BACKGROUND OF THE INVENTION 
Histone deacetylases (HDACs) and histone acetyltrans-
ferases (HATs) are two functionally opposing enzymes which 
tightly regulate chromatin structure and function by main-
taining the equilibrium between the acetylated- and deacety-
lated-states of nucleosomal histones. Aberrations in intracel-
lular histone acetylation-deacetylation equilibrium have been 
linked to the repression of a subset of genes resulting in 
excessive proliferation and are implicated in a number of 
malignant diseases (Jenuwein, T.; Allis, C. D., Science 293, 
1074-1080 (2001); Marks, P.; Rifkind, R. A.; Richan, V. M.; 
Breslow, R.; Miller, T.; Kelly, W. K., Nat. Rev. Cancer, 1, 
194-202 (2001)). HDACs function as part of multiprotein 
complexes that catalyze the removal ofacetyl groups from the 
E-amino groups of specific lysine residues located near the 
N-termini of nucleosomal core histones (Grozinger, C. M.; 
Schreiber, S. L., Chem. Biol. 9, 3-16 (2002)). HDAC-cata-
lyzed deacetylation results in positively charged, hypoacety-
lated histones which bind tightly to the phosphate backbone 
of DNA, thus inducing gene-specific repression of transcrip-
tion. Inhibition of HD AC function results in the weakening of 
the bond between histones and DNA, thus increasing DNA 
accessibility and gene transcription. 
Eighteen distinct human HDACs have been identified to 
date. They are classified into three major families based on 
their homology to three Saccharomyces cerevisiae HDACs: 
RPD3, HDAl, and SIR2. Class I includes HDACs 1, 2, 3 and 
8. Class II includes HDACs 4, 5, 6, 7, 9, 10 and 11. The third 
class of HDACs is the sirtuins, which are homologically 
distinct from all the currently known HDACs. HDAC inhibi-
tion by small molecules has been observed for the natural 
product (R)-trichostatinA which induced cell differentiation 
of murine erythroleukemia cells and hyperacetylation ofhis-
tone proteins at nanomolar concentrations. Suberoylanilide 
hydroxamic acid (SAHA) has also been identified as a HDAC 
inhibitor. 
Inhibition ofHDACs is an emerging therapeutic strategy in 
cancer therapy. HDAC inhibitors have demonstrated ability to 
arrest proliferation of nearly all transformed cell types, 
including epithelial (melanoma, lung, breast, pancreas, ovary, 
prostate, colon and bladder) and hematological (lymphoma, 
leukemia and multiple myeloma) tumors (Kelly, W. K; 
O'Connor, 0. A.; Marks, P.A., Expert. Opin. Investig. Drugs, 
11, 1695-1713 (2002)). Additionally, HDAC inhibitors have 
demonstrated other biological activity including anti-inflam-
nates have been reported. The cap-group may present oppor-
tunities to discover more potent and/or selective HDAC 
inhibitors. Toward this end, recent work by Schreiber and 
15 co-workers has led to the identification of cap group-modified 
agents that display differential inhibition against specific 
HDAC sub-types (Wong, J.; Hong, R.; Schreiber, S., J. Am. 
Chem. Soc. 125, 5586-5587 (2003); Haggarty, S. J.; Koeller, 
K. M.; Wong, J.C.; Grozinger, C. M.; Schreiber, S. L., Proc. 
20 Natl. Acad. Sci. USA, 100, 4389-4394 (2003)). 
Cyclic-peptide moieties are the most complex of all HDAC 
inhibitor cap-groups and present an opportunity for the 
modulation of the biological activities of HDAC inhibitors. 
The macrocycle group is made up of hydrophobic amino 
25 acids and the prominent difference among the members of 
this class is in the amino acid side-chain substitution on the 
ring. Mechanistically, cyclic-peptide HDAC inhibitors can be 
divided into two classes: (i) reversible HDAC inhibitors and 
(ii) irreversible HDAC inhibitors, due to the alkylative modi-
30 fication of HDAC enzyme by the epoxy-ketone moiety on 
their side-chain. HDAC inhibitory activity and selectivity can 
vary significantly by changing the side-chain of each amino 
acid and/or the pattern of the combination of amino acid 
35 chirality. 
Although cyclic-peptide HDAC inhibitors may possess 
potent HDAC inhibitory activity, their broad application in 
specific therapies, such as cancer therapy, currently remains 
largely unproven. The absence of clinically effective cyclic-
40 peptide HDAC inhibitors may be in part due to development 
problems characteristic of large peptides, particularly poor 
oral bioavailability. In fact, the overall in vivo efficacy of 
cyclic-peptide HDAC inhibitors is complicated by their 
membrane penetration ability. HDAC inhibitory potency has 
45 been noted to increase with increase in the hydrophobicity of 
the macrocyclic ring (Meinke, P. T.; Liberator, P., Curr. Med. 
Chem., 8, 211-235 (2001)). Unfortunately, SAR studies for 
this class of compounds have been impaired largely because 
most macrocyclic HDAC inhibitors known to date contain 
50 peptide macrocycles. In addition to retaining the pharmaco-
logically disadvantaged peptidyl-backbone, they offer only 
limited opportunity for side-chain modifications. 
To date, several other structurally distinct small molecule 
HDAC inhibitors have been reported including hydroxam-
55 ates, benzamides, short-chain fatty acids, electrophilic 
ketones and cyclic-peptides (Miller, T. A.; Witter, D. J.; 
Belvedere, S., J. Med. Chem. 46, 5097-5116 (2003); Rosato, 
R.R.; Grant, S.,ExpertOpin. Invest. Drugs, 13, 21-38 (2004); 
Monneret, C.,Eur. J. of Med. Chem., 40, 1-13 (2005);Yoo, C. 
60 B.; Jones, P.A., Nature Reviews Drug Discovery, 5, 37-50 
(2006)). Most of these agents have been shown to non-selec-
tively inhibit the deacetylase activity of class I/II HDAC 
enzymes. The HDAC inhibitor SAHA has been approved by 
the FDA for the treatment of cutaneous T cell lymphoma. 
65 However, a large number of the identified HDAC inhibitors 
have elicited only limited in vivo antitumor activities and 
have not progressed beyond preclinical characterizations. 
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Therefore, there is a need to develop new HDAC inhibitors 
with improved efficacy, and better pharmacokinetic proper-
ties for use as therapeutic agents, such as anti-cancer agents 
and anti-parasitic agents. 
It is therefore an object of the invention to provide non-
peptide macrocyclic HDAC inhibitors having improved effi-
cacy and methods of making and using thereof. 
SUMMARY OF THE INVENTION 
Compounds of Formula I and II, and methods of making 
and using thereof, are described herein. 
4 
ate group, a substituted or unsubstituted C2 _6 carbonate 
group, a substituted or unsubstituted C2 _6 carbamate group, or 
a substituted or unsubstituted C2 _6 thiocarbamate group. 
The macrolide subunit can be attached to the pyran moiety 
at multiple locations on the macrolide subunit. In one 
embodiment, the compound contains the macrolide M9, 
M27, M28, M29, or M30 in Table 2, z is 1, nis 1, Dis an aryl 
group, such as a phenyl group, A is a 1,2,3-triazolyl group, B 
is an alkyl group having from 5-8 carbons, and ZBG is a 
10 hydroxamate group. 
I 15 
The compounds can be administered as the free acid or 
base, or as a pharmaceutically acceptable salt, prodrug, or 
solvate. The compounds can be formulated with a pharma-
ceutically acceptable carrier and, optionally one or more 
pharmaceutically acceptable exc1p1ents, for enteral, 
parenteral, or topical administration. The compounds can be D-A-B-ZBG I 
;°x:,, 
M \-{_ 
R1s 
R13Q, N-R16 
rnG-B-A-D\ ;°J---\_R., 
E-M \-{_ 
R1s 
wherein M represents a macrolide subunit, 
II 
formulated for immediate release and/or controlled release. 
Examples of controlled release formulations include sus-
tained release, delayed release, pulsatile release, and combi-
20 nations thereof. 
The compounds may be useful as anti-cancer agents, anti-
inflammatory agents, anti-infective agents, anti-parasitic 
agents, such as anti-malarial agents and antileishmanial 
agents, cytoprotective agents, chemopreventive agents, pro-
25 kinetic agents, and/or cognitive enhancing agents. The pres-
ence of the macro Ii de group may allow for the targeted deliv-
ery of the HDAC inhibitor in view on the ability of macrolides 
to accumulate in specific tissues. 
30 DETAILED DESCRIPTION OF THE INVENTION 
I. Definitions 
E is a substituted or unsubstituted C1 _6 group, optionally 35 
containing one or more heteroatoms, wherein the carbon 
atoms and/or heteroatoms are in a linear and/or cyclic 
arrangement, 
"Macrolide", as used herein, includes, but is not limited to, 
multi-member lactonic ring molecules, wherein "member" 
refers to the carbon atoms and heteroatoms in the ring, and 
"multi" is a number greater than about 10, preferably from 10 
to about 20, more preferably 12-, 14-, 15-, 16-, 17- or 
18-member lactonic rings. Suitable macrolides include, but D is a substituted or unsubstituted alkyl, substituted or 
unsubstituted heteroalkyl, substituted or unsubstituted aryl, 
substituted or unsubstituted heteroaryl group, 
A is a linking group connected to D, 
B is an alkyl, heteroalkyl, alkylaryl or alkylheteroaryl 
spacer group, 
ZBG is a Zinc Binding Group, 
R13 is selected from hydrogen, a substituted or unsubsti-
tuted cl-6 alkyl group, a substituted or unsubstituted c2-6 
alkenyl group, a substituted or unsubstituted C2 _6 alkynyl 
group, a substituted or unsubstituted alkanoate group, a sub-
stituted or unsubstituted C2 _6 carbamate group, a substituted 
or unsubstituted C2 _6 carbonate group, a substituted or unsub-
stituted C2 _6 carbamate group, or a substituted or unsubsti-
tuted c2-6 thiocarbamate group, 
R14 and R16 is selected from hydrogen, hydroxyl, a substi-
tuted or unsubstituted C1 _6 alkyl group, a substituted or 
unsubstituted C2 _6 alkenyl group, a substituted or unsubsti-
tuted c2-6 alkynyl group, a substituted or unsubstituted cl-6 
alkanoate group, a substituted or unsubstituted C2 _6 carbam-
ate group, a substituted or unsubstituted C2 _6 carbonate 
group, a substituted or unsubstituted C2 _6 carbamate group, or 
a substituted or unsubstituted C2 _6 thiocarbamate group, 
R15 is hydrogen or -OR17, 
R1 7 is selected from a group consisting of hydrogen, a 
substituted or unsubstituted C1_6 alkyl group, a substituted or 
unsubstituted C2 _6 alkenyl group, a substituted or unsubsti-
tuted c2-6 alkynyl group, a substituted or unsubstituted cl-6 
alkanoate group, a substituted or unsubstituted C2 _6 carbam-
40 are not limited to, azithromycin and its derivatives; clarithro-
mycin and its derivatives; erythromycin and its derivatives; 
bridged bicyclic macrolides, such as EDP-420 and its deriva-
tives; dirithromycin and its derivatives, 9-dihydro-9-deoxo-
9a-aza-9a-homoerythrornycin and its derivatives; HMR 3004 
45 and its derivatives, HMR3647 and its derivatives; HMR3787 
and its derivatives; josamycin and its derivatives; erythromy-
cylamine and its derivatives; ABT 773 and its derivatives; TE 
802 and its derivatives; flurithromycin and its derivatives; 
tylosin and its derivatives; tilmicosin and its derivatives; ole-
50 andomycin and its derivatives; desmycosin and its deriva-
tives; CP-163505 and its derivatives; EDP-420 and its deriva-
tives; roxithromycin and its derivatives; miocamycin and its 
derivatives; rokitamycin and derivatives thereof, such as 
ketolides (e.g., 3-ketone), lactams (e.g., Sa- or 9a-lactams) 
55 and derivatives lacking one or more sugar moieties. 
"Ary!", as used herein, refers to 5-12-membered, prefer-
ably 5-, 6- and 7-membered aromatic, heterocyclic, fused 
aromatic, fused heterocyclic, biaromatic, or bihetereocyclic 
ring systems, optionally substituted, for example, by halo-
60 gens, alkyl-, alkenyl-, and alkynyl-groups. Broadly defined, 
"Ar", as used herein, includes 5-, 6- and 7-membered single-
ring aromatic groups that may include from zero to four 
heteroatoms, for example, benzene, pyrrole, furan, 
thiophene, imidazole, oxazole, thiazole, triazole, pyrazole, 
65 pyridine, pyrazine, pyridazine and pyrimidine, and the like. 
Those aryl groups having heteroatoms in the ring structure 
may also be referred to as "aryl heterocycles" or "heteroaro-
US 8,871,728 B2 
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matics". The aromatic ring can be substituted at one or more 
ring positions with such substituents as described above, for 
example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, 
cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, 
imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, 
silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, alde-
hyde, ester, heterocyclyl, aromatic or heteroaromatic moi-
eties, -CF3 , -CN, or the like. The term "Ar" also includes 
polycyclic ring systems having two or more cyclic rings in 
which two or more carbons are common to two adjoining 10 
rings (i.e., "fused rings") wherein at least one of the rings is 
aromatic, e.g., the other cyclic ring or rings can be 
cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or het-
erocycles. Examples ofheterocyclic ring include, but are not 15 
limited to, benzimidazolyl, benzofuranyl, benzothiofuranyl, 
benzothiophenyl, benzoxazolyl, benzoxazolinyl, benzthiaz-
olyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, ben-
zisothiazolyl, benzimidazolinyl, carbazolyl, 4aH carbazolyl, 
carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydro- 20 
quinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3 b ]tet-
rahydrofuran, (uranyl, furazanyl, imidazolidinyl, imidazoli-
nyl, imidazolyl, lH-indazolyl, indolenyl, indolinyl, 
indolizinyl, indolyl, 3H-indolyl, isatinoyl, isobenzofuranyl, 
isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, iso- 25 
quinolinyl, isothiazolyl, isoxazolyl, methylenedioxyphenyl, 
morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxa-
diazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadia-
zolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxindolyl, 
pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, 30 
phenothiazinyl, phenoxathinyl, phenoxazinyl, phthalazinyl, 
piperazinyl, piperidinyl, piperidonyl, 4-piperidonyl, pipero-
nyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, 
pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyri-
doimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, 35 
pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, 
quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, tet-
rahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinoli-
nyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2, 
4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, 40 
thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienoox-
azolyl, thienoimidazolyl, thiophenyl and xanthenyl. 
"Zinc binding group" or "ZBG", as used herein, refers to a 
moiety or moieties capable of inhibiting the activity of zinc 
metalloenzymes including, but not limited to, HDAC and 45 
matrix metalloproteinase (MMP) activity. Suitable examples 
include, but are not limited to, hydroxamates, N-formyl 
hydroxylamine (or retro-hydroxamate ), carboxylates, thiols, 
dithiols, trithiocarbonates, thioesters, benzamide, keto 
groups, mercaptoacetamides, 2-ketoamides, epoxides, 50 
epoxyketones, trifluoromethyl ketones, hydroxypyridinones, 
such as 2-hydroxy and 3-hydroxypyridinones, pyrones, 
hydroxylpyridinethiones, such as 3-hydroxy-2-methylpyri-
dine-4-thione, and thiopyrones. 
"Alkyl", as used herein, refers to the radical of saturated or 55 
unsaturated aliphatic groups, including straight-chain alkyl, 
alkenyl, or alkynyl groups, branched-chain alkyl, alkenyl, or 
alkynyl groups, cycloalkyl, cycloalkenyl, or cycloalkynyl 
(alicyclic) groups, alkyl substituted cycloalkyl, cycloalkenyl, 
or cycloalkynyl groups, and cycloalkyl substituted alkyl, alk- 60 
enyl, or alkynyl groups. Unless otherwise indicated, a straight 
chain or branched chain alkyl has 30 or fewer carbon atoms in 
its backbone (e.g., Cl-C30 for straight chain, C3-C30 for 
branched chain), preferably 20 or fewer, more preferably 10 
or fewer, most preferably 6 or less. Likewise, preferred 65 
cycloalkyls have from 3-10 carbon atoms in their ring struc-
ture, and more preferably have 5, 6 or 7 carbons in the ring 
6 
structure. "Heteroalkyl", as used herein, refers to an alkyl 
group containing one or more heteroatoms, such as 0, S, or N. 
"Alkoxycarbonyl", as used herein, refers to a substituent 
having the following chemical formula: 
wherein Risa linear, branched, or cyclic alkyl group, wherein 
j is from about 1 to about 12, 
"Alkoxycarbamido", as used herein, refers to a substituent 
having the following chemical formula: 
wherein R8 is alkoxy and R9 is hydrogen, alkoxy-alkyl, or 
alkanoyl, andj is from about 1 to about 12. 
"Alkylaryl", as used herein, refers to an alkyl group sub-
stituted with an aryl group (e.g., an aromatic or hetero aro-
matic group). 
"Heterocycle" or "heterocyclic", as used herein, refers to a 
cyclic radical attached via a ring carbon or nitrogen of a 
monocyclic or bicyclic ring containing 3-10 ring atoms, and 
preferably from 5-6 ring atoms, consisting of carbon and one 
to four heteroatoms each selected from the group consisting 
of non-peroxide oxygen, sulfur, and N(Y) wherein Y is absent 
or is H, 0, (C1_4 )alkyl, phenyl or benzyl, and optionally 
containing 1-3 double bonds and optionally substituted with 
one or more substituents. Examples of heterocyclic ring 
include, but are not limited to, benzimidazolyl, benzofuranyl, 
benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzox-
azolinyl, benzthiazolyl, benztriazolyl, benztetrazolyl, ben-
zisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, 
4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnoli-
nyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydro-
furo[2,3-b ]tetrahydrofuran, (uranyl, furazanyl, imidazolidi-
nyl, imidazolinyl, imidazolyl, lH-indazolyl, indolenyl, 
indolinyl, indolizinyl, indolyl, 3H-indolyl, isatinoyl, isoben-
zofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoin-
dolyl, isoquinolinyl, isothiazolyl, isoxazolyl, methylenediox-
yphenyl, morpholinyl, naphthyridinyl, 
octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2, 
4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazo-
lidinyl, oxazolyl, oxindolyl, pyrimidinyl, phenanthridinyl, 
phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathinyl, 
phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, piperi-
donyl, 4-piperidonyl, piperonyl, pteridinyl, purinyl, pyranyl, 
pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, 
pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, 
pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, 
pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinox-
alinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquino-
linyl, tetrahydroquinolinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 
1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3, 
4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiaz-
olyl, thienooxazolyl, thienoimidazolyl, thiophenyl and xan-
thenyl. 
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"Heteroaryl", as used herein, refers to a monocyclic aro-
matic ring containing five or six ring atoms consisting of 
carbon and 1, 2, 3, or 4 heteroatoms each selected from the 
group consisting of non-peroxide oxygen, sulfur, and N(Y) 
where Y is absent or is H, 0, (C1 -C8 ) alkyl, phenyl or benzyl. 
Non-limiting examples of heteroaryl groups include fury!, 
imidazolyl, triazolyl, triazinyl, oxazoyl, isoxazoyl, thiazolyl, 
isothiazoyl, pyrazolyl, pyrazinyl, tetrazolyl, pyridyl, (or its 
N-oxide), thienyl, pyrimidinyl (or its N-oxide), indolyl, iso-
quinolyl (or its N-oxide), quinolyl (or its N-oxide) and the 10 
like. The term "heteroaryl" can include radicals of an ortho-
fused bicyclic heterocycle of about eight to ten ring atoms 
derived therefrom, particularly a benz-derivative or one 
derived by fusing a propylene, trimethylene, or tetramethyl-
ene diradical thereto. Examples of heteroaryl can be fury!, 15 
imidazolyl, triazolyl, triazinyl, oxazoyl, isoxazoyl, thiazolyl, 
isothiazoyl, pyraxolyl, pyrrolyl, pyrazinyl, tetrazolyl, pyridyl 
8 
and Use," P. Heinrich Stahl and Camille G. Wermuth, Eds., 
Wiley-VCR, Weinheim, 2002. 
As generally used herein "pharmaceutically acceptable" 
refers to those compounds, materials, compositions, and/or 
dosage forms which are, within the scope of sound medical 
judgment, suitable for use in contact with the tissues of 
human beings and animals without excessive toxicity, irrita-
tion, allergic response, or other problems or complications 
commensurate with a reasonable benefit/risk ratio. 
"Prodrug", as used herein, refers to a pharmacological 
substance (drug) which is administered in an inactive (or 
significantly less active) form. Once administered, the pro-
drug is metabolized in the body (in vivo) into the active 
compound. 
"Solvate", as used herein, refers to a compound which is 
formed by the interaction of molecules of a solute with mol-
ecules of a solvent. (or its N-oxide), thientyl, pyrimidinyl (or its N-oxide), 
indolyl, isoquinolyl (or its N-oxide), quinolyl (or its N-ox-
ide ), and the like. 
"Halogen", as used herein, refers to fluorine, chlorine, 
bromine, or iodine. 
"Reverse ester", as used herein, refers to the interchange of 
the positions of the oxygen and carbon groups in a series of 
20 structurally related compounds 
The terms "alkenyl" and "alkynyl" refer to unsaturated 
aliphatic groups analogous in length and possible substitution 
to the alkyls described above, but that contain at least one 25 
double or triple bond respectively. 
The terms ortho, meta and para apply to 1,2-, 1,3- and 
1,4-disubstituted benzenes, respectively. For example, the 
names 1,2-dimethylbenzene and ortho-dimethylbenzene are 
synonymous. 30 
"Substituted", as used herein, means that the functional 
group contains one or more substituents including, but not 
limited to, hydroxyl, halogen, nitro, aldehyde, ketone, car-
boxylic acid, ester, ether, amino, alkyl amino, dialkyl amino, 
amide, thiol, thioether, thione, sulfate, phosphate, and com- 35 
binations thereof. 
"Pharmaceutically acceptable salt", as used herein, refer to 
derivatives of the compounds defined by Formula I and II 
wherein the parent compound is modified by making acid or 
base salts thereof. Example of pharmaceutically acceptable 40 
salts include but are not limited to mineral or organic acid 
salts of basic residues such as amines; and alkali or organic 
salts of acidic residues such as carboxylic acids. The pharma-
ceutically acceptable salts include the conventional non-toxic 
salts or the quaternary ammonium salts of the parent com- 45 
pound formed, for example, from non-toxic inorganic or 
organic acids. Such conventional non-toxic salts include 
those derived from inorganic acids such as hydrochloric, 
hydrobromic, sulfuric, sulfamic, phosphoric, and nitric acids; 
and the salts prepared from organic acids such as acetic, 50 
propionic, succinic, glycolic, stearic, lactic, malic, tartaric, 
citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylace-
tic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, 
fumaric, tolunesulfonic, naphthalenesulfonic, methane-
sulfonic, ethane disulfonic, oxalic, and isethionic salts. 55 
The pharmaceutically acceptable salts of the compounds 
can be synthesized from the parent compound, which con-
tains a basic or acidic moiety, by conventional chemical meth-
ods. Generally, such salts can be prepared by reacting the free 
acid or base forms of these compounds with a stoichiometric 60 
amount of the appropriate base or acid in water or in an 
organic solvent, or in a mixture of the two; generally, non-
aqueous media like ether, ethyl acetate, ethanol, isopropanol, 
or acetonitrile are preferred. Lists of suitable salts are found in 
Remington's Pharmaceutical Sciences, 20th ed., Lippincott 65 
Williams & Wilkins, Baltimore, Md., 2000, p. 704; and 
"Handbook of Pharmaceutical Salts: Properties, Selection, 
"Reverse amide", as used herein, refers to the interchange 
of the positions of the nitrogen and carbon groups in a series 
of structurally related compounds. 
II. Compounds 
Compounds of Formula I or II, and methods of making and 
using thereof, are described herein. 
D-A-B-ZBG 
I ;°x:., 
M \-{_ 
R1s 
II 
R13Q. N-R16 
ZBG-B-A-D\ ;° R1s 
E-M 
R1s 
wherein M represents a macrolide subunit, 
E is a substituted or unsubstituted C1 _6 group, optionally 
containing one or more heteroatoms, wherein the carbon 
atoms and/or heteroatoms are in a linear and/or cyclic 
arrangement, 
D is a substituted or unsubstituted alkyl, substituted or 
unsubstituted heteroalkyl, substituted or unsubstituted aryl, 
substituted or unsubstituted heteroaryl group, 
A is a linking group connected to D, 
B is an alkyl, heteroalkyl, alkylaryl or alkylheteroaryl 
spacer group, 
ZBG is a Zinc Binding Group, 
R13 is selected from hydrogen, a substituted or unsubsti-
tuted cl-6 alkyl group, a substituted or unsubstituted c2-6 
alkenyl group, a substituted or unsubstituted C2 _6 alkynyl 
group, a substituted or unsubstituted C1_6 alkanoate group, a 
substituted or unsubstituted C2 _6 carbamate group, a substi-
tuted or unsubstituted C2 _6 carbonate group, a substituted or 
US 8,871,728 B2 
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unsubstituted C2 _6 carbamate group, or a substituted or 
unsubstituted c2-6 thiocarbamate group, 
R14 and R16 is selected from hydrogen, hydroxyl, a substi-
tuted or unsubstituted C1 _6 alkyl group, a substituted or 
unsubstituted C2 _6 alkenyl group, a substituted or unsubsti- 5 
tuted c2-6 alkynyl group, a substituted or unsubstituted cl-6 
alkanoate group, a substituted or unsubstituted C2 _6 carbam-
10 
and its derivatives; clarithromycin and its derivatives; eryth-
romycin and its derivatives; bridged bicyclic macrolides, 
such as EDP-420 and its derivatives; dirithromycin and its 
derivatives, 9-dihydro-9-deoxo-9a-aza-9a-homoerythromy-
cin and its derivatives; HMR 3004 and its derivatives, HMR 
3647 and its derivatives; HMR 3787 and its derivatives; josa-
mycin and its derivatives; erythromycylamine and its deriva-
tives; ABT 773 and its derivatives; TE 802 and its derivatives; 
flurithromycin and its derivatives; tylosin and its derivatives; 
ate group, a substituted or unsubstituted C2 _6 carbonate 
group, a substituted or unsubstituted C2 _6 carbamate group, or 
a substituted or unsubstituted C2 _6 thiocarbamate group, 
R15 is hydrogen or -OR17, 
10 tilmicosin and its derivatives; oleandomycin and its deriva-
tives; desmycosin and its derivatives; CP-163505 and its 
derivatives; EDP-420 and its derivatives; roxithromycin and 
its derivatives; miocamycin and its derivatives; rokitamycin 
R17 is selected from a group consisting of hydrogen, a 
substituted or unsubstituted C1_6 alkyl group, a substituted or 
unsubstituted C2 _6 alkenyl group, a substituted or unsubsti-
tuted c2-6 alkynyl group, a substituted or unsubstituted cl-6 15 
alkanoate group, a substituted or unsubstituted C2 _6 carbam-
ate group, a substituted or unsubstituted C2 _6 carbonate 
group, a substituted or unsubstituted C2 _6 carbamate group, or 
a substituted or unsubstituted C2 _6 thiocarbamate group. 
Examples of the linking group A include, but are not lim- 20 
ited to, amide, reverse amide, ester, reverse ester, alkoxyl, 
sulfonyl, sulfonyl, sulfonyl, sulfonamido, ketone, sp3 hybrid-
ized carbon, sp2 hybridized carbon, sp hybridized carbon, 5 or 
6 membered heterocyclic rings including but not limiting to 
1,2,3-triazolyl, 1,2,4-triazolyl, 1-tetrazolyl, 1-indolyl, 1-in- 25 
dazolyl, 2-isoindolyl, 7-oxo-2-isoimdolyl, 1-pirinyl, 
3-isothiazolyl, 4-isothiazolyl and 5-isothiazolyl, 1,3,4,-oxa-
diazole, 4-oxo-2-thiazolinyl or 5-methyl-1,3,4-thiadiazol-2-
y I, thiazoledione, 1,2,3,4-thiatriazole, 1,2,4-dithiazolone, 
pyridine, thiophene, furan, pyrazoline, pyrimidine, 2-pyridyl, 30 
3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrim-
idinyl, 3-pyridazinyl, 4-pyridazinyl, 3-pyrazolyl, 2-quinolyl, 
3-quinolyl, 1-isoquinolyl, 3-isoquinolyl, 4-isoquinolyl, 
2-quinazolinyl, 4-quinazolinyl, 2-quinoxalinyl, 1-phthalazi-
nyl, 4-oxo-2-imidazolyl, 2-imidazolyl, 4-imidazolyl, 3-isox- 35 
azolyl, 4-isoxazolyl, 5-isoxazolyl, 3-pyrazolyl 4-pyrazolyl, 
5-pyrazolyl, 2-oxazolyl, 4-oxazolyl, 4-oxo-2-oxazolyl, 5-ox-
azolyl, 4,5-dihydrooxazole, 1,2,3-oxathiole, 1,2,3-oxadiaz-
ole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, 
2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 3-isothiazole, 4-isothia- 40 
zole, 5-isothiazole, 2-indolyl, 3-indolyl, 3-indazolyl, 2-ben-
zoxazolyl, 2-benzothiazolyl, 2-benzimidazolyl, 2-benzofura-
nyl, 3-benzofuranyl, benzoisothiazole. benzisoxazole, 
2-furanyl, 3-furanyl, 2-thienyl, 3-thienyl, 2-pyrrolyl, pyrro-
lyl, 3-pyrrolyl, 3-isopyrrolyl, 4-isopyrrolyl, 5-isopyrrolyl, 45 
1,2,3-oxathiazole-l-oxide, 1,2,4-oxadiazol-3-yl, 1,2,4-oxa-
diazol-5-yl, 5-oxo-1,2,4-oxadiazol-3-yl, 1,2,4-thiadiazol-3-
yl, 1,2,3-thiadiazol-5-yl, 3-oxo-1,2,3-thiadiazol-5-yl, 1,3,4-
thiadiazol-5-yl, 2-oxo-1,3,4-thiadiazol-5-yl, 1,2,4-triazol-3-
yl, 1,2,4-triazol-5-yl, 1,2,3,4-tetrazol-5-yl, 5-oxazolyl, 50 
1-pyrrolyl, 1-pyrazolyl. Each of these moieties may be sub-
stituted as appropriate. 
Bis a substituted or unsubstituted alkyl, alkylaryl or alky-
lheteroaryl spacer group. Suitable alkyl spacer group chain 
length ranges from about C4 to about Cw optionally substi- 55 
tuted by one or more double and/or triple bonds. The total 
number of atoms in the alkylaryl and alkylheteroaryl groups 
is from about 6 to about 50, preferably from about 6 to about 
30, more preferably from about 6 to about 20, most preferably 
from about 6 to about 10. 60 
M is a macrolide subunit. Suitable macrolide subunits 
include, but are not limited to, multi-member lactonic ring 
molecules, wherein "member" refers to the carbon atoms or 
heteroatoms in the ring, and "multi" is a number greater than 
about 10, preferably from 10 to about 20, more preferably 65 
12-, 14-, 15-, 16, 17-, or 18-member lactonic rings. Exem-
plary macrolides include, but are not limited to, azithromycin 
and derivatives thereof, such as ketolides (e.g., 3-ketone), 
lactams (e.g., Sa- or 9a-lactams) and derivatives lacking one 
or more sugar moieties. 
In one embodiment, the macrolide M has the formula: 
as described in U.S. Patent Application Publication No. 2007 I 
0149463, which is incorporated herein by reference, wherein 
W is selected from -C(O)-, -C(=NORu)-, -CH 
(-ORu)-, -NRuCH2-, -CH2NRu-, -CH 
(NRu Ru)-, --C(=NNRu Ru)-, -NRu C(O)-, 
--C(O)NRu-, and--C( NRu)-; 
R is selected from the group consisting ofH and C1 _6 alkyl; 
R1 is selected from the group H, halogen, -NRuRu, 
NRuC(O)Ru,--OR11 ,--0C(O)R1 u-OC(O)OR11 ,--0C 
(O)NRuRw --OC1 _6alcyl-Rw -OC(O)C1_6 alkyl-Rw 
--OC(O)OC1 _6 alkyl-R12, -OC(O)NRuC1_6 alkyl-Rw 
cl-6 alkyl, cl-6 alkenyl, cl-6 alkynyl, optionally is substituted 
with one or more R12 groups; 
R2 isH; 
R3 is selected from H, --ORw --OC1 _6 alkyl-R12, -DC 
(O)Ru, --OC(O)C1 _6 alkyl-R12, -OC(O)ORu, --OC(O) 
OC1_6 alkyl-Rw --OC(O)NRuRw --OC(O)NRuC1 _6 
alkyl-R12 ; alternatively, R3 is a pyran ring which can be sub-
stituted as defined above in Formulae I and II; 
R4 is selected from H, Ru, -C(O)Ru, -C(O)ORu, 
--C(O)NRuR1 u -C1_6 alkyl-T-Ru, -C2 _6 alkenyl-T-Ru, 
and --C2 _6 alkynyl-T-Ru; alternatively R3 and R4 taken 
together form 
US 8,871,728 B2 
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T is selected from ---C(O)-, ---C(O)O-, ---C(O) 
NR11-, -C(=NR11)-, -C-(=NR11)0-, 
-C( NR11)NR11-, g)-OC(O)-, ---OC(O)O-, -DC 
(O)NR11-, -NR11C(O)-, -NR11C(O)O-, -NR11C 
(O)NR11-, -NR11C( NR11)NR11-, and -S(O)P-, 5 
wherein p 0-2; 
Rs is selected from R1u -OR11 , -NR11R1u ---OC1_6 
alkyl-Rw ---C(O)Rw ---C(O)C1_6 alkyl-Rw ---OC(O)Rw 
-OC(O)G1_6 alkyl-Rw ---OC(O)OR1u -OC(O)OC1_6 10 
alkyl-Rw ---OC(O)NR11R1u -OC(O)NR11 C1_6 alkyl-Rw 
-C(O)C2_6 alkenyl-R12, and-C(O)C2_6 alkynyl-R12; 
alternatively, R4 and Rs taken together with the atoms to 
which they are bonded, form: 
12 
R7 is selected from C1_6 alkyl, C2_6 alkenyl, and C2_6 alky-
nyl, optionally is substituted with one or more R12 groups; 
R1u for each occurrence, is selected from H, C1_6 alkyl, 
c2-6 alkenyl, c2-6 alkynyl, c6-10 saturated, unsaturated, or 
aromatic carbocycle, 3-12 membered saturated, unsaturated, 
or aromatic heterocycle containing one or more heteroatoms 
selected from nitrogen, oxygen, and sulfur, ---C(O)---C1_6 
alkyl, ---C(O)---C2_6 alkenyl, ---C(O)-C2_6 alkynyl, 
---C(O)-C6_10 saturated, unsaturated or aromatic car-
bocycle, ---C(0)-3-12 membered saturated, unsaturated, or 
aromatic heterocycle containing one or more heteroatoms 
selected from nitrogen, oxygen, and sulfur, ---C(O)O---C1_6 
ally!, -C(O)O---C2_6 alkenyl, ---C(O)O---C2_6 alkynyl, 
15 ---C(O)O-C6_10 saturated, unsaturated, or aromatic car-
bocycle, -C(O )0-3-12 membered saturated, unsaturated, or 
aromatic heterocycle containing one or more heteroatoms 
selected from the group consisting of nitrogen, oxygen, and 
sulfur, and -C(O)NR13R13, optionally is substituted with 
20 one or more R12 groups, 
wherein, Q is CH or N, and R23 is -OR11 or R11 ; 
R6 is selected from -ORw alkoxy-R12, -C(O)Rw 
-OC(O)R1u -OC(O)OR11 , -OC(O)NR11 R11 , NR11 R11 ; 
R12 is selected from R14, C1_8 alkyl, C2_8 alkenyl, C2_8 
alkynyl, C3_12 saturated, unsaturated, or aromatic carbocycle, 
3-12 membered saturated, unsaturated, or aromatic hetero-
25 cycle containing one or more heteroatoms selected from 
nitrogen, oxygen, and sulfur, optionally substituted with one 
or more substituents. 
alternatively, Rs and R6 taken together with the atoms to 
which they are attached form a 5-membered ring by attach- 30 
ment to each other through a linker selected from -OC(R 12)2 
0-, ---OC(O)O-, ---OC(O)NR11-, d)-NR11C(O)O-, 
-OC(O)NOR11-, -NOR11C(O)O-, ---OC(O) 
NNR11R11-, -NNR11 R11C(O)O-, ---OC(O)C(R12)2-, 
-C(R12) 2C(O)O-, ---OC(S)O-, -OC(S)NR11-, 35 
-NR. 11C(S)O-, n) ---OC(S)NOR11-, -NOR11 C(S) 
0-, -OC(S)NNR11 R11-, -NNR11 R11C(S)O-, -DC 
(S)C(R12)2-, -C(R12)2C(S)O-; 
alternatively, W, Rs, and R6 taken together with the atoms 
to which they are attached form: 
wherein J is selected from the group consisting of 0, S, and 
40 
45 
50 
NR11 ; 55 
R6. is selected from H, unsubstituted or substituted C1_4 
alkyl, c2-4 alkenyl, which can be further substituted with cl-2 
alkyl or one or more halogens, C2_4 alkynyl, which can be 
further substituted with C1_2 alicyl or one or more halogens, 
aryl or heteroaryl, which can be further substituted with C1_2 60 
alkyl or one or more halogens, -C(O)H, -COOR, -CN, 
-COOR11 , -C(O)NR11 R11 , -C(O)R11 , -C(O)SR11 ; 
alternatively R6 and R6. taken together with the atom to 
which they are attached to form an epoxide, a carbonyl, an 
olefin, or a substituted olefin, or a C3-C7 carbocyclic, carbon- 65 
ate, or carbamate, wherein the nitrogen of the carbamate can 
be further substituted with a C1 -C6 alkyl; 
Exemplary macrolides are shown in Tables 1 and 2. 
TABLE 1 
Macrolide Subunits 
0 Ml 
0 M2 
HO 
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TABLE I-continued TABLE I-continued 
Macrolide Subunits Macrolide Subunits 
0 M3 0 M7 
10 
15 
"'•o,,,,Q; 
.. ..,,,,,OH 
~ 
~ 
20 O-CH3 
0 M4 
0 MS 
25 
30 
35 
M9 
\ MS 
N 
HOl ,.... OH 
,,,, 
,.... ,,,,,, 
,,, 0 ~ .. 
I 
40 
45 
0 
50 \ MIO 
N 
0 M6 HOl ,,.... OH 
,,, 
,.... ,,,,,, 
,,, 0 ... 
I 
55 
0 
60 
65 
15 
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Macrolide Subunits 
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0 
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TABLE I-continued 
Mll 
10 
15 
20 
25 
M12 
30 
35 
40 
45 
M13 50 \ 
N 
55 HOl ,.... OH ,,,, 
,,~.. ,,,,,, 
,,, 0 ... 
I 
0 
60 
65 
Macrolide Subunits 
··· ... .,} 
/'''''''' 
... ,,,,o,,,,,.Q? 
0 
~ ~ O-CH3 
M14 
M15 
M16 
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TABLE I-continued 
Macrolide Subunits 
\ M17 
N 
HOl 10 ,,.... OH 
,,, 
,,... ,,,,,, 
,,.. 0 ... 
I 15 
0 '""o,,,,~ 
OH 
-.,_ --NR11R12 
~O-CH3 20 
25 
0 M18 30 
35 
40 
The pyran-ZBG group can be attached to macrolide at 
various points as shown in Table 2: 45 
TABLE2 
14-Membered Macrolides 
50 
0 M19 
55 
60 
65 
HO 
HO 
18 
TABLE 2-continued 
14-Membered Macrolides 
0 
0 
0 
0 
0 
. .,,, \ 
''o/"\. 
M20 
M21 
M22 
M23 
M24 
19 
TABLE 2-continued 
14-Membered Macrolides 
x 
I 
HO 
x 
I 
HO 
0 
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10 
15 
20 
M26 
25 
30 
35 
20 
TABLE 2-continued 
14-Membered Macrolides 
\ 
N 
HOl ,,,..· OH 
,,, 
... ,,,, 
,, .. ,, 0 '• ... 
I 
0 
\ 
N 
HOl 
'"... OH 
'" 
... ,,,, 
,, .. ,, 0 '"·· 
I 
0 
. .,,, \ 
''o./\. 
M29 
M30 
In M25 and M26, the bond between the starred carbon and 
the nitrogen can be a single bond or a double bond. This is 
represented by a dashed line in the structures of M25 and 
M26. 
Mn 
40 
The zinc binding group may be any moiety or moieties that 
inhibit(s) the activity of zinc metalloenzymes such as HDAC. 
Exemplary zinc binding groups include hydroxamates, 
N-formyl hydroxylamine (or retro-hydroxamate), carboxy-
lates, thiols, dithiols, phosphonic acids, thiadiazoles, sulfodi-
M28 
45 imines, thiadiazines, trithiocarbonates, thioesters, benza-
mide, keto groups, mercaptoacetamides, 2-ketoamides, 
epoxides, epoxyketones, trifluoromethyl ketones, hydroxy-
pyridinones, such as 2-hydroxy and 3-hydroxypyridinones, 
pyrones, hydroxylpyridinethiones, such as 3-hydroxy-2-me-
50 thylpyridine-4-thione, and thiopyrones. 
55 
60 
65 
In some embodiments, the zinc binding group is a heter-
cyclic moiety. In particular embodiments, the heterocyclic 
moiety is a heterocyclic group substituted with one or more 
thiones, hydroxyl groups, thiols, ketones, or combinations 
thereof. Exemplary zinc binding groups of this type include: 
R' R' R-Q R-Q O~N-R 
HO 0 HO S HO 
Pyron es Thiopyrones 3-hydroxy-
pyridine-4-ones 
US 8,871,728 B2 
R R-Q 
HO S 
Hydroxypyridinethione 
21 
-continued 
'Y-RQ-OH 
HO R 0 
3-Hydroxy 
pyridine-4-ones 
3-Hydroxy 
pyridine-2-ones 
R R-Q 
HO 0 
3-Hydroxy N-Hydroxypyridine-2-one 
pyridine-2-thiones 
In some embodiments, the zinc binding group can be 
selected to provide selectivity for a particular HDAC isoform. 
22 
wherein R is: 
or 
10 
15 
20 
.< ;°x::: 
E-M \-{_ 
R1s 
and mis an integer from 1-12, preferably from 1-10, more 
In some instances, HDAC inhibitors bearing a zinc binding 
group containing a heterocyclic group substituted with one or 25 
more thiones possesses a higher activity that the same inhibi-
tor bearing a zinc binding group containing a heterocyclic 
group substituted with one or more ketones. In certain 
embodiments, the zinc binding group is a 3-hydroxypyridine-
2-thione. 30 preferably from 4-10, most preferably from 5-9 inclusive. However, compounds where m is greater than 12 may be 
prepared and their activity determined as described in the 
examples. 
The compounds described herein may have one or more 
chiral centers and thus exist as one or more stereoisomers. 
Such stereoisomers can exist as a single enantiomer, a mix-
ture of diastereomers or a racemic mixture. 
R can be positioned ortho, meta, or para to the triazolyl 
35 group. In one embodiment, R is para to the triazolyl group. In 
another embodiment, R is meta to the triazolyl group. As used herein, the term "stereoisomers" refers to com-
pounds made up of the same atoms having the same bond 
order but having different three-dimensional arrangements of 
atoms which are not interchangeable. The three-dimensional 
structures are called configurations. As used herein, the term 40 
"enantiomers" refers to two stereoisomers which are non-
superimposable mirror images of one another. As used herein, 
the term "optical isomer" is equivalent to the term "enanti-
omer". As used herein the term "diastereomer" refers to two 
stereoisomers which are not mirror images but also not super- 45 
imposable. The terms "racemate", "racemic mixture" or 
"racemic modification" refer to a mixture of equal parts of 
enantiomers. The term "chiral center" refers to a carbon atom 
The macrolide can be any suitable maroclide. In one 
embodiment, the macrolide is selected from M9 or M27-M30 
in Table 2. 
In another embodiment, the HDAC inhibitors have the 
following formula: 
0-z ~ ,.......oH R,/\( ~1i 
to which four different groups are attached. Choice of the 50 
appropriate chiral column, eluent, and conditions necessary 
wherein R and M are as defined above and z is oxygen or 
-NCO-. 
to effect separation of the pair of enantiomers is well known 
to one of ordinary skill in the art using standard techniques 
(see e.g. Jacques, J. et al., "Enantiomers, Racemates, and 
Resolutions", John Wiley and Sons, Inc. 1981). 
In one embodiment, the HDAC inhibitors have the formula 
shown below: 
RO-{lJl,,oH 
m 1i 
In still another embodiment, the HDAC inhibitor has one of 
the formulas above, wherein the zinc binding group is a 
pyridine thione, diamino benzene, or hydroxypyridone 
55 group. 
60 
65 
In another embodiment, the HDAC inhibitors have the 
formula shown below: 
23 
wherein R is: 
R14 7' ;°x:., 
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and mis an integer from 1-12, preferably from 1-10, more 
preferably from 4-10, most preferably from 5-9 inclusive. 
However, compounds where m is greater than 12 may be 
prepared and their activity determined as described in the 
5 examples. 
R can be positioned ortho, meta, or para to the triazolyl 
10 group. In one embodiment, R is para to the triazolyl group. In 
another embodiment, R is meta to the triazolyl group. M \-{_ 
R 15 or 
R14 
A: ;°x::: 
E-M \-{_ 
The macrolide can be any suitable maroclide. In one 
15 embodiment, the macrolide is selected from M9 or M27-M30 
in Table 2. 
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Non-limiting examples of HDAC inhibitors of Formula I 
and II are shown in Table 3. 
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It is believed that substitution of the cyclic peptide moiety 
of a prototypical cyclic-peptide HDAC inhibitor with mac-
rolide skeletons will generate a new class of potent HDAC 
inhibitors. Furthermore, this class of HDAC inhibitors may 
possess targeted activity, such as targeted anti-cancer activity 25 
due to selective tissue distribution conferred by the macrolide 
moiety. The biological effects of macrolides are aided by their 
high distribution into target tissues. Macro Ii des accumulate in 
higher concentration within leukocytes as compared to levels 
found in serum. 30 
III. Formulations 
Examples of suitable coating materials include, but are not 
limited to, cellulose polymers such as cellulose acetate phtha-
late, hydroxypropyl cellulose, hydroxypropyl methylcellu-
lose, hydroxypropyl methylcellulose phthalate and hydrox-
ypropyl methylcellulose acetate succinate; polyvinyl acetate 
phthalate, acrylic acid polymers and copolymers, and meth-
acrylic resins that are commercially available under the trade 
name EUDRAGIT® (Roth Pharma, Westerstadt, Germany), 
zein, shellac, and polysaccharides. 
Additionally, the coating material may contain conven-
tional carriers such as plasticizers, pigments, colorants, 
glidants, stabilization agents, pore formers and surfactants. 
Optional pharmaceutically acceptable excipients present 
in the drug-containing tablets, beads, granules or particles The compounds described herein can be formulated for 
enteral, parenteral, and/or topical (e.g., transdermal, mucosa!, 
etc.) administration. The compounds and their pharmaceuti-
cally-acceptable addition salts, prodrugs, and/or solvates can 
also be used in the form of pharmaceutical preparations 
which facilitate bioavailability. One or more compounds 
described herein may be administered in a single dosage form 
or in multiple dosage forms 
35 include, but are not limited to, diluents, binders, lubricants, 
disintegrants, colorants, stabilizers, and surfactants. Diluents, 
also referred to as "fillers," are typically necessary to increase 
the bulk of a solid dosage form so that a practical size is 
provided for compression of tablets or formation of beads and 
Formulations containing one or more of the compounds 
described herein may be prepared using a pharmaceutically 
acceptable carrier composed of materials that are considered 
safe and effective and may be administered to an individual 
without causing undesirable biological side effects or 
unwanted interactions. The carrier is all components present 
in the pharmaceutical formulation other than the active ingre-
dient or ingredients. As generally used herein "carrier" 
includes, but is not limited to, diluents, binders, lubricants, 
disintegrators, fillers, pH modifying agents, preservatives, 
antioxidants, solubility enhancers, and coating compositions. 
40 granules. Suitable diluents include, but are not limited to, 
dicalcium phosphate dihydrate, calcium sulfate, lactose, 
sucrose, mamiitol, sorbitol, cellulose, microcrystalline cellu-
lose, kaolin, sodium chloride, dry starch, hydrolyzed 
starches, pregelatinized starch, silicone dioxide, titanium 
45 oxide, magnesium aluminum silicate and powdered sugar. 
Binders are used to impart cohesive qualities to a solid 
dosage formulation, and thus ensure that a tablet or bead or 
granule remains intact after the formation of the dosage 
forms. Suitable binder materials include, but are not limited 
50 to, starch, pregelatinized starch, gelatin, sugars (including 
sucrose, glucose, dextrose, lactose and sorbitol), polyethyl-
ene glycol, waxes, natural and synthetic gums such as acacia, 
tragacanth, sodium alginate, cellulose, including hydrox-
ypropylmethylcellulose, hydroxypropylcellulose, ethylcellu-Carrier also includes all components of coating composi-
tions which may include plasticizers, pigments, colorants, 
stabilizing agents, and glidants. Delayed release, extended 
release, and/or pulsatile release dosage formulations may be 
prepared as described in standard references such as "Phar-
maceutical dosage form tablets", eds. Liberman et. al. (New 
York, Marcel Dekker, Inc., 1989), "Remington-The science 60 
and practice of pharmacy", 20th ed., Lippincott Williams & 
Wilkins, Baltimore, Md., 2000, and "Pharmaceutical dosage 
forms and drug delivery systems", 6th Edition, Ansel et al., 
(Media, Pa.: Williams and Wilkins, 1995). These references 
provide information on carriers, materials, equipment and 65 
process for preparing tablets and capsules and delayed release 
dosage forms of tablets, capsules, and granules. 
55 lose, and veegum, and synthetic polymers such as acrylic acid 
and methacrylic acid copolymers, methacrylic acid copoly-
mers, methyl methacrylate copolymers, aminoalkyl meth-
acrylate copolymers, polyacrylic acid/polymethacrylic acid 
and polyvinylpyrrolidone. 
Lubricants are used to facilitate tablet manufacture. 
Examples of suitable lubricants include, but are not limited to, 
magnesium stearate, calcium stearate, stearic acid, glycerol 
behenate, polyethylene glycol, talc, and mineral oil. 
Disintegrants are used to facilitate dosage form disintegra-
tion or "breakup" after administration, and generally include, 
but are not limited to, starch, sodium starch glycolate, sodium 
carboxymethyl starch, sodium carboxymethylcellulose, 
US 8,871,728 B2 
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hydroxypropyl cellulose, pregelatinized starch, clays, cellu-
lose, alginine, gums or cross linked polymers, such as cross-
linked PVP (Polyplasdone XL from GAF Chemical Corp). 
Stabilizers are used to inhibit or retard drug decomposition 
reactions which include, by way of example, oxidative reac-
tions. 
68 
Surfactants may be anionic, cationic, amphoteric or non-
ionic surface active agents. Suitable anionic surfactants 
include, but are not limited to, those containing carboxylate, 
sulfonate and sulfate ions. Examples of anionic surfactants 
include sodium, potassium, ammonium of long chain alkyl 
sulfonates and alkyl aryl sulfonates such as sodium dodecyl-
benzene sulfonate; dialkyl sodium sulfosuccinates, such as 
sodium dodecylbenzene sulfonate; dialkyl sodium sulfosuc-
cinates, such as sodium bis-(2-ethylthioxyl)-sulfosuccinate; 
and alkyl sulfates such as sodium lauryl sulfate. Cationic 
surfactants include, but are not limited to, quaternary ammo-
nium compounds such as benzalkonium chloride, benzetho-
nium chloride, cetrimonium bromide, stearyl dimethylbenzyl 
ammonium chloride, polyoxyethylene and coconut amine. 20 
Examples of nonionic surfactants include ethylene glycol 
monostearate, propylene glycol myristate, glyceryl 
monostearate, glyceryl stearate, polyglyceryl-4-oleate, sorbi-
tan acylate, sucrose acylate, PEG-150 laurate, PEG-400 
monolaurate, polyoxyethylene monolaurate, polysorbates, 25 
polyoxyethylene octylphenylether, PEG-1000 cetyl ether, 
polyoxyethylene tridecyl ether, polypropylene glycol butyl 
ether, Poloxamer® 401, steamy! monoisopropanolamide, 
and polyoxyethylene hydrogenated tallow amide. Examples 
sodium carbonate, ( e) solution retarding agents such as par-
affin, (f) absorption accelerators such as quaternary ammo-
nium compounds, (g) wetting agents such as, for example, 
cetyl alcohol and glycerol monostearate, (h) absorbents such 
as kaolin and bentonite clay and (i) lubricants such as talc, 
calcium stearate, magnesium stearate, solid polyethylene gly-
cols, sodium lauryl sulfate and mixtures thereof. In the case of 
capsules, tablets and pills, the dosage form may also contain 
buffering agents. 
10 Solid compositions of a similar type may also be employed 
as fill materials in soft and hard-filled gelatin capsules using 
such excipients as lactose or milk sugar as well as high 
molecular weight polyethylene glycols and the like. The solid 
15 dosage forms of tablets, dragees, capsules, pills and granules 
can be prepared with coatings and shells such as enteric 
coatings and other coatings well known in the pharmaceutical 
formulating art. 
Parenteral Formulations 
Pharmaceutical preparations in the form suitable for injec-
tion are subjected to conventional pharmaceutical operations 
such as sterilization and/or may contain adjuvants including, 
but not limited to, preservatives, stabilizers, wetting or emul-
sifying agents, and buffers. 
Injectable preparations, for example, sterile injectable 
aqueous or oleaginous suspensions may be formulated as 
known in the art using suitable dispersing or wetting agents 
and suspending agents. The sterile injectable preparation may 
also be a sterile injectable solution, suspension, or emulsion 
in a nontoxic parenterally acceptable diluent or solvent, for 
example, as a solution in 1,3-butanediol. Among the accept-
of amphoteric surfactants include sodium N-dodecyl-.beta.- 30 
alanine, sodium N-lauryl-.beta.-iminodipropionate, myristo-
amphoacetate, lauryl betaine and lauryl sulfobetaine, able vehicles and solvents that may be employed are water, 
Ringer's solution, U.S.P. and isotonic sodium chloride solu-
tion. In addition, sterile, fixed oils can be employed as a 
solvent or suspending medium. For this purpose any bland 
fixed oil can be employed including synthetic mono- or dig-
If desired, the tablets, beads, granules, or particles may also 
contain minor amount of nontoxic auxiliary substances such 
as wetting or emulsifying agents, dyes, pH buffering agents, 35 
or preservatives. 
Enteral Formulations 
Pharmaceutical compositions for oral administration can 
be liquid or solid. Liquid dosage forms suitable for oral 
administration include, but are not limited to, pharmaceuti-
cally acceptable emulsions, microemulsions, solutions, sus-
pensions, syrups and elixirs. In addition to an encapsulated or 
unencapsulated HDAC inhibitor, the liquid dosage forms 
may contain inert diluents commonly used in the art such as, 
for example, water or other solvents, solubilizing agents and 
emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl 
carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, 
propylene glycol, 1,3-butylene glycol, dimethylformamide, 
oils (in particular, cottonseed, groundnut, corn, germ, olive, 
castor and sesame oils), glycerol, tetrahydrofuryl alcohol, 
polyethylene glycols and fatty acid esters of sorbitan and 
mixtures thereof. Besides inert diluents, the oral composi-
tions can also include adjuvants, wetting agents, emulsifying 
and suspending agents, sweetening, flavoring and perfuming 
agents. 
Solid dosage forms for oral administration include, but are 
not limited to, capsules, tablets, caplets, dragees, powders and 
granules. In such solid dosage forms, the encapsulated or 
unencapsulated compound is typically mixed with at least 
one inert, pharmaceutically acceptable excipient or carrier 
such as sodium citrate or dicalcium phosphate and/or (a) 
fillers or extenders such as starches, lactose, sucrose, glucose, 
mannitol and silicic acid, (b) binders such as, for example, 
carboxymethylcellulose, alginates, gelatin, polyvinylpyrroli-
dinone, sucrose and acacia, ( c) humectants such as glycerol, 
(d) disintegrating agents such as agar-agar, calcium carbon-
ate, potato or tapioca starch, alginic acid, certain silicates and 
lycerides. In addition, fatty acids such as oleic acid can be 
used in the preparation of injectable formulations. In a par-
ticularly preferred embodiment, the compound is suspended 
40 in a carrier fluid containing 1 % (w/v) sodium carboxymethyl 
cellulose and 0.1 % (v/v) TWEEN™ 80. The injectable for-
mulations can be sterilized, for example, by filtration through 
a bacteria-retaining filter, or by incorporating sterilizing 
agents in the form of sterile solid compositions which can be 
45 dissolved or dispersed in sterile water or other sterile inject-
able medium prior to use. 
Topical Formulations. 
The compounds described here can also be formulated for 
topical, transdermal, or mucosa! delivery. Dosage forms for 
50 topical or transdermal administration include, but are not 
limited to, ointments, pastes, creams, lotions, gels, powders, 
solutions, sprays, inhalants, or patches. The compounds are 
typically admixed under sterile conditions with a pharmaceu-
tically acceptable carrier and any excipients (e.g., preserva-
55 tives, buffers, etc.) that may be required. Ophthalmic formu-
lations, ear drops and eye drops can also be prepared. The 
ointments, pastes, creams and gels may contain, in addition to 
the active agent, excipients such as animal and vegetable fats, 
oils, waxes, paraffins, starch, tragacanth, cellulose deriva-
60 tives, polyethylene glycols, silicones, bentonites, silicic acid, 
talc and zinc oxide, or mixtures thereof. 
Transdermal patches have the added advantage of provid-
ing controlled delivery of a compound to the body. Such 
dosage forms can be made by dissolving or dispensing the 
65 compounds described herein in a proper medium. Absorption 
enhancers can also be used to increase the flux of the com-
pound across the skin. The rate can be controlled by either 
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providing a rate controlling membrane or by dispersing the 
compound(s) in a polymer matrix or gel. 
Powders and sprays can contain, in addition to the active 
agent, excipients such as lactose, talc, silicic acid, aluminum 
hydroxide, calcium silicates and polyamide powder, or mix-
tures of these drugs. Sprays can additionally contain custom-
ary propellants such as chlorofluorohydrocarbons. 
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methyldopa, methylphenidate, methylsalicylate, methyser-
gid( e ), metoclopramide, mianserin, mifepristone, milnacip-
ran, minaprine, mirtazapine, moclobemide, modafinil (an 
anti-narcoleptic), molindone, morphine, morphine hydro-
chloride, nabumetone, nadolol, naproxen, naratriptan, nefaz-
odone, neurontin, nomifensine, nortriptyline, olanzapine, 
olsalazine, ondansetron, opipramol, orphenadrine, oxafloz-
ane, oxaprazin, oxazepam, oxitriptan, oxycodone, oxymor-Compositions for rectal or vaginal administration are pref-
erably suppositories which can be prepared by mixing the 
compounds described herein with suitable non-irritating 
excipients or carriers such as cocoa butter, polyethylene gly-
col, or a suppository wax which are solid at ambient tempera-
ture but liquid at body temperature and therefore melt in the 
rectum or vaginal cavity and release the compound(s). 
10 phone, pancrelipase, parecoxib, paroxetine, pemoline, penta-
zocine, pepsin, perphenazine, phenacetin, phendimetrazine, 
phemnetrazine, phenylbutazone, phenytoin, phosphati-
dylserine, pimozide, pirlindole, piroxicam, pizotifen, pizoty-
A. Other Active Agents 
The HDAC inhibitors described herein can be adminis-
15 line, pramipexole, prednisolone, prednisone, pregabalin, pro-
panolol, propizepine, propoxyphene, protriptyline, 
quazepam, quinupramine, reboxitine, reserpine, risperidone, 
tered adjunctively with other active compounds. These com- ritanserin, rivastigmine, rizatriptan, rofecoxib, ropinirole, 
pounds include but are not limited to analgesics, anti-inflam-
20 
rotigotine, salsalate, sertraline, sibutramine, sildenafil, sul-
matory drugs, antipyretics, antidepressants, antiepileptics, fasalazine, sulindac, sumatriptan, tacrine, temazepam, tetra-
antihistamines, antimigraine drugs, antimuscarinics, anxiol- benozine, thiazides, thioridazine, thiothixene, tiapride, tia-
tyics, sedatives, hypnotics, antipsychotics, bronchodilators, s1p1rone, tizanidine, tofenacin, tolmetin, toloxatone, 
anti-asthma drugs, cardiovascular drugs, corticosteroids, topiramate, tramadol, trazodone, triazolam, trifluoperazine, 
dopaminergics, electrolytes, gastro-intestinal drugs, muscle 25 trimethobenzamide, trimipramine, tropisetron, valdecoxib, 
relaxants, nutritional agents, vitamins, parasympathomimet- valproic acid, venlafaxine, viloxazine, vitamin E, zimeldine, 
ics, stimulants, anorectics and anti-narcoleptics. "Adjunctive ziprasidone, zolmitriptan, zolpidem, zopiclone and isomers, 
administration", as used herein, means the HDAC inhibitors salts, and combinations thereof. 
can be administered in the same dosage form or in separate 30 
dosage forms with one or more other active agents. IV. Methods of Preparation 
Compound numberings, e.g., 1, 2, 3, etc. as used below are 
for reference within this section only are not to be confused 
35 with any similar numberings in the synthetic schemes 
Specific examples of compounds that can be adjunctively 
administered with the GDAC inhibitors include, but are not 
limited to, aceclofenac, acetaminophen, adomexetine, almot-
riptan, alprazolam, amantadine, amcinonide, aminocyclopro-
pane, amitriptyline, amolodipine, amoxapine, amphetamine, 
aripiprazole, aspirin, atomoxetine, azasetron, azatadine, 
beclomethasone, benactyzine, benoxaprofen, bermoprofen, 
betamethasone, bicifadine, bromocriptine, budesonide, 
40 
buprenorphine, bupropion, buspirone, butorphanol, butrip-
tyline, caffeine, carbamazepine, carbidopa, carisoprodol, 
celecoxib, chlordiazepoxide, chlorpromazine, choline salicy-
late, citalopram, clomipramine, clonazepam, clonidine, 
clonitazene, clorazepate, clotiazepam, cloxazolam, clozap-
ine, codeine, corticosterone, cortisone, cyclobenzaprine, 
cyproheptadine, demexiptiline, desipramine, desomorphine, 
dexamethasone, dexanabinol, dextroamphetamine sulfate, 
dextromoramide, dextropropoxyphene, dezocine, diazepam, 
described below or in the examples. 
The schemes below describe exemplary chemistries that 
can be used to synthesize the compounds described herein. It 
is to be appreciated the compounds described herein may be 
synthesized by other methods known in the art. 
General Synthetic Schemes 
Scheme la-c illustrates representative general syntheses of 
compounds of types 5 and 6, 9 and 10, and 12 and 13. The 
45 
starting des-N-methyl macrolide 1 could be sourced from a 
50 dibenzepin, diclofenac sodium, diflunisal, dihydrocodeine, 
dihydroergotamine, dihydromorphine, dimetacrine, dival-
proxex, dizatriptan, dolasetron, donepezil, dothiepin, dox-
epin, duloxetine, ergotamine, escitalopram, estazolam, etho-
suximide, etodolac, femoxetine, fenamates, fenoprofen, 55 
fentanyl, fludiazepam, fluoxetine, fluphenazine, flurazepam, 
flurbiprofen, flutazolam, fluvoxamine, frovatriptan, gabapen-
tin, galantamine, gepirone, ginko bilboa, granisetron, halo-
peridol, huperzine A, hydrocodone, hydrocortisone, hydro-
morphone, hydroxyzine, ibuprofen, imipramine, indiplon, 60 
indomethacin, indoprofen, iprindole, ipsapirone, ketaserin, 
ketoprofen, ketorolac, lesopitron, levodopa, lipase, 
lofepramine, lorazepam, loxapine, maprotiline, mazindol, 
mefenamic acid, melatonin, melitracen, memantine, meperi- 65 
dine, meprobamate, mesalamine, metapramine, metaxalone, 
methadone, methadone, methamphetamine, methocarbamol, 
variety ofN-demethylation reactions of the tertiary amities of 
basic sugars on macrolides known in the art (see Flynn et al. 
(1954)J. Am. Chem. Soc., 76: 3121; U.S. Pat. No. 3,725,385; 
Ku et al. (1997) Bioorg. Med. Chem. Lett., 7: 1203; Stenmark 
et al. (2000) J. Org. Chem., 65: 3875; Randolph et al. (2004) 
J. Med. Chem., 47, 1085; and U.S. Pat. No. 7,335,753). 
Reaction of 1 with electrophiles 2 and 7 yields alkynes and 
nitriles 3 and 8 respectively. Reactions of azide 4 and nitrile 
oxide 11 with alkynes 3 generate two regioisomeric triazole 
and isoxazole products 5 and 6 and 12 and 13 respectively. 
The triazole products' regioisomeric ratios and reaction rates 
could be altered by heating the reaction and/or by the use of 
catalysts (such as, but not limited to, copper (I) and Ru (H) 
salts and complexes: see Rostovtsev et al. (2002) Angew. 
Chem. Int. Ed., 41: 2596; Tornoe et al. (2002) J. Org. Chem., 
67: 3057; Zhang et al. (2005)J. Am. Chem. Soc., 127: 15998). 
Similarly, reaction of nitrile 8 and azide 4 generates two 
regioisomeric tetrazole products, 9 and 10. The ZBG in azide 
4 can be protected if necessary. Suitable ZBG protecting 
groups include are described herein. 
US 8,871,728 B2 
71 
a) 
........... 
M HO""··~ 
~0A0A. 
X~[Y]~ 
2 
X - OMs, OTs, I, Br, Cl 
b) 
M 
M 
'-....N~ ~-[Y] ;~ 
HO ~ 
. 4 
~o o 
5 (1,4-isomer) 
'-....N~ cp-gzBG 
HO , \ 
-::::'N n
[Y]; N 
M N 
~o o 
6 (1,5-isomer) 
X~[Y]' ~N 
7 
X ~ OMs, OTs, I, Br, Cl 
'-....N~ ~ 
n
[Y] ;~ 
HO N 
~o o 
4 
'-....N~ ~N ZBG 
HO N g 
N,.._ I 
--=N 
M n
[Y] ; 7''\. _J 
~o o 
9 (1,4-isomer) 
72 
-continued 
........... N~ TpgZBG 
n
[Y], N 
HO } \ 
'-. -::::'N 
M N 
~o o 
10 10 (1,5-isomer) 
c) 
........... 
» M HO•., •. ~ 
~0A0A. 
X~[Y]~ 
2 
X OMs, OTs, I, Br, Cl 
20 
25 
M 
30 
35 
40 
45 
'-....N~ ~-
n
[Y] ;~ 
HO ~ 
. 
~o o 
12 (1,4-isomer) 
-o 
'w ~ZBG 
g 
11 
l3 (1,5-isomer) 
Scheme 2 illustrates re resen . 
50 compounds with amid p h .tatJve general syntheses of 
. east e hnke 
m01ety and benzamide com d r-cap group connection 
and 23 respectively. Reacti:noun s ~f types 17 and 19 and 21 
ester 15. Compound 15 ~fl ':"1th electrophile 14 yields 
amine 18 to yield can e dJrectly reacted with ZBG 
55 compound 19 Al 
obtained from acid 16 d Z . tematively, 19 can be 
imide coupling Add't' an BG amine 18 through carb d' 
· 1 10nally h d o I -
appropriate aromatic . ' y roxamate 17' containing an 
1 gth m01ety and ap . en can be obtained fi propnate alkyl cha1·n 
60 · ram the r f with ester 15. Similarly b . eac wn of hydroxylamine 
b ' enzam1de com d 
e prepared from the . poun s 21 and 23 can 
·1· react10n of est 15 
am mes 20 and 22 In th er or acid 16 with 
'd · e case of the 
m1 e 23, the intermediate nit .. para-substituted benza-
65 obtain the desired benz 'd ro amhde must be reduced to 
ft . am1e23Th h. 
s I uted mtro aniline 22 . kn . . e synt es1s of para-sub-
M is ownm th 
oradei et al. (2007) J. M d e art (for example, see 
e . Chem., 45, 5543). 
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Scheme 2 
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Scheme 3 illustrates representative general syntheses of 
ketolide and bridged-ketolide based triazole derivatives. 
'-.... ~ ~N...._/ZBG 
N h [Y] ; \\ Mg 25 
M Ho,,,,,.,~ 0 
Clarithromycin 24 can be N-demethylated to give des-N-
methyl clarithromycin 25. Reaction of 25 with electrophile 2 
yields alkyne 26. Alternatively, alkyne 26 can be obtained by 
'oAo~ 
'-....N~[Y]~R 
M HO,,~.~ O 
'oAo~ 
LiOHr---15:R~OMe 
~16:R~OH 
19 
20 
EDC, THF 
22 
2) SnCli, NJLiOAc, 
THF,MeOH, 
H20 
reductive amination of appropriate aldehydes and ketones. 
Descladinose 27 can be prepared from the treatment of alkyne 
26 with dilute mineral acid, such as HCI. Compound 27, 
30 where R13 is CH3 , can be similarly obtained from reaction of 
24 with dilute mineral acid. Selective acylation of the 
hydroxyl group of the amine sugar can be achieved by treat-
ment of compound 27 with acetic anhydride in appropriate 
non-protic solvents such as, but not limited to, acetone, in the 
35 absence of base to yield compound 28. Oxidation of28 under 
Corey-Kim or similar conditions (see Corey & Kim (1972) J. 
Am. Chem. Soc., 94: 7586; Pfitzner & Moffatt (1965) J. Am. 
Chem. Soc., 87: 5661; Ley et al. (1994) Synthesis, 639) leads 
to ketolide 29. Treatment of 29 with carbonyldiimidazole and 
40 NaHMDS will give carbamate 30. Reaction of30 with amines 
31, 32 and ethane-1,2-diamine will afford intermediate 33, 
34, and 35, respectively (see U.S. Pat. No. 5,631,355; Kash-
imura et al. (2003), J. Antibiot., 56: 1062; Randolph et al. 
(2004) J. Med. Chem., 47, 1085; Plata et al. (2004) Tetr., 60: 
45 10171 ). Subsequent reactions of intermediates 33, 34, and 35 
with azide 4 will lead to bridged-ketolides 36 and 37, 38 and 
39, and 40 and 41, respectively. When R13 contains an appro-
priate aromatic moiety and alkyl chain length, ketolide 29 can 
be modified to form compound 30 by methanolysis at 
50 elevated temperatures. Subsequent reaction of30 with azide 4 
will furnish ketolide 43. Again, it should be appreciated that 
the ZBG in azides of type 4 can be appropriately protected. 
Moreover, similar chemistries can be applied for the synthesis 
of the tetrazoles and oxazoles analogs of the ketolide and 
bridged-ketolide exemplified in scheme 3. 
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Scheme 4 illustrates representative general synthesis of 
triazole compounds with HDAC recognition cap-group con-
nected to the macrocyclic ring at 06 position of 14-membered 
macrolide such as, but not limiting to, erythromycin. Adapt-
ing known protocols (see, Plata et al. (2004) Tetra., 60: 5 
10171), the aryl alkyne 47 can be obtained from readily 
available erythromycin A-9-oxime (see, Morimoto et al. 
(1990) J. Antibiot., 43:286) through the intermediacy of 45. 
84 
Sequential base treatment with aqueous alkali and potassium 
carbonate in methanol will lead to alkyne 48 which can be 
reacted with azide 4 to give triazole 49. Methanolysis of 49 
will afford triazole 50. Triazole 50 can be modified to form 
compound 51 by treatment with dilute mineral acid. Alterna-
tively, methanolysis of alkyne 48 yields alkyne 51. Reaction 
of 51 with azide 4 will yield triazole 50. 
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Scheme 5 illustrates representative general syntheses of 
triazole compounds with HDAC recognition cap-groups con-
nected to the macrocyclic ring at the 06 position of 14-mem-
bered ketolides and carbamate modified macrolides. Selec- 65 
tive benzoyl deprotection and silyl group removal will afford 
aryl alkyne 53. The oxime group in 53 can be removed by 
heating 53 in a THF/H2 0 containing NaHS03 and L-tartaric 
acid to afford aryl alkyne 54 (adapting protocols described by 
Plata et al. (2004) Tetra., 60: 10171). Reaction of 54 with 
azide 4 followed by debenzoylation by sequential treatment 
with potassium carbonate in methanol and methanolysis at 
elevated temperatures will yield triazole 55. Triazole 55 can 
US 8,871,728 B2 
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be modified to form compound 56 by treatment with dilute 
mineral acid. Ary! alkyne 54 can be modified to form aryl 
alkyne 57 by adapting procedures exemplified for similar 
transformations in scheme 3 or alternative protocols 
described in the art (see U.S. Pat. No. 5,631,355; Kashimura 5 
et al. (2003), J. Antibiot., 56: 1062; Randolph et al. (2004) J. 
Med. Chem., 47, 1085; Plata et al. (2004) Tetra., 60: 10171). 
Reaction of 57 with azide 4 followed by debenzoylation by 
88 
sequential treatment with potassium carbonate in methanol 
and methanolysis at elevated temperatures will yield triazole 
58. Triazole 58 can be converted to compound 59 by treat-
ment with dilute mineral acid. A direct treatment of 57 with 
dilute mineral acid will afford alcohol 60. Oxidation of 60 
under Corey-Kim or similar conditions followed by metha-
nolysis at elevated temperatures will yield alkyne ketolide 61. 
Reaction of 61 with azide 4 will yield triazole 62. 
Scheme 5 
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60 
1) NCS, methyl sulfide, 
Et3N or EDC•HCl, DMSO, 
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2) MeOH, heat 
61 
57 
4 
90 
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62 
Intermediates such as electrophiles 2, 7 and 14, azide 4, 
nitrile oxide 11, amine 30 and carbonate alkyne 46 are all 
easily accessible by synthetic protocols known in the art. 
Exemplary examples for the synthesis of compounds whose 
general structures fit the forgoing are illustrated in schemes 6, 
50 appropriately protected with a silyl group to provide silyl 
azide 71 (Muri et al. Org. Lett., (2000) 2: 539). Hagihara-
Sonogashira coupling between alcohol 72 and TMS-acety-
lene should yield alkyne 73. TMS deprotection should furnish 
alkyne 74, which can be reacted with MsCl to provide mesy-
55 late 7 5. Reaction of phthalimide salt with 7 5 should provide 
phthalimide 76, which can be converted to amine 77 by 
hydrazinolysis or other suitable protocol known in the art. 
Treatment of alcohol 78, incorporating ZBG (appropriately 
protected when necessary), with oxidants such as PDC, 
7, 8, and 9. Halogenated aryl alkyne 63 can undergo Heck 
coupling with ethyl acrylate to furnish a,~-unsaturated ester 
64. Reduction of 64 with DIBAL should generate alkenol 65, 
which can be transformed to carbonate 66 using methods 
known in the art (see U.S. Pat. No. 6,579,986; Plata et al. 
(2004), Tetra., 60: 10171). Alternatively, alkenol 65 can be 
prepared from alkenol 67 through Hagihara-Sonogashira 
coupling (Belema et al. Tet. Lett., (2004), 45: 1693). Reac-
tions of carboxylic acid 68 with thionyl chloride in methanol 
follow by treatment with sodium azide should furnish azido 
methyl ester 69. Treatment of 69 with hydroxylamine should 65 
provide azido hydroxamate 70 (Ho et al., (2005), J. Org, 
Chem., 70, 4873). The hydroxamate group of 70 can be 
60 should provide aldehyde 79. Reaction of 79 with hydroxy-
!amine should furnish oxime 80, which can be converted to 
nitrile oxide 81 by treatment with NBS or other reagents such 
NCS, chloramine T, etc. Because of the likely instability of 
nitrile oxides, the generation of nitrile oxide can be performed 
in the presence of the appropriate alkyne 3 (scheme 1) to 
furnish the regioisomeric mixture of the isoxazoles. 
91 
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Scheme 9 
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Schemes 10 and 11 illustrate the synthesis of compounds 
7-14 and 23-30 in Table 3. 
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Scheme 10: Synthesis ofcompunds 7-14 
"'-.N '-NH 
HO;{:,/ O:,, ..... 
<>' 
,... 0 
OHHOn 11,,,, 
... ,,,,,, 
"''
1110 0 
Msj ( ) 
2 
\' .. ,,,o~ ''''·· 
•• .. ,
1110H 
,• 
cf 
\ 
Hunig's Base, 
DMSO, 85° C. 
~ ' 0 ~ ;t
N N N3~ _....OTBDPS 
00 00 N ~ H 
, """· .• ,,,O~ IBTA. °'"· TIIT. HO OH .. .,,,, 5 
..,,· o Hunig's base, Argon, 
"" \ rt \ "'''OR 
C 3: R~ cladinose HCl 4:R~H 
~N 
HO;t... O: .... 
,,, 
.. 0 ( 
,/----0---(:Z ~ 
~ ~ OHHO~ ~ _....OTBDPS 
... ,,,, 
·•1110 0 
... ,,0 S{: 
'''·· 
... · .. ,,,OH 
cf 
\ 
6 
"° Ul
"° O'I
c 
(/J 
00 
00 
--..) 
......... 
':._i 
N 
00 
OJ 
N 
-continued 
0 
0 
-......__O~N3 
16 
N3 II ,.....oH ~N
" 
N 
HO~OH 
...... · 
,,... . ''''"· 
,,.... 0 
\ 
0 
TBTA, Cul, THF, 
Hunig's base, Argon, 
rt 
,Nr-0---(:% ~ ~~Hon,'·· ~o/ 
.,,,, 
·•1110 0 
1 7: R ~ cladinose 
lS:R~H 
15a-e 
NH20H,KCN 
THF/MeOH 
H 
0 
i TBAF, THF, rt, 2h 
~~Hon,,'N,,--Q--{:X w "'" ~N,OH ~ H 
0 
7, n = 1, R = cladinose 
8,n~l,R~H 
9, n = 2, R = cladinose 
10,n~2,R~H 
11, n ~ 3, R ~ cladinose 
12,n~3,R~H 
13, n ~ 4, R ~ cladinose 
14, n ~ 5, R ~ cladinose 
"° -....J
"° QO
c 
(/J 
00 
00 
-....J 
......... 
':._i 
N 
00 
OJ 
N 
Scheme 11: Synthesis of compunds 23-30 
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Scheme 12 illustrates the synthesis of compounds 36 and 38 
in Table 3. 
104 
Scheme 12: Synthesis of compounds 36 and 38 
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Schemes 13, 14 and 15 below illustrate the synthesis of 
compounds 40, 44 and 47 in Table 3. 
Scheme 13: Synthesis of compound 40 
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Scheme 14: Synthesis of compound 44 
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-continued 
0 _N/ ( ) 
HO .:P-
0 
46 
47 
Schemes 16A and 16B. Synthesis of Compound 56 Com-
pound 56 can be synthesized via the 4'-ethynylbenzylketolide 
intermediate 9. Demethylation of clarithromycin 1 under 
standard conditions forms 4-desmethyl-clarithromycin 2 in 
70% yield. Subsequent alkylation of 2 with 4-ethynylbenzyl 
methanesulfonate afforded the modified 4'-ethynylbenzyl-
clarithromycin 4 which was treated with IN HCl to selec-
tively cleave the cladinose sugar to form compound 5. Reac-
tion time for this step should be carefully controlled as longer 
reaction times led to the formation of significant amounts of 
byproduct. Selective acetylation of the 2'-0H group was 
accomplished by treating an acetone solution of 5 with acetic 
anhydride at 40° C. for 24 h to give compound 6 in 70% yield. 
Compound43 
TBTA, Cul, THF, 
HWlig 1s base, Argon, 
rt 
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Subsequent oxidation of the 3-hydroxyl group of compound 
40 6 to a 3-keto functional group, under anhydrous condition 
with NCS, afforded the ketolide 7 almost quantitatively. 
Treatment of 7 with excess carbonyldiimidazole (CDI) and 
NaHMDS in a mixture of THF/DMF afforded the 12-acyl 
imidazolide 8 in 52% yield. Transformation into the desired 
45 tricyclic ketolide was achieved in two successive cyclization 
steps adapting literature procedures. Reaction of imidazolide 
8 with ethylenediamine followed by intramolecular Michael 
addition led to the formation of 11, 12-cyclic carbamate. Sub-
sequent intramolecular dehydration completed the cycliza-
50 tion process, affording the desired product 9 in 42% yield 
(Scheme 16A). 
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Copper (I) catalyzed cycloaddition of 9 with 0-trityl pro-
tectedazidohydoxamate analogs lOa-e (route A), afforded the 
1,2,3-triazole linked derivatives lla-e. Deprotection of the 
trityl group in 1 la-e with TFA (route 13) gave the desired 
products (56a-e) in good yields. A similar outcome was 5 
obtained when trityl group deprotection was effected with 
BF3 .0Et2 (route C). Additionally, the desired hydroxamates 
could be obtained through direct copper (I) catalyzed 
cycloaddition between unprotected azidohydroxamate 13 
and alkyne 9 (route D). 
120 
Scheme 16B. Preparation of compounds 56a-e 
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Methods of Purifying HDAC Intermediates on Multi-
Gram Scales 
To improve the efficiency of the multi-gram synthesis, 
methods of purifying intermediates, such as compound B 
below (where R is a macrolide such as azithromycin or 
clarithromycin) by extraction were developed. 
B 
Compound B containing an azithromycinmacrolide can be 
purified by dissolving Bin a suitable alcohol, such as metha-
nol, and adding an aqueous buffer solution, such as an acetate 
buffer, to form a weakly acidic solution. The solution can then 
124 
mania donovani. P. falciparum and L. donovani are the caus-
ative parasites of malaria and leishmaniasis, two human dis-
eases which constitute a serious threat to public health in 
tropical and sub-tropical countries. Antimalarial activity was 
evaluated in vitro using chloroquine-sensitive (D6, Sierra 
Leone) and chloroquine-resistant (W2, Indochina) strains of 
P.falciparum. Antileishmanial activity was evaluated in vitro 
against the promastigote stage of L. donovani. 
Plasmodium growth inhibition was determined by a para-
10 site lactate dehydrogenase assay using Malstat reagent. Inhi-
bition of viability of the promastigote stage of L. donovani 
was determined using standard Alamar blue assay, modified 
to a fluorometric assay. Amphotericin B and pentamidine, 
standard antileishmanial agents; chloroquine and artemisi-
15 nin, standard antimalarials; and suberoylanilide hydroxamic 
acid (SAHA), a standard HDAC inhibitor (HDACi) were all 
used as positive controls. To determine selective toxicity 
index, all compounds were tested against nontransformed 
mammalian cell lines namely, monkey kidney fibroblasts 
20 (Vero) and murine macrophages (1774.1) using Neutral Red 
assay. 
The non-peptide macrocyclic HDAC inhibitors potently 
be extracted with one or more mixtures of a polar and non-
polar organic solvent, such as mixtures ofhexanes and ethyl 
acetate. The aqueous phase is then basified, for example by 25 
addition of aqueous ammonium hydroxide, and extracted 
with one or more organic solvents, such as hexanes and/or 
mixtures ofhexanes and ethyl acetate. The organic phases can 
then be collected and dried in vacu to obtain B. 
inhibited the proliferation of both the sensitive and resistant 
strains of P.falciparum with an IC50 ranging from 0.1 µg/mL 
to 3.5 µg/mL. In particular, compounds 5-8 in Table 16, 
derived from either the 14- or 15-membered macrolide ana-
logs and having 6 methylene spacers separating the triazole 
ring from the zinc-binding hydroxamic acid group (n=6), had 
the most potent antimalarial activities in this series. These 
Compound B containing a clarithromycin macrolide can 
be purified by dissolving B in a suitable alcohol, such as 
methanol, and adding an aqueous buffer solution, such as an 
acetate buffer, to four a weakly acidic solution. The solution 
can then be extracted with one or more mixtures of a polar and 
non-polar organic solvent, such as mixtures ofhexanes and 
ethyl acetate. The organic phases can then be collected and 
dried in vacu. Compound B containing a clarithromycin mac-
rolide can be purified by recrystallization, for example, from 
a mixture ofhexanes and dichloromethane. 
V. Methods of Use 
The compounds described herein may be used as anti-
cancer agents, anti-inflammatory agents, anti-infective 
agents, anti-malarial agents, cytoprotective agents, neuropro-
tective agents, chemopreventive agents, prokinetic agents, 
and/or cognitive enhancing agents. Examples of cancer 
which may be treated include, but are not limited to, epithelial 
cancers, such as melanoma, lung cancer, breast cancer, pan-
creatic cancer, ovarian cancer, prostate cancer, colon cancer, 
and bladder cancer; hematological cancers, such as multiple 
myeloma, leukemia, and lymphoma; cervical cancer; and 
liver cancer. 
The potency of the compounds described herein were 
investigated by determining the drug concentrations neces-
sary for 50% inhibition of cell viability (IC50) in SKMES 1, 
NCI-H69, DU 145 cells, lung fibroblasts, and HMEC. Drug 
concentrations necessary for 50% inhibition of cell viability 
(EC50) were quantitatively measured using trypan blue exclu-
sion according to literature protocol. Table 5 in the examples 
shows the EC50 values for each compound. All compounds 
inhibited the proliferation of the transformed cells studied 
with EC50 in the low micromolar range. Most importantly, the 
compounds we less toxic to untransformed cell-lines (lung 
fibroblast and HMEC). 
The compounds described herein were also evaluated for 
parasitic activity against Plasmodium falciparum and Leis-
30 compounds are equipotent or >4-fold more potent than the 
control compound SAHA. Moreover, they are several folds 
more selectively toxic to either strains of P. falciparum com-
pared to SAHA. 
The antimalarial activities of these macrocyclic HDACi 
35 followed a similar trend as their anti-HDAC activity against 
HDACl/2 from HeLa nuclear extract, suggesting that para-
site HDACs could be an intracellular target of the these com-
pounds. 
Compounds 5 and 9 exhibited modest activity against the 
40 promastigote stage of L. donovani. A comparison of the anti-
leishmanial activities of compounds 13and14, analogs with 
n=S, revealed a disparity between the activity of 14- and 
15-membered macrocyclic rings. 14-Membered compound 
13 is 5- to 6-fold more potent than its 15-membered congener 
45 14. However, this disparity dissipates after a single methylene 
group extension (n=9), as compounds 15 and 16 have virtu-
ally indistinguishable antileishmanial activities. Compara-
tively, compounds 13, 15and16, analogs with the most potent 
antileishmanial activities, are about 7- to 10-fold more potent 
50 than SAHA and approximately 3-fold less potent than penta-
midine. 
Since these non-peptide macrocyclic HDACi have nano-
molar anti-HDAC activities, the observed disparity in the 
trend of their antimalarial and antileishmanial activities may 
55 have implication in the organization of the active sites of the 
relevant P. falciparum and L. donovani HDAC isozymes. 
These observations provide additional evidence of the suit-
ability of HDAC inhibition as a viable therapeutic option to 
curb infections caused by apicomplexan protozoans and try-
60 panosomatids (1, 5, 6, 14) and could facilitate the identifica-
tion of other HDACi that are more selective for either para-
site. 
The formulations contain an effective amount of one or 
more HDAC inhibitors. The doses in which the HDAC inhibi-
65 tors and their salts, prodrugs, or solvates can be administered 
may vary widely depending on the condition of the patient 
and the symptoms to be treated. One of ordinary skill in the art 
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can readily determine the necessary dosage based on the 
condition of the patient and the disease to be treated. 
Unless defined otherwise, all technical and scientific terms 
used herein have the same meanings as commonly under-
stood by one of skill in the art to which the disclosed invention 5 
belongs. Publications cited herein and the materials for which 
they are cited are specifically incorporated by reference. 
Those skilled in the art will recognize, or be able to ascer-
tain using no more than routine experimentation, many 
equivalents to the specific embodiments of the invention 10 
described herein. Such equivalents are intended to be encom-
passed by the following claims. 
EXAMPLES 
126 
base (4 ml) and 4-ethynylbenzyl methanesulfonate 2 (0.760 
g, 3 .60 mmol). The reaction mixture was heated with stirring 
under argon at 85° C. for 2.5 h. The reaction was cooled and 
diluted with ethyl acetate (EtOAc, lOOmL) and washed with 
saturated NaHC03 (3x60 mL) and saturated brine (60 mL). 
The organic layer was dried over N a2 SO 4 and concentrated in 
vacuo. The crude product was purified by flash chromatogra-
phy (silica, 12:1:0.05 CH2 Cl2 /MeOH/conc. NH4 0H) to give 
1.2 g (52%) of3 as a brownish white solid. 1H-NMR(CDC13 , 
400 MHz) ll 0.84 (m), 0.97 (d, J=7.6 Hz), 1.04 (m), 1.12-1.32 
(m), 1.36-1.53 (m), 1.66-1.75 (m), 1.81-2.07 (m), 2.19 (s), 
2.25-2.29 (m), 2.48 (m), 2.63-2.73 (m), 2.89 (bs), 2.96 (1, 
J=9.8 Hz), 3.02 (s), 3.08 (s), 3.27-3.32 (m), 3.38-3.45 (m), 
3.56 (d, J=6.8 Hz), 3.63 (s), 3.72 (d, J=13.2 Hz), 3.97 (m), 
Materials 
"Preparative TLC" or "prep TLC" refers to preparative thin 
layer chromatography and was performed on Analtech pre-
parative TLC plates (UV 254, 2000 µm), unless otherwise 
stated. "Colunm chromatography" or "flash colunm chroma-
tography" was performed with 200-400 Mesh silica gel, 
unless otherwise noted. 
15 4.19 (m), 4.36 (d, J=7.2 Hz), 4.63 (d, J=lO Hz), 5.04 (d, J=4.4 
Hz), 7.21 (d, J=8 Hz), 7.39 (d, J=8 Hz); 13C-NMR (CDC13 , 
100 MHz) ll 7.5, 9.2, 11.3, 14.9, 16.3, 18.3, 21.3, 21.4, 21.6, 
22.0, 26.8, 27.6, 29.6, 34.7, 36.3, 36.9, 42.0, 42.3, 45.2, 49.2, 
57.7, 62.3, 63.7, 65.4, 68.5, 70.0, 70.6, 72.7, 73.5, 73.8, 74.2, 
20 77.1, 77.9, 78.0, 83.4, 83.7, 94.5, 102.6, 120.8, 128.5, 132.0, 
139.6, 178.3; HRMS (FAB, nmba) calc for [C46H76N20 12+ 
Ht 849.5476. found 849.5411. 
Nuclear magnetic resonance (NMR) spectra were recorded 
on a Varian-Gemini 400 magnetic resonance spectrometer. 25 
1 H NMR spectra were recorded in parts per million (ppm) 
relative to the peak of CDC13 , (7.24 ppm), CD30D (3.31 
ppm), or DMSO-d6 (2.49 ppm). 13C spectra were recorded 
relative to the central peak of the CDC13 triplet (77.0 ppm), 
CD3 0D (49.0 ppm), or the DMSO-d6 septet (39.7 ppm), and 30 
were recorded with complete hetero-decoupling. 
Common reaction solvents were either high performance 
liquid chromatography (HPLC) grade or American Chemical 
Society (ACS) grade, and used without further purification. 
Anliydrous solvents and other reagents were purchased and 35 
used without further purification. 
Fluor de Lys™ is a fluorescence based HDAC activity 
assay comprising a combination of fluorogenic Histone 
deAcetylase Lysyl substrate and a developer. The kit is a 
highly sensitive and convenient alternative to radiolabeled, 40 
acety lated histones or peptide/HP LC methods for the assay of 
histone deacetylases. This assay is based on the ability of 
HeLa nuclear extract, which is enriched in HDAC activity, to 
mediate the deacetylation of the acetylated lysine side chain 
of the Fluor de Lys substrate. The assay procedure requires 45 
two steps. First, incubation of the HeLa nuclear extract with 
the Fluor de Lys substrate results in substrate deacetylation 
and thus sensitizes it to the second step. In the second step, 
treatment of the deacetylated substrate with the Fluor de Lys 
developer produces a fluorophore. The substrate-developer 50 
reaction, under normal circumstances goes to completion in 
less than 1 min at 25° C. The kit used was the Fluorimetric 
Assay/Drug Discovery Kit-AK-500 Manual Fluorescent 
Assay System available from BIO MOL® International, Ply-
mouth Meeting, Pa. 55 
The numbers used to identify the compounds described in 
the examples correspond to the references numbers in Table 3 
and/or reaction schemes 10-15. 
Synthesis of Azithromycin-arylalkyltriazolyl methyl 
ester (17) 
Azithromycin-N-phenylacetylene 3 (0.045 g, 0.053 mmol) 
and azido-ester 16 (0.014 g, 0.080 mmol) were dissolved in 
anhydrous THF (5 mL) and stirred under argon at room tem-
perature. Copper (I) iodide (0.010 g, 0.053 mmol), and 
Hunig's base (0.05 mL) were then added to the reaction 
mixture, and stirring continued for 12 h. The reaction mixture 
was diluted with CH2 Cl2 (30 mL) and washed with 1:4 
NH4 0H/saturated NH4 Cl (3x25 mL) and again with satu-
rated NH4Cl (25 mL). The organic layer was dried over 
Na2S04 and concentrated under vacuum. The crude product 
was purified by preparative TLC, eluting with Hexane/ 
Et0Ac/Et3 N 3:2:0.1 to give 50 mg (92%) of 17 as a white-
brown solid. 1H-NMR (CDC13 , 400 MHz) ll 0.82-0.90 (m), 
0.98 (d, J=7.6 Hz), 1.05-1.13 (m), 1.19-1.23 (m), 1.25-1.30 
(m), 1.40-1.52 (m), 1.60-1.74 (m), 1.80-1.96 (m), 2.00-2.06 
(m), 2.22-2.37 (m), 2.56 (m), 2.67 (m), 2.95 (t, J=9.8 Hz), 
3.07 (s), 3.29-3.34 (m), 3.46 (bs), 3.54 (d, J=6.8 Hz), 3.61 (s), 
3.68 (bs), 3.77 (m), 3.97 (m), 4.18 (m), 4.34-4.38 (m), 4.69 
(m), 5.06 (d, J=4 Hz), 7.32 (d, J=6.4 Hz), 7.73-7.75 (m); 
13C-NMR (CDC13 , 100 MHz) ll 8.7, 9.2, 11.3, 14.2, 14.7, 
16.5, 18.2, 21.4, 21.5, 22.2, 24.2, 25.9, 26.6, 27.3, 29.7, 30.0, 
33.6, 34.6, 36.4, 36.9, 42.4, 45.3, 45.8, 49.3, 50.0, 51.5, 57.7, 
63.9, 65.5, 68.6, 69.4, 70.5, 72.7, 73.8, 74.2, 77.2, 77.6, 78.0, 
83.4, 94.4, 102.7, 119.3, 125.5, 129.1, 129.4, 147.2, 173.4, 
178.1. MS (FAB, mnba) 1020.3 (M+Hr. 
Synthesis of 
Descladinoseazithromycin-arylalkyltriazolyl methyl 
ester (18) 
A mixture of compound 3 (0.12 g, 0.14 mmol) in 0.25 N 
HCl (15 mL) was stirred at room temperature for 20 hand 
poured into EtOAc (20 mL). The two layers were separated 
Example 1 
Synthesis of Compounds 7-14 and 23-30 in Table 3 
Synthesis of Azithromycin-N-phenylacetylene (3) 
60 and the aqueous layer was washed with EtOAc (2x20 mL), 
basified with concentrated NH4 0H and then extracted with 
5% MeOH in CH2Cl2 (2x30 mL). The combined organic 
layer was washed with saturated brine (30 mL) and dried over 
Na2S04 . Solvent was evaporated off to give 89 mg (91%) of 
To a solution of N-demethylated azithromycin 1 (2.0 g, 
2.56 mmol) in anhydrous DMSO (30 ml) was added Hunig's 
65 descladinose compound 4 as a white solid. 1 H-NMR (CDC13 , 
400 MHz) ll 0.81-0.87 (m), 0.90-1.07 (m), 1.17-1.27 (m), 
1.31-1.59 (m), 1.68-1.71 (m), 1.80-1.87 (m), 1.99-2.03 (m), 
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2.08 (s), 2.23-2.27 (m), 2.31 (s), 2.44-2.48 (m), 2.59-2.73 
(m), 3.32-3.39 (m), 3.48-3.53 (m), 3.60-3.65 (m), 3.73 (d, 
1=9.6 Hz), 3.84-3.91 (m), 4.43 (d, J=7.2 Hz), 4.69-4.72 (m), 
7.16 (d, J=8.0Hz), 7.39 (d, J=8.4 Hz); 13CNMR(CDC13 , 100 
MHz) o 7.7, 7.9, 10.9, 14.2, 16.1, 20.9, 21.1, 21.2, 25.9, 26.6, 
29.3, 36.0, 36.4, 37.1, 42.1, 44.5, 57.6, 60.3, 62.5, 65.3, 69.9, 
70.5, 70.9, 73.0, 74.1, 75.4, 77.2, 79.5, 83.3, 94.9, 106.5, 
120.8, 128.3, 132.0, 139.3, 177.2. MS (FAB, mnba) 691.2 
(M+Ht. 
The descladinose compound 4 (0.080 g, 0.115 mmol) and 
azido-ester 16 (0.030 g, 0.173 mmol) were dissolved in anhy-
drous THF (5 mL) and stirred under argon at room tempera-
ture. Copper (I) iodide (0.010 g, 0.053 mmol), and Hunig's 
base (0.05 mL) were then added to the reaction mixture, and 
stirring continued for 12 h. The reaction mixture was diluted 
with CH2 Cl2 (30 mL) and washed with 1 :4 NH4 0H/saturated 
NH4 Cl (3x25 mL) and again with saturated NH4Cl (25 mL). 
The organic layer was dried over N a2 SO 4 and concentrated in 
vacuo. The crude product was purified by preparative TLC, 
eluting with Hexane/Et0Ac/Et3 N 3:2:0.1 to give 65 mg 
(65%) of 18 as a white-brown solid. 1H-NMR (CDC13 , 400 
MHz) o 0.79-0.86 (m), 1.00-1.07 (m), 1.17-1.35 (m), 1.42-
1.51(m),1.55-1.72 (m), 1.80-1.94 (m), 2.00-2.05 (m), 2.1 (s), 
2.23-2.27 (m), 2.33 (s), 2.47 (d, J=l0.4 Hz), 2.58-2.72 (m), 
3.32-3.41 (m), 3.52-3.73 (m), 3.92-4.00 (m), 4.34 (t, J=7.0 
Hz), 4.41 (d, J=7.6 Hz), 4.69 (d, J=l0.8 Hz), 7.24 (d, J=8.4 
Hz), 7.71 (d, J=8 Hz), 7.73 (s); 13C NMR (CDC13 , 100 MHz) 
0 7.7, 7.9, 8.7, 10.9, 16.1, 16.1, 20.9, 21.2, 24.2, 25.8, 25.9, 
26.6, 29.2, 29.6, 30.0, 33.6, 36.0, 36.3, 37.1, 42.0, 44.5, 45.8, 
50.0, 51.5, 57.7, 62.6, 65.1, 69.9, 70.4, 73.1, 74.1, 75.3, 79.4, 
94.8, 106.4, 119.3, 125.5, 128.9, 129.6, 138.2, 147.1, 173.4, 
177.2. MS (FAB, mnba) 862.2 (M+Ht. 
Synthesis of 
Azithromycin-N-phenyltriazolylhexahydroxamic 
acid (7) 
Method A 
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mmol) were dissolved in anhydrous THF (5 mL) and stirred 
under argon at room temperature (Note: compound 6 was 
prepared from the corresponding azido carboxylic acid, 
t-BuPh2 SiCl and NaH, according to the procedure described 
5 by Muri et al. ORG. LETT (2000) 2: 539). Copper (I) iodide 
(0.010 g, 0.05 mmol), Hunig's base (0.5 mL) and tris[(l-
benzyl-lH-1,2,3-triazol-4-yl)methyl]amine, (TBTA) (0.016 
g, 0.030 mmol) were then added to the reaction mixture, and 
stirring continued for 2 h (Note: TBTA was synthesized 
10 according to Chen et al. Org. Lett., (2004) 6: 2853). The 
reaction mixture was diluted with CH2Cl2 (40 mL) and 
washed with 1:4 NH40H/saturated NH4 Cl (2x30 mL) and 
saturated NH4 Cl (30 mL). The organic layer was dried over 
Na2S04 and concentrated in vacuo. The crude product was 
15 purified by prep TLC (silica, 12:1:0.1 CH2 CliMeOH/conc. 
NH4 0H) to give 38 mg (60%) of silyl protected compound 6 
as a brownish white solid. 1H-NMR (CDC13 , 400 MHz) o 
0.82-0.92 (m), 1.00-1.14 (m), 1.17-1.27 (m), 1.30-1.32 (m), 
1.35-1.59 (m), 1.73-1.92 (m), 2.01-2.15 (m), 2.24-2.32 (m), 
20 2.36 (br s), 2.56 (d, J=l0.4 Hz), 2.69 (m), 2.98 (d, J=lO Hz), 
3.07-3.09 (m), 3.32-3.36 (In), 3.42-3.46 (m), 3.55-3.63 (m), 
3.66 (s), 3.78 (d, J=13.2 Hz), 4.01(m),4.15-4.25 (m), 4.40 (d, 
J=6.8 Hz), 4.63 (d, J=7.2 Hz), 4.69 (s), 5.10 (d, J=4.4 Hz), 
7.31-7.43 (m), 7.65-7.75 (m). 
25 To a solution of silyl protected compound 6 (0.025 g, 0.02 
mmol) in THF (1 mL) was added 1 M TBAF in THF (0.030 
mL, 0.030 mmol) and the mixture was stirred at room tem-
perature for 2 h during which TLC revealed a near quantita-
tive conversion to a lower Rf product. The reaction was par-
30 titioned between CH2 Cl2 (30 mL) and saturated NH4 Cl (25 
mL ), the two layers were separated and the organic layer dried 
over Na2S04 and concentrated in vacuo. The crude product 
was purified by prep TLC (silica, 12:1:0.1 CH2 CliMeOH/ 
Et3 N) to give 15 mg (73%) of7 as a brownish white solid. 
35 1H-NMR(Acetone-d6, 400MHz) o0.83-0.92 (m), 1.02 (d, 
J=7.6Hz), 1.08-1.11(m),1.14(d,J=7.6Hz), 1.18(d,J=6Hz), 
1.24-1.29 (m), 1.33-1.47 (m), 1.54 (dd, J=4.8 Hz, 15.2 Hz), 
1.66 (m), 1.80-2.01 (m), 2.06-2.12 (m), 2.18-2.24 (m), 2.26 
(s), 2.28-2.31 (m), 2.35-2.41 (m), 2.51 (d, J=lO Hz), 2.65-
40 2.96 (m), 3.12 (s), 3.22-3.29 (m), 3.41-3.47 (m), 3.54-3.69 
(m), 3.81 (d, J=13.2 Hz), 4.11 (m), 4.24 (m), 4.45 (t, J=7.0 
Hz), 4.50 (d, J=6.8 Hz), 4.75 (d, J=7.2 Hz), 4.97 (d, J=5.2 Hz), 
7.42 (d, J=8.0 Hz), 7.84 (d, J=8.0 Hz), 8.35 (s). MS (FAB, 
mnba) 1021.2 (M+Ht. 
To a solution of compound 17 (0.04 g, 0.04 mmol) in 1: 1 
THF/MeOH (3 mL)was addedhydroxylamine (50% inH20) 
(0.03 mL, 0.54 mmol) and a catalytic amount of KCN. The 
mixture was stirred at room temperature for 24 h. The reaction 
was partitioned between 5% MeOH in CH2Cl2 (30 mL) and 
saturated sodium bicarbonate (25 mL), the two layers were 
separated and the aqueous layer was extracted with 5% 45 
MeOH in CH2Cl2 (2x20 mL). The combined organic layer 
was washed with saturated brine ( 40 mL) and dried over 
Na2S04 . Solvent was evaporated off and the crude was puri-
fied by preparative TLC, eluting with CH2 Cl2/MeOH/ 
NH40H 10:1:0.1 to give compound 7 (6.5 mg, 16%) as 50 
brown-white solid. 
Synthesis of Descladinose-Azithromycin-N-pheny 1-
triazolylhexahydroxamic acid (8) 
Method A 
To a solution of compound 18 (0.04 g, 0.05 mmol) in 1: 1 
THF/MeOH (3 mL)was addedhydroxylamine (50%inH20) 
(0.04 mL, 0.54 mmol) and a catalytic amount of KCN. The 
mixture was stirred at room temperature for 24 h. The reaction 
was partitioned between 5% MeOH in CH2Cl2 (30 mL) and 
saturated sodium bicarbonate (25 mL), the two layers were 
separated and the aqueous layer was extracted with 5% 
MeOH in CH2Cl2 (2x20 mL). The combined organic layer 
was washed with saturated brine ( 40 mL) and dried over 
Na2S04 . Solvent was evaporated off and the crude was puri-
fied by preparative TLC, eluting with CH2CliMeOH/ 
NH40H 10:1:0.1 to give compound 8 (9.0 mg, 23%) as 
brown-white solid. 
MethodB 
MethodB 
Azithromycin-N-pheny lacety lene 3 (0 .100 g, 0 .109 mmol) 
and 6-azidohexahydroxamic acid 15a (0.081 g, 0.117 mmol) 
were dissolved in anhydrous THF (5 mL) and stirred under 55 
argon at room temperature. Copper (I) iodide (0.011 g, 0.07 
mmol) and Hunig's base (0.5 mL) were then added to the 
reaction mixture, and stirring continued for 4 h. The reaction 
mixture was diluted with CH2Cl2 ( 40 mL) and washed with 
1:4 NH40H/saturated NH4 Cl (3x30 mL) and saturated 60 
NH4 Cl (30 mL). The organic layer was dried over Na2 S04 
and concentrated in vacuo. The crude product was purified by 
prep TLC (silica, 12:1:0.1 CH2CliMeOH/cone. NH4 0H) to 
give 71 mg (59%) of7 as a brownish white solid. Reaction of descladinose-azithromycin-N-phenylacety-
65 lene 4 (0.134 g, 0.188 mmol) and 6-azidohexahydroxamic 
acid 15a (0.130 g, 0.755 mmol) within 8 h (according to the 
protocols of Method B described for the synthesis of com-
MethodC 
Azithromycin-N-phenylacetylene 3 (0.045 g, 0.050mmol) 
and 6-azido-0-silyl hexahydroxamate 6 (0.060 g, 0.146 
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pound 7 above), followed by prep TLC (silica, 10:1:0.1 
CH2 Cl2/MeOH/conc. NH40H) gave 73 mg (43%) of8 as a 
brownish white solid. 
1 H-NMR (Acetone-d6, 400 MHz) ll 0.82-0.90 (m), 1.02 ( d, 
1=7.2 Hz), 1.07 (s), 1.09 (d, 1=6.8 Hz), 1.18-1.23 (m), 1.28 5 
(bs), 1.31-1.39 (m), 1.46-1.56 (m), 1.65 (m), 1.81-1.83 (m), 
1.87-1.99 (m), 2.05-2.11 (m), 2.18-2.21 (m), 2.18-2.21 (m), 
2.24 (s), 2.25-2.29 (m), 2.35 (s), 4.47(d,1=9.2 Hz), 2.61-2.67 
(m), 2.70-2.77 (m), 3.30-3.34 (m), 3.41 (m), 3.52-3.65 (m), 
2.81 (d, 1=13.2 Hz), 4.44 (t, 1=7.0 Hz), 4.59 (d, 1=7.6 Hz), 10 
4.87 (dd, 1=1.8 Hz, 11.0 Hz), 7.43 (d, 1=8.4 Hz), 7.83 (d, 
1=8.4 Hz), 8.34 (m); HMRS (ESI) calcd for [C44H74N60 11 + 
Ht863.5488. found 863.5528. 
Accordingly, compounds 9-14 and 23-30 (in this section) 
were synthesized according to the protocols of Method B 15 
described for the synthesis of compound 7 above. 
Synthesis of 
Azithromycin-N-pheny ltriazoly lheptahydroxamic 
acid (9) 20 
Reaction of azithromycin-N-phenylacetylene 3 (0.134 g, 
0.158mmol) and 7-azidoheptahydroxamic acid 15b (0.125 g, 
0.672 mmol) within 4 h, followed by prep TLC (silica, 12:1: 
0.1 CH2 Cl2/MeOH/conc. NH40H) gave 93 mg (56%) of9 as 25 
a brownish white solid. 1H-NMR (CDCl3, 400 MHz) ll 0.81-
1.51 (m), 1.54-1.65 (m), 1.70-2.14 (m), 2.20-2.38 (m), 2.46-
2.56 (m), 2.60-2.70 (m), 3.00 (s), 3.31(t,1=8.8 Hz), 3.38-3.54 
(m), 3.60 (s), 3.78 (d, 1=12.8 Hz), 3.98-4.20 (m), 4.36 (d, 
1=7.2 Hz), 4.49 (d, 1=7.2 Hz), 5.11(d,1=4.0 Hz), 7.32 (d, 30 
1=7.6Hz), 7.73 (s), 7.75(d,1=7.6Hz); 13CNMR(CDCl3, 100 
MHz) ll 6.6, 8.8, 11.5, 14.4, 16.6, 17.7, 21.3, 21.6, 21.8, 25.1, 
26.0, 26.7, 27.1, 28.2, 29.2, 29.6, 30.0, 33.1, 34.5, 35.7, 36.7, 
41.8, 42.7, 45.3, 49.3, 50.3, 50.7, 57.9, 62.7, 63.0, 65.8, 68.6, 
69.4, 70.4, 72.6, 73.2, 73.8, 77.8, 78.1, 78.2, 83.5, 94.4, 102.8, 35 
119.3, 125.7, 129.4, 129.7, 138.4, 147.4, 171.3, 178.4; 
HMRS (ESI)calcdfor[C53H90N60 14+Ht 1035.6587. found 
1035.6628. 
Synthesis of Descladinose-Azithromycin-N-pheny 1-
triazoly lheptahydroxamic acid (10) 
40 
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4.40 (m), 4.65(d,1=8.0 Hz), 5.11(d,1=4.8 Hz), 7.34(d,1=8.0 
Hz), 7.72 (s), 7.77 (d, 1=8.0 Hz); 13C NMR (DMSO-d6, 400 
MHz) ll 7.5, 9.8, 11.6, 15.4, 18.2, 19.1, 21.5, 22.1, 22.7, 25.6, 
26.3, 26.6, 28.7, 29.0, 29.6, 30.2, 32.0, 32.8, 35.2, 36.4, 37.2, 
42.2, 45.3, 49.2, 50.1, 58.3, 63.2, 65.4, 67.7, 70.8, 73.3, 74.2, 
77.0, 78.4, 83.4, 102.8, 121.6, 125.6, 129.7, 130.0, 135.0, 
147.0, 177.8; HRMS (FAB, thioglycerol) calc for 
[C54H92N6014+Hr 1049.6749. found 1049.6648. 
Synthesis of Descladinose-Azithromycin-N-pheny 1-
triazoly loctahydroxamic acid (12) 
Reaction of azithromycin-N-phenylacetylene 4 (0.10 g, 
0.144 mmol) and 8-azidooctahydroxamic acid 15c (0.049 g, 
0.246 mmol) within 2.5 h, followed by prep TLC (silica, 
10:1:0.1 CH2 Cl2/MeOH/conc. NH40H) gave 94 mg (73%) 
of 12 as a brownish white solid. HRMS (FAB, thioglycerol) 
calc for [C46H79N60 11 +Ht 891.5806. found 891.5910. 
Synthesis of 
Azithromycin-N-pheny ltriazoly lnonahydroxamic 
acid (13) 
Reaction of azithromycin-N-phenylacetylene 3 (0.10 g, 
0.120 mmol) and 9-azidononahydroxamic acid 15d (0.043 g, 
0.20mmol) within2.5 h, followed by prep TLC (silica, 12:1: 
0.1 CH2Cl2/MeOH/conc. NH40H) gave 64 mg (51 %) of 13 
as a brownish white solid. 1H NMR (CDCl3, 400 MHz) ll 
0.84-1.30 (m), 1.33-2.26 (m), 2.30 (s), 2.38-2.68 (m), 2.99 
(s), 3.32-3.84 (m), 4.03-4.08 (m), 4.35-4.41 (m), 4.53 (d, 
1=8.0 Hz), 5.13 (d, 1=4.0 Hz), 7.35 (d, 1=8.0 Hz), 7.75 (s), 
7.78 (d, 1=8.0 Hz); 13C NMR (DMSO-d6, 400 MHz) ll 6.9, 
9.0, 11.6, 14.7, 16.9, 18.0, 21.6, 21.8, 22.1, 25.6, 26.4, 26.9, 
27.3, 28.8, 29.0, 29.1, 29.5, 29.9, 30.4, 34.8, 36.0, 37.0, 42.1, 
43.0, 45.6, 49.5, 50.5, 58.1, 63.5, 66.1, 68.8, 70.7, 72.9, 74.1, 
78.1, 78.3, 78.5, 83.7, 94.4, 94.7, 103.1, 119.6, 126.0, 129.7, 
130.0, 147.6, 178.7; LRMS (MALDI) calc for 
[C55H94N6014+Hr 1063.6. found 1063.7. 
Synthesis of 
Azithromycin-N-phenyltriazoly ldecahydroxamic 
acid (14) 
Reaction of azithromycin-N-phenylacetylene 3 (0.10 g, 
0.120 mmol) and 10-azido-decahydroxamic acid 15e (0.045 
g, 0.20 mmol) within 4.5 h, followed by prep TLC (silica, 
12:1:0.1 CH2 Cl2/MeOH/conc. NH40H) gave 70 mg (56%) 
of14 as a brownish white solid. 1HNMR (CDCl3, 400 MHz) 
ll 0.85-1.36 (m), 1.41-2.24 (m), 2.28, 2.36 (s), 2.33-3.10 (m), 
3.05 (s), 3.23-3.82 (m), 4.06-4.10 (m), 4.36-4.41(m),4.49 (d, 
1=8.0 Hz), 5.15(d,1=4.0 Hz), 7.34(d,1=8 Hz), 7.75 (s), 7.78 
(d, 1=8.0 Hz); 13C NMR (DMSO-d6, 400 MHz) ll 6.7, 9.0, 
11.7, 14.6, 16.9, 17.9, 21.6, 21.9, 22.0, 25.6, 26.4, 26.8, 27.0, 
27.3, 28.8, 29.0, 21.9, 29.3, 29.5, 29.9, 30.3, 33.6, 34.9, 35.8, 
Reaction of descladinose-azithromycin-N-pheny !acety-
lene 4 (0.130 g, 0.188 mmol) and 7-azidoheptahydroxamic 
acid 15b (0.130 g, 0.755 mmol) within 8 h, followed by prep 45 
TLC (silica, 10:1:0.1 CH2 Cl2/MeOH/conc. NH40H) gave78 
mg (47%) oflO as a brownish white solid. 1H-NMR (CDCl3, 
400 MHz) ll 0.66-2.32 (m), 2.47 (d, 1=10.8 Hz), 2.63-2.70 
(m), 3.34-3.51 (m), 3.62-3.69 (m), 4.20-4.40 (m), 4.74 (br s), 
7.26 (br s), 7.73 (br s); 13C NMR (CDCl3, 100 MHz) ll 7.4, 50 
7.9, 10.7, 16.0, 16.1, 20.9, 21.1, 25.0, 25.7, 26.5, 28.0, 28.9, 
29.8, 35.8, 36.3, 36.9, 42.0, 44.4, 50.1, 57.9, 62.7, 63.9, 69.9, 
70.4, 70.8, 73.3, 74.1, 75.2, 79.5, 94.9, 106.6, 119.7, 125.7, 
129.2, 129.6, 138.4, 147.3, 177.5; HMRS (ESI) calcd for 
[C45H76N6011+Hr 877.5645. found 877.5665. 55 37.0, 42.1, 43.0, 45.6, 49.6, 50.6, 51.6, 58.0, 62.8, 63.9, 66.2, 
68.9, 69.6, 70.7, 72.9, 73.5, 74.0, 74.1, 78.2, 78.6, 83.6, 94.6, 
103.0, 119.6, 126.0, 129.6, 129.9, 138.9, 147.6, 178.6; 
HRMS (MALDI) calc for [C56H96N60 14+Ht 1077.7057. 
found 1077.6971. 
Synthesis of 
Azithromycin-N-phenyltriazolyloctahydroxamic acid 
(11) 
Reaction of azithromycin-N-phenylacetylene 3 (0.10 g, 
0.120 mmol) and 8-azidooctahydroxamic acid 15c (0.047 g, 
0.24 mmol) within 2.5 h, followed by prep TLC (silica, 12:1: 
0.1 CH2CliMeOH/conc. NH40H) gave 72 mg (58%) of 11 
60 
as a brownish white solid. 1 H NMR (CDCl3, 400 MHz) ll 0.85 65 
(t, 1=4.0 Hz), 0.87-1.22 (m), 1.29 (s), 1.30-2.28 (m), 2.29 (s), 
2.30-3.00 (m), 3.10 (s), 3.20-3.79 (m), 3.99-4.03 (m), 4.35-
Synthesis of Clarithromycin-N-phenylacetylene (20) 
To a solution ofN-demethylated clarithromycin 19 (2.40 g, 
3.34 mmol) in anhydrous DMSO (30 ml) was added Hunig's 
base (3 ml) and 4-ethynylbenzyl methanesulfonate 2 (0.920 
g, 4.34 mmol). The reaction mixture was then heated with 
stirring under argon at 85° C. for 2.5 h. The reaction was 
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cooled and diluted with EtOAc (100 mL) and washed with 
saturated NaHC03 (3x60 mL) and saturated brine (60 mL). 
The organic layer was dried over N a2 SO 4 and concentrated in 
vacuo. The crude product was purified by flash chromatogra-
phy (silica, gradient 12:1; 10: 1; 8: 1; CH2Cl2/acetone) to give 5 
1.8 g (63%) of 20 as a brownish white solid. 1H-NMR 
(CDCl3, 400 MHz) o 0.82 (t, 1=7.2 Hz), 1.03-1.28 (m), 
1.37 (s), 1.40-1.55 (m), 1.65-1.90 (m), 2.03 (d, 1=10.0 Hz), 
2.22 (s), 2.30 (d, 1=15.2 Hz), 2.40-2.60 (m), 2.80-2.90 (m), 
2.94-3.00 (m), 3.04 (s), 3.09 (s), 3.16 (s), 3.24-3.29 (m), 10 
3.38-3.46 (m), 3.59 (d, 1=6.8 Hz), 3.70-3.75 (m), 3.88-3.95 
(m), 4.37(d,1=7.2 Hz), 4.88 (d, 1=4.4 Hz), 5.02 (dd, 1=11.6, 
2.4 Hz), 7.23 (d, 1=12.0 Hz), 7.42 (d, 1=8.0 Hz); 13C NMR 
(CDCl3, 100 MHz) o 9.2, 10.7, 12.4, 16.1, 18.1, 18.7, 19.9, 
21.1, 21.5, 29.3, 32.4, 34.8, 36.9, 37.2, 39.2, 45.0, 45.2, 49.3, 15 
50.6, 53.4, 57.6, 63.3, 65.6, 68.5, 69.0, 70.6, 72.5, 74.2, 76.5, 
77.8, 78.1, 78.2, 80.8, 95.8, 102.5, 120.9, 128.6, 132.0, 133.5, 
139.4, 175.4; HRMS (ESI) calc for [C46H73N013+Ht 
848.5155. found 848. 5181. 
Synthesis of 
Descladinose-Clarithromycin-N-pheny !acetylene 
(21) 
20 
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Synthesis of Descladinose-Clarithromycin-N-phe-
nyltriazolylhexahydroxamic acid (24) 
Reaction of descladinose-clarithromycin-N-phenylacety-
lene 21 (0.075 g, 0.109 mmol) and 6-azidohexahydroxamic 
acid 15a (0.040 g, 0.233 mmol) within 4 h, followed by prep 
TLC (silica, 10:1:0.1 CH2Cl2/MeOH/conc. NH40H) gave 47 
mg (51 %) of24 as a brownish white solid. 1H-NMR (CDCl3, 
400 MHz) o 0.79(t,1=7.2 Hz), 1.08-1.32 (m), 1.39-1.64 (m), 
1.71-1.81 (m), 1.82-1.96 (m), 2.04-2.18 (m), 2.51-2.70 (m), 
2.92-2.98 (m), 3.18-3.38 (m), 3.45-3.55 (m), 3.60-3.74 (m), 
3.81 (s), 3.90 (s), 4.33 (br s), 5.13(d,1=10.4 Hz), 7.29 (br s), 
7.74 (br s); 13C NMR (CDCl3, 100 MHz) o 8.6, 10.7, 12.9, 
15.5, 16.4, 18.0, 19.0, 21.5, 21.6, 29.5, 29.9, 36.1, 36.7, 37.7, 
39.0, 44.7, 45.7, 49.8, 50.3, 58.2, 64.6, 70.0, 70.3, 70.9, 74.4, 
78.3, 79.1, 88.5, 106.7, 120.3, 126.1, 129.6, 129.9, 147.7, 
175.4; HMRS (ESI) calcd for [C44H71N50 12+Ht 862.5172. 
found 862.5155. 
Synthesis of 
Clarithromycin-N-phenyltriazolylheptahydroxamic 
acid (25) 
Reaction of clarithromycin-N-phenylacetylene 20 (0.130 
To a solution of clarithromycin-N-phenylacetylene 20 
(0.500 g, mmol) in ethanol (20 mL) was added IN HCI (20 
mL ), and stirring continued for 22 hat room temperature. The 
reaction mixture was basified with concentrated NH40H to 
about pH=9. The reaction mixture was diluted with distilled 
water (40 mL) and extracted with EtOAc (3x60 mL). The 
combined organic layers were washed with saturated brine 
( 40 mL), dried over Na2S04, and concentrated in wino. The 
crude product was purified by flash chromatography (silica, 
25 g, 0.153 mmol) and 7-azidoheptahydroxamic acid 15b (0.105 
g, 0.565 mmol) within 2.5 h, followed by prep TLC (silica, 
12:1:0.1 CH2Cl2/MeOH/conc. NH40H) gave 105 mg (67%) 
of25 as yellowish solid. 1H-NMR (CDCl3, 400 MHz) o 0.82 
(t, 1=8.0 Hz), 1.04-1.52 (m), 1.67-1.92 (m), 2.14-2.29 (m), 
30 2.52-2.60 (m), 2.82-2.90 (m), 2.95-3.00 (m), 3.10 (s), 3.16 
(s), 3.27-3.32 (m), 3.41-3.46 (m), 3.59 (d, 1=6.8 Hz), 3.69-
3.79 (m), 3.90-3.95 (m), 4.34-4.39 (m), 4.87 (d, 1=4.4 Hz), 
5.02(d,1=9.2 Hz), 7.33(d,1=6.4 Hz), 7.77(d,1=8.4 Hz); 13C 
NMR (CDCl3, 100 MHz) o 9.1, 10.5, 12.2, 15.9, 17.9, 18.5, 8:1 CH2Cl2/acetone) to give 320 mg (79%) of21 as a brown-
ish white solid. 1H-NMR (CDCl3, 400 MHz) o 0.82 (t, 1=7.6 
Hz), 1.09-1.28 (m), 1.34 (s), 1.40-1.55 (m), 1.70-1.74 (m), 
1.87-1.94 (m), 2.08-2.15 (m), 2.54-2.66 (m), 2.94-2.98 (m), 
3.05 (s), 3.25 (s), 3.31-3.42 (m), 3.48-3.56 (m), 3.66 (d, 
1=10.0 Hz), 3.82 (s), 3.90 (s), 4.35 (d, 1=7.6 Hz), 5.14 (dd, 
1=10.8, 2.0 Hz), 7.18 (d, 1=8.0 Hz), 7.42 (d, 1=8.4 Hz); 13C 40 
NMR (CDCl3, 100 MHz) o 8.4, 10.5, 12.7, 15.3, 16.3, 17.8, 
18.8, 21.4, 29.2, 35.9, 36.6, 37.5, 38.7, 44.5, 45.5, 49.6, 57.8, 
65.0, 69.7, 70.1, 70.6, 74.1, 77.9, 78.9, 83.3, 88.5, 106.5, 
35 19.8, 20.9, 21.2, 21.4, 24.7, 25.5, 27.7, 29.8, 34.7, 36.8, 37.1, 
39.1, 45.0, 45.2, 49.3, 50.0, 50.5, 57.6, 63.6, 65.6, 68.6, 69.0, 
70.7, 72.4, 74.2, 77.8, 78.3, 80.9, 95.9, 102.7, 119.5, 125.7, 
129.4, 147.5, 175.8; HMRS (ESI) calcd for [C53H37N50 15+ 
Ht 1034.6271. found 1034.6246. 
Synthesis of Descladinose-Clarithromycin-N-phe-
nyltriazolylheptahydroxamic acid (26) 
121.0, 128.4, 132.1, 139.1, 174.7; HRMS (ESI) calc for Reaction of descladinose-clarithromycin-N-phenylacety-
[C38H59N010+Ht 690.4212. found 690.4259. 45 lene 21 (0.075 g, 0.109 mmol) and 7-azidoheptahydroxamic 
Synthesis of 
Clarithromycin-N-pheny ltriazoly lhexahydroxamic 
acid (23) 
acid 15b (0.040 g, 0.233 mmol) within 4 h, followed by prep 
TLC (silica, 10:1:0.1 CH2Cl2/MeOH/conc. NH40H) gave 80 
mg (84%) of26 as a brownish white solid. 1H-NMR (CDCl3, 
400 MHz) o 0.78(t,1=7.2 Hz), 1.06-1.31(m),1.40-1.53 (m), 
Reaction of clarithromycin-N-phenylacetylene 20 (0.100 
g, 0.120 mmol) and 6-azidohexahydroxamic acid 15a (0.080 
g, 0.470 mmol) within 2.5 h, followed by prep TLC (silica, 
12:1:0.1 CH2Cl2/MeOH/cone. NH40H) gave 70 mg (58%) 
of23 as a brownish white solid. 1H-NMR (CDCl3, 400 MHz) 
50 1.71(d,1=11.6 Hz), 1.80-1.91(m),2.01-2.20 (m), 2.50-2.65 
(m), 2.91-2.97 (m), 3.16 (t, 1=6.4 Hz), 3.26-3.35 (m), 3.42-
3.54 (m), 3.64-3.71(m),3.80 (brs), 3.90 (brs), 4.30-4.34 (m), 
5.12(dd,1=11.6, 2.4 Hz), 7.27(d,1=8.0 Hz), 7.72 (d, 1=7.2 
Hz), 7.80 (s); 13C NMR (CDCl3, 100 MHz) o 8.3, 10.3, 12.5, 
55 15.2, 16.1, 17.6, 18.6, 21.1, 21.3, 24.8, 25.1, 25.5, 26.2, 27.8, 
28.5, 29.1, 29.6, 29.7, 32.3, 35.8, 36.3, 37.4, 38.6, 44.3, 45.4, 
49.5, 50.0, 51.2, 57.8, 64.2, 69.7, 69.9, 70.6, 74.1, 77.9, 78.7, 
88.0, 106.3, 119.9, 125.7, 129.3, 129.5, 138.3, 147.3, 175.1; 
HMRS (ESI) calcd for [C45H73N50 12+Ht 876.5329. found 
o 0.81 (t, 1=7.6 Hz), 1.03-1.52 (m), 1.62-1.92 (m) 2.04-2.29 
(m), 2.48-2.60 (m), 2.82-2.90 (m), 2.93-2.99 (m), 3.09 (s), 
3.19 (s), 3.28-3.33 (m), 3.42-3.46 (m), 3.60 (d, 1=7.6 Hz), 
3.70-3.80 (m), 3.90-3.98 (m), 4.37-4.40 (m), 4.87 (d, 1=4.8 
Hz), 5.03 (dd, 1=11.6, 2.4 Hz), 7.34 (d, 1=7.6 Hz), 7.77 (d, 
1=7.6 Hz), 7.82 (s); 13C NMR (CDCl3, lOOMHz) o 9.1, 10.5, 
12.2, 15.9, 17.9, 18.5, 19.7, 20.9, 21.2, 21.4, 24.3, 25.5, 29.4, 
29.6, 34.7, 36.8, 37.1, 39.0, 39.1, 45.0, 45.1, 49.3, 49.9, 50.5, 
53.3, 57.5, 63.6, 65.5, 68.5, 69.0, 70.7, 72.4, 74.2, 77.8, 78.2, 
80.9, 95.9, 102.6, 119.8, 125.6, 129.4, 147.4, 175.8; HMRS 65 
(ESI) calcd for [C52H85N50 15+Ht 1020.6114. found 
1020.6121. 
60 876.5301. 
Synthesis of 
Clarithromycin-N-Pheny ltriazoly loctahydroxamic 
acid (27) 
Reaction of clarithromycin-N-phenylacetylene 20 (0.101 
g, 0.120 mmol) and 8-azidooctahydroxamic acid 15e (0.047 
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g, 0.24 mmol) within 2.5 h, followed by prep TLC (silica, 
12:1:0.1 CH2 Cl2/MeOH/conc. NH40H) gave 92 mg (74%) 
of27 as a brownish white solid. 1 H NMR (CDC13, 400 MHz) 
o 0.81 (t, 1=7.2 Hz), 1.04-2.05 (m), 2.22 (s), 2.19-2.82 (m), 
3.00 (s), 3.08 (s), 2.91-3.80 (m), 3.95 (m), 4.38 (m), 4.88 (d, 5 
1=4.4 Hz), 5.04(dd,1=10.8, 2.0 Hz), 7.33(d,1=7.6 Hz), 7.71 
(s), 7.77 (d, 1=8.0 Hz); 13C NMR (CDC13, 400 MHz) o 8.8, 
9.4, 10.8, 12.5, 16.2, 18.2, 18.8, 20.0, 21.2, 21.5, 21.6, 25.1, 
26.0, 26.7, 28.2, 28.6, 28.9, 29.9, 30.1, 35.0, 36.9, 37.4, 39.2, 
39.4, 45.2, 45.4, 46.1, 49.6, 50.4, 50.8, 51.6, 58.1, 63.6, 65.9, lO 
68.4, 69.3, 70.9, 72.8, 74.4, 78.0, 78.5, 81.2, 96.1, 120.1, 
102.6, 126.1, 130.2, 147.4, 176.0; HRMS (ESI) calc for 
[C54H90Ns015+Hr 1048.6427. found 1048.6486. 
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45.4, 49.6, 50.5, 50.8, 51.6, 57.8, 63.8, 65.8, 68.8, 69.2, 70.9, 
72.7, 74.5, 76.8, 78.1, 78.5, 81.1, 96.1, 102.9, 119.7, 125.9, 
129.6, 129.8, 138.9, 147.6, 176.1; HRMS (ESI) calc for 
[Cs6H93N5015+Hr 1076.6740. found 1076. 6667. 
Example 2 
Synthesis of Compounds 36 and 38 in Table 3 
Synthesis of Methyl 
8-( 4-(hydroxymethyl)phenylamino )-8-oxooctanoate 
(33) 
To a mixture of 8-methoxy-8-oxooctanoic acid (0.40 g, 
Synthesis of Descladinose-Clarithromycin-N-Phe-
nyltriazolyloctahydroxamic acid (28) 
15 2.10 mmol), benzotriazole (0.28 g, 2.23 mmol) in anhydrous 
CH2Cl2 (15 mL) was added SOC12 (0.17 mL, 2.23 mmol) at 
0° C., the mixture was kept stirring at 0° C. for 2.5 hand then 
filtered. The solvent was evaporated off to give crude acid Reaction of clarithromycin-N-phenylacetylene 21 (0.10 g, 
0.144 mmol) and 8-azidooctahydroxamic acid 15c (0.049 g, 
0.246 mmol) within 2.5 h, followed by prep TLC (silica, 20 
10:1:0.1 CH2 Cl2/MeOH/conc. NH40H) gave 117 mg (90%) 
of28 as a brownish white solid. 1 H NMR (CDC13, 400 MHz) 
o 0.81 (t, 1=7.2 Hz), 1.10-2.09 (m), 2.18 (s), 2.19-2.68 (m), 
2.98-3.73 (m), 3.83 (s), 3.93 (m), 4.36 (m), 5.16(d,1=8.0 Hz), 
7.31 (d, 1=8.0 Hz), 7.77 (2H, d, 1=8.0 Hz), 7.79 (lH, s); 13C 
NMR (CDC13, 400 MHz) o 8.5, 10.6, 12.8, 15.4, 16.4, 17.9, 
18.9, 21.4, 21.6, 29.4, 36.1, 36.7, 37.7, 38.9, 44.7, 45.7, 49.8, 
58.0, 65.2, 70.0, 70.4, 70.8, 74.4, 76.8, 78.2, 79.2, 83.6, 88.8, 
106.9, 121.3, 128.7, 132.5, 139.6, 175.2; HRMS (FAB, 
thioglycerol) calc for [C46H76N50 12+Ht 890.5490. found 
890.5562. 
Synthesis of 
Clarithromycin-N-Pheny ltriazoly lnonahydroxamic 
acid (29) 
Reaction of clarithromycin-N-phenylacetylene 20 (0.100 
g, 0.120 mmol) and 9-azidononahydroxamic acid 15d (0.043 
chloride 31 which was used without further purification. 
To a solution of ( 4-aminophenyl)methanol 32 (0.31 g, 2.50 
mmol) in anhydrous pyridine (8 mL) was added chlorotrim-
ethylsilane (0.32 mL, 2.50 mmol) at room temperature and 
stirring continued for 2 h. The mixture, together with a cata-
lytic amount of DMAP, was added to a mixture of crude 
25 chloride 31 (obtained as described above) in pyridine at 0° C. 
The reaction was allowed to warm to room temperature and 
stirring continued overnight. Water ( 5 mL) and I M TBAF in 
tetrahydrofuran (THF) (0.25 mL, 0.25 mmol) were added and 
stirring continued for additional 30 min. EtOAc (50 mL) and 
30 IN HCl (30 mL) were added, the two layers were separated, 
the organic layer was washed with IN HCl (30 mL) and 
saturated brine (30 mL) and dried over Na2S04. Solvent was 
evaporated off and the crude was purified by preparative TLC, 
eluting with acetone/hexanes I: I to give compound 33 (195 
35 mg, 30%) as yellow-white solid. 1H-NMR (CDC13, 400 
MHz) o 1.24 ( 4H, m), 1.49-1.59 ( 4H, m), 2.17-2.25 ( 4H, m), 
3.58 (3H, s), 4.50 (2H, s), 7.13 (2H, d, 1=8.4 Hz), 7.37 (2H, d, 
1=8.4 Hz). 
g, 0.20 mmol) within 2.5 h, followed by prep TLC (silica, 
12:1:0.1 CH2 Cl2/MeOH/conc. NH40H) gave 54 mg (42%) 40 
of 29 as a brownish white solid. 1 H NMR (CDC13, 400 MHz) 
Synthesis of Azithromycin-arylalkyl methyl ester 
(35) 
o 0.81 (t, 1=7.2 Hz), 1.04-2.02 (m), 2.24 (s), 2.10-2.97 (m), 
3.00 (s), 3.09 (s), 3.20-3.82 (m), 3.88 (m), 4.39 (m), 4.88 (d, 
1=4.0 Hz), 5.05 (d, 1=10.0 Hz), 7.35 (d, 1=8.0 Hz), 7.77 (d, 
1=4.0 Hz); 13C NMR (CDC13, 400 MHz) o 9.0, 9.3, 10.8, 45 
12.5, 16.1, 18.2, 18.8, 21.2, 21.5, 21.6, 21.7, 21.8, 26.3, 26.8, 
28.7, 28.9, 29.1, 29.9, 30.3, 35.0, 37.0, 37.4, 39.3, 39.4, 45.2, 
45.4, 49.6, 50.5, 50.8, 51.6, 57.8, 63.8, 65.8, 68.8, 69.2, 70.9, 
72.7, 74.5, 76.8, 78.1, 78.4, 78.5, 81.1, 96.1, 102.9, 119.7, 
125.9, 129.6, 129.9, 138.7, 147.6, 176.1; HRMS (ESI) calc 50 
for [C55H91N50 15+Ht 1062.6584. found 1062.6586. 
Synthesis of 
Clarithromycin-N-Pheny ltriazoly ldecahydroxamic 
acid (30) 55 
To a solution of crude preparation of compound 33 (0.64 g, 
2.20 mmol) in CH2 Cl2 (15 mL) and triethylamine (Et3N) 
(0.90 mL, 6.60 mmol) was added mesyl chloride (0.70 mL, 
8.85 mmol) at 0° C. and the reaction was allowed to warm to 
room temperature. Stirring continued for 2 h, CH2Cl2 ( 40 
mL) and saturated sodium bicarbonate (30 mL) were added. 
The two layers were separated; the organic layer was washed 
with sodium bicarbonate (I x30 mL ), saturated brine (30 mL) 
and dried over Na2S04. Solvent was evaporated off and the 
crude was purified by flash chromatography (silica gel, elut-
ing with Hexane/EtOAc, gradient 3:1, 2: I, 1: I) to give com-
pound 34 (320 mg, 40%) as white solid. 
A mixture of 4'-Desmethylazithromycin I (0.45 g, 0.62 
mmol), compound 34 (0.32 g, 0.86 mmol), catalytic amount 
of potassium iodide in THF (15 mL) andHunig's base (3 mL) 
was heated under refluxing condition for 48 h. CH2 Cl2 (80 
mL) and saturated sodium bicarbonate (40 mL) were added 
Reaction of clarithromycin-N-phenylacetylene 20 (0.10 g, 
0.120mmol) and 10-azidodecahydroxamic acid 15e (0.045 g, 
0.197 mmol) within 2.5 h, followed by prep TLC (silica, 
12:1:0.1 CH2 Cl2/MeOH/conc. NH40H) gave 68 mg (53%) 
of30 as a brownish white solid. 1 H NMR (CDC13, 400 MHz) 
o 0.82 (t, 1=7.2 Hz), 1.05-2.12 (m), 2.24 (s), 2.26-2.97 (m), 
3.01, 3.10 (s), 3.19-3.80 (m), 3.95 (m), 4.39 (m), 4.89 (d, 
1=4.0 Hz), 5.04 (d, 1=8.0 Hz), 7.35 (d, 1=8.0 Hz), 7.76 (s), 
7.79 (d, 1=8.0 Hz); 13C NMR (CDC13, 400 MHz) o 9.3, 10.8, 
12.5, 16.1, 18.2, 18.8, 20.0, 21.2, 21.5, 21.7, 25.4, 26.2, 28.9, 
29.0, 29.3, 29.6, 29.9, 30.2, 35.0, 37.0, 37.4, 39.3, 39.4, 45.2, 
60 and the two layers were separated. The organic layer was 
washed with sodium bicarbonate ( 40 mL ), saturated brine ( 40 
mL) and dried over Na2 S04. Solvent was evaporated off and 
the crude was purified by preparative TLC, eluting with 
Et0Ac/hexanes/Et3N 3:2:0.1 to give compound 35 (176 mg, 
65 28%) as brown-white solid. 1H-NMR (CDC13, 400 MHz) o 
0.79-0.83 (m), 0.94-1.01 (m), 1.09-1.20 (m), 1.22-1.32 (m), 
1.37-1.59 (m), 1.62-1.73 (m), 1.77-2.01 (m), 2.08-2.28 (m), 
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2.38-2.52 (m), 2.61-2.71 (m), 2.91-3.01 (m), 3.11 (s), 3.25-
3.33 (m), 3.42 (m), 3.54-3.65 (m), 3.97 (m), 4.18 (m), 4.36 (d, 
1=6.8 Hz), 4.61 (m), 5.03 (d, 1=4.4 Hz), 7.14 (d, 1=8.4 Hz), 
7.42(d,1=8.4 Hz), 7.73 (s), 8.97 (bs); 13C-NMR (CDC13, 100 
MHz) o 7.5, 9.1, 11.3, 14.8, 16.2, 16.9, 18.2, 20.5, 21.2, 21.4, 5 
21.5, 21.9, 24.6, 25.3, 26.7, 27.5, 28.7, 29.6, 33.9, 34.7, 36.2, 
36.7, 37.3, 39.1, 41.9, 42.2, 45.1, 48.5, 49.3, 51.4, 57.3, 62.2, 
64.3, 65.4, 68.5, 69.9, 70.5, 72.7, 73.5, 73.8, 74.1, 77.7, 77.9, 
83.4, 94.4, 102.6, 119.5, 129.0, 134.2, 137.0, 171.0, 173.8, 
178.4. MS (FAB, mnba) 1010.3 (M+Ht. 10 
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Example 3 
Synthesis of Compounds 40, 44 and 47 in Table 3 
Synthesis of 
Azithromycin-N-pheny ltriazolylhepta-2-methy 1 
ketone (40) 
Compound 3 (0.040 g, 0.047 mmol) and azido-2-methyl 
ketone39 (0.011g,0.071 mmol)weredissolvedinanhydrous 
THF (7 mL) and stirred under argon at room temperature. 
Copper (I) iodide (0.010 g, 0.053 mmol) and Hunigs' base 
(0.1 mL) were then added to reaction mixture and stirring Synthesis of Azithromycin-arylalkyl hydroxamic 
acid (36) 
15 continued for 2 h. The reaction mixture was diluted with 
CH2Cl2 (40 mL) and washed with 1:4 NH4 0H/saturated 
NH4 Cl (3 x30 mL) and saturated NH4 Cl (30 mL). The organic 
layer was dried over Na2S04 and concentrated in vacua. The 
crude product was purified by preparative TLC (12: 1 CH2 Cl2 : 
To a solution of compound 35 (0.09 g, 0.09 mmol) in 1: 1 
THF/MeOH (3 mL)was addedhydroxylamine (50% inH20) 
(0.03 mL, 0.54 mmol) and a catalytic amount of KCN. The 
mixture was stirred at room temperature for 24 h. The reaction 
was partitioned between 5% MeOH in CH2Cl2 (30 mL) and 
saturated sodium bicarbonate (25 mL), the two layers were 
separated and the aqueous layer was extracted with 5% 
MeOH in CH2Cl2 (2x20 mL). The combined organic layer 
was washed with saturated brine ( 40 mL) and dried over 
Na2S04 . Solvent was evaporated off and the crude was puri-
fied by preparative TLC, eluting with CH2 Cl2/MeOH/ 
NH4 0H 10:1:0.1 to give compound 36 (22 mg, 25%) as 
brown-white solid. 1H-NMR (CD30D, 400 MHz) o 0.87-
0.92 (m), 1.02-1.12 (m), 1.17-1.37 (m), 1.43-1.69 (m), 1.75- 30 
1.88 (m), 1.99 (m). 2.08 (m), 2.13-2.19 (m), 2.24 (s), 2.30 (s), 
2.33-2.41 (m), 2.54 (d, 1=11.2 Hz), 2.75-2.80 (m), 3.00 (d, 
1=9.6 Hz), 3.19 (bs), 3.47-3.51(m),3.60 (bs), 3.63-3.78 (m), 
4.14-4.22 (m), 4.50(d,1=7.2 Hz), 5.02(d,1=4.8 Hz), 7.29 (d, 
1=8.0 Hz), 7.49 (d, 1=8.4 Hz). MS (FAB, mnba) 1011.3 35 
(M+Ht. 
Synthesis of Desclasinose-azithromycin-arylalkyl 
hydroxamic acid (38) 
20 MeOH) to give 38 mg (81%)of40 as a white solid. 1 H NMR 
(CDC13, 400 MHz) o 0.86-0.89 (t, 1=7.2 Hz), 0.92-0.98 (m), 
1.01-1.02 (d, 1=7.2 Hz), 1.086 (s), 1.12-1.24 (m), 1.29-1.34 
(m), 1.42-1.66 (m), 1.74-1.78 (d, 1=16 Hz), 1.84-2.08 (m), 
2.11 (s), 2.15 (m), 2.26-2.48 (m), 2.56-2.74 (m), 2.84 (s), 
25 2.74-3.08 (m), 3.11 (s), 3.32-3.40 (m), 3.46-3.84 (m), 3.98-
4.46 (m), 4.23 (broad singlet), 4.38-4.51 (m), 4.72 (broad 
singlet), 5.06-5.12 (m), 7.31-7.38 (m), 7.75 (s), 7.77-7.79 (d, 
1=8 Hz); HRMS (ESI) calc for [C53H89N50 13+Ht 
1004.6529. found 1004.6482. 
Synthesis of Azidobenzamide ( 43) 
A solution of azido acid 41 (0.150 g, 0.877 mmol) in dry 
THF (10 mL) was treated with 1,2-diaminobenzene 42 (0.568 
g, 5.26 mmol) and EDC (0.219 g, 1.14 mmol). The resulting 
mixture was stirred at room temperature for about 24 h and 
then concentrated in vacua. The crude was diluted with 
EtOAc (40 mL), washed in succession with water (30 mL) 
40 and brine (30 mL) and the organic layer was dried over 
Na2S04 . Solvent was evaporated off and the crude was puri-
fied by flash chromatography (silica, Hexanes/EtOAc 1:2) to 
give 79 mg (35%) of 43 as a yellow solid. 1 H NMR (CDC13, 
400 MHz) o 1.34-1.68 (m), 2.27-2.31(m),3.84 (s), 6.72-6.75 
A mixture of compound 35 (0.05 g, 0.05 mmol) in 0.25 N 
HCl (15 mL) was stirred at room temperature for 20 hand 
poured into EtOAc (20 mL). The two layers were separated 
and the aqueous layer was washed with EtOAc (2x20 mL), 
basified with concentrated NH4 0H and then extracted with 
5% MeOH in CH2Cl2 (2x30 mL). The combined organic 
layer was washed with saturated brine (30 mL) and dried over 
Na2S04 . Solvent was evaporated off to give compound 37 
which was used for the next reaction without further purifi- 50 
45 (m), 7.00-7.05 (m), 7.09-7.11(d,1=8 Hz); HRMS (ESI) calcd 
for [C13H19N50+Hr 262.1662. found 262.1635. 
Synthesis of 
Azithromycin-N-phenyltriazoly lheptabenzamide 
(44) 
cation. 
To a solution of compound 37 (obtained as described 
above) in 1:1 THF/MeOH (2 mL) was addedhydroxylamine 
(50% in H20) (0.05 mL, 0.79 mmol) and a catalytic amount 
ofKCN. The mixture was stirred at room temperature for 24 
h. The reaction was partitioned between 5% MeOH in 
CH2 Cl2 (30 mL) and saturated brine (20 mL), the two layers 
were separated and the organic layer was dried over Na2 S04 . 
Solvent was evaporated off and the crude was purified by 
preparative TLC, eluting with CH2 Cl2/MeOH/NH40H 9:1: 
0.1 to give compound 38 (7 mg, 16%) as brown-white solid. 
1H-NMR (CD30D, 400 MHz) o 0.78 (m), 0.85(d,1=7.2 Hz), 
0.91(d,1=8.0 Hz), 0.99 (s), 1.11(m),1.26-1.76 (m), 1.98 (t, 
1=7.4 Hz), 2.08 (m), 2.17 (s), 2.25 (t, 1=7.4 Hz), 2.40 (bs), 
2.58 (m), 2.95 (bs), 3.24 (m), 3.37-3.56 (m), 3.67 (d, 1=13.2 
Hz), 4.53(d,1=7.6 Hz), 7.19(d,1=8.4 Hz), 7.39(d,1=8.4 Hz). 
MS (FAB, mnba) 853.3 (M+Ht. 
Compound 3 (0.050 g, 0.059 mmol) and azido benzamide 
43 (0.023 g, 0.088 mmol) were dissolved in anhydrous THF 
(10 mL) and stirred under argon at room temperature. Copper 
55 (I) iodide (0.010 g, 0.0526 mmol) and Hunigs' base (0.1 mL) 
were then added to reaction mixture and stirring continued for 
2 h. The reaction mixture was diluted with CH2 Cl2 ( 40 mL ), 
washed with 1:4 NH40H/saturated NH4 Cl (3x30 mL) and 
saturated NH4 Cl (30 mL). The organic layer was dried over 
60 Na2S04 and concentrated in vacuo. The crude product is 
purified by prep TLC (12:1 CH2 Cl2/MeOH) to give 38 mg 
(59%) of 44 as a white solid. 1H NMR (CDC13, 400 MHz) o 
0.80-1.57 (m), 1.70-1.75 (m), 1.85-1.91 (m), 2.01-2.07 (m), 
2.13 (s), 2.22-2.26 (m), 2.36-2.41(m),2.58 (br s), 2.68 (br s), 
65 2.75-3.07 (m), 3.25-3.62 (m), 3.69 (s), 3.81 (br s), 3.98 (br s), 
4.17 (s), 4.32-4.48 (m), 4.72 (br s) 5.05 (s), 6.70-6.76 (m), 
6.92-7.02 (m), 7.18-7.21(d,1=12 Hz), 7.32 (br s), 7.71-7.73 
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(d, 1=8 Hz), 7.78 (s). 7.87 (br s); HRMS (ESI) calcd for 
[C59H95N7013+Hr 11 I0.7060. found I I I0.70I2. 
Synthesis of Descladinose-clarithromycin-N-pheny-
lacetylene-0-Acetate ( 45) 
Descladinose-clarithromycin-N-pheny lacety lene 2 I (3 .80 
g, 5.5 mmol) was dissolved in acetone (20 ml) followed by 
addition of acetic anhydride (0.62 g, 6.0 mmol) and stirred at 
40° C. for 36 h. The reaction mixture was diluted with EtOAc 
(I 00 mL ), washed with aqueous NaHC03 and brine, and then 
purified on silica colunm eluting with 6: I CH2Cli Acetone to 
obtain 2.8 g (70%) of 45 as a brownish white solid. 1 H NMR 
(CDC13 , 400 MHz) ll 0.80 (t, 1=7.2 Hz), 0.90 (d, 1=7.2 Hz), 
1.08-I.47 (m), 1.58 (s), 1.63-2.05 (m), 2.08 (s), 2.I6 (s), 
2.42-2.80 (m), 2.92 (s), 2.94-3.00 (m), 3.03-3.68 (m), 3.79 
(s), 3.94 (s), 4.08 (m), 4.54 (d, 1=8.0 Hz), 4.80 (m), 5.I5 (dd, 
l=I l.6, 2.4 Hz), 7 .I 7 ( d, 1=8.4 Hz), 7 .38 ( d, 1=8.0 Hz). 
Synthesis of clarithromycin-N-pheny lacety lene 
ketolide ( 46) 
Methyl sulfide (0.35 g, 5.7 mmol), was added to a mixture 
ofN-chlorosuccinimide (0.65 g, 4.8 mmol) and CH2 Cl2 (3 
mL) while maintaining the temperature at - I 5° C. Compound 
45 (2.5 g, 3.4 mmol) dissolved in CH2Cl2 (20 mL) was added 
138 
4'-Desmethylclarithromycin (2) 
To a solution of clarithromycin I (50.0 g, 68. I mmol) and 
sodium acetate (50.3 g, 6I .3 mmol) in 80% aqueous methanol 
5 (350 mL) at 75-80° C. was added iodine (I9.0 g, 74.8 mmol) 
in three batches within 5 min. The reaction was maintained at 
pH 8-9 by additions of IM NaOH (2x50 ml, once at IO min 
and 45 min of reaction time). Stirring was continued at 80° C. 
for 4.5 h. A solution of 5% sodium thiosulfate (300 mL) and 
10 dichloromethane (250 mL) were added and the two layers 
were separated. The aqueous layer was extracted with 
CH2Cl2 (I 50 mL ), the combined organic layers were washed 
with saturated brine, dried over Na2S04 , and concentrated in 
vacuo to give 44.0 g of 2, which was used without further 
15 purification. 
4-Ethyny lbenzy 1 methanesulfonate (3) 
To a solution of 4-ethynylbenzyl alcohol (5.0 g, 37.8 
20 mmol) in CH2Cl2 (50 mL) and triethylamine (Et3N) (I4.4 
mL, I 04.0 mmol) was added mesyl chloride (8.04 mL, I 04.0 
mmol) at 0° C. and the reaction was allowed to warm to room 
temperature. Stirring continued for 2 h under argon during 
which TLC revealed a quantitative conversion into a higher 
25 Rf product. Ice cold water was added into the reaction mixture 
and extracted with Et2 0 (200 ml). The organic layer was 
washed with IN HCL (70 ml), H2 0 (100 ml), aqueous 
NaHC03 (70 ml), and finally H20 (100 ml); and then dried 
over Na2S04 . Solvent was evaporated off and dried in vacuo 
to the reaction mixture, followed by triethylamine (0.39 g, 3.8 
mmol). The mixture was stirred at -I5° C. for 3.5 hand 
partitioned between EtOAc (100 mL) and 0.5 N aqueous 
NaOH (I50 mL). The organic layer was separated, washed 
with brine (70 mL), and dried over Na2S04 . Solvent was 
evaporated off and the crude was purified on silica column 
eluting with 1:4:0.I Et0Ac/Hexane/Et3 N, increasing solvent 
polarity to 2:3:0.I, to afford 2.0 g (80%) of 46 as off-white 
solid. 1 H NMR (CDC13 , 400 MHz) ll 0.80-0.86 (m), I .09-I .57 35 
(m), 1.58 (s), 1.62-2.02 (m), 2.05 (s), 2.I5 (s), 2.44-2.80 (m), 
2.92 (s), 2.95-3.00 (m), 3.05-3.82 (m), 4.I2 (m), 4.38 (d, 
1=8.0 Hz), 4.79-4.83 (m), 5.I4 (dd, l=I 1.2, 2.0 Hz), 7.I6 (d, 
1=7.6 Hz), 7.38 (d, 1=7.6 Hz). 
30 to give 7.0 g of compound 3 as brownish oil which was used 
without further purification. 
4'-Ethynylbenzylclarithromycin ( 4) 
To a solution of 4'-desmethylclarithromycin 2 (2.4 g, 3.34 
mmol) in anhydrous DMSO (4 ml), was added Hunig's base 
(3 ml), and 4-ethynylbenzyl methanesulfonate 2 (0.92 g, 4.34 
mmol). The reaction mixture was heated at 85° C. for 2.5 h. 
The reaction was cooled and diluted with EtOAc (30 ml), then 
Synthesis of 
Ketolide-N-phenyltriazolylheptabenzamide ( 47) 
Ketolide 46 (0.050 g, 0.069 mmol) andazido benzamide 43 
(0.027 g, O.I03 mmol) were dissolved in anhydrous THF (IO 
mL) and stirred under argon at room temperature. Copper (I) 
iodide (0.010 g, 0.0526 mmol) and Hunigs' base (O.I mL) 
were then added to reaction mixture and stirring continued for 
2 h. The reaction mixture was diluted with CH2Cl2 ( 40 mL) 
and washed with I:4 NH4 0H/saturated NH4 Cl (3x30 mL) 
and saturated NH4 Cl (30 mL). The organic layer was dried 
over Na2S04 and concentrated in vacuo. The crude was puri-
fied by prep TLC (3 :2 CH2Cli Acetone) to give 5 I mg (7 5%) 
of 47 as a white solid. 1H NMR (CDC13 , 400 MHz) ll 0.78-
0.88 (m), 1.18-1.25 (m), 1.3I-1.70 (m), 1.87-2.00 (m), 2.I4 
(s), 2.28-2.35 (m), 2.42-2.5I (m), 2.62-2.75 (m), 3.I2 (s), 
3.3I-3.35 (t, 1=8 Hz), 3.42 (s), 3.47 (br s), 3.62-3.82 (m), 
4.32-4.40 (m), 5.05-5.09 (d, l=I6 Hz), 5.44 (s), 5.77 (s), 
6.64-6.74 (m), 6.95-7.00 (m), 7.I0-7.I5 (m), 7.I8-7.2I (m), 
7.27-7.3I (m), 7.60 (s) 7.72-7.74 (d, 1=8 Hz), 7.77 (s). 
Example 4 
Synthesis of Compounds 56a-e 
The procedure for the synthesis of compounds 56a-e as 
shown in Scheme I 6 is described below. 
40 washed with saturated NaHC03 (3xIO ml) and saturated 
brine (IO ml). The organic layer was dried over Na2 S04 and 
the solvent evaporated. The crude product was purified on 
silica colunm using I2:I CH2 Cl2/C2 H6CO gradually increas-
ing the solvent polarity to I 0: I and 8: I to afford 1.8 g (63%) 
45 of the title compound. 
1H-NMR (CDC13 , 400 MHz) ll 0.82 (3H, t, 1=7.2 Hz), 
1.03-1.28 (I8H, m), 1.37 (3H, s), I.40-1.55 (3H, m), 1.65-
I.90 (6H, m), 2.03 (lH, d, l=IO.O Hz), 2.22 (3H, s), 2.30 (lH, 
d, l=I5.2 Hz), 2.40-2.60 (2H, m), 2.80-2.90 (2H, m), 294-
50 3.00 (6H, m), 3.04 (lH, s), 3.09 (3H, s), 3.I6 (lH, s), 3.24-
3.29 (lH, m), 3.38-3.46 (3H, m), 3.59 (lH, d, 1=6.8 Hz), 
3.70-3.75 (3H, m), 3.88-3.95 (lH, m), 4.37 (lH, d, 1=7.2 Hz), 
4.88 (lH, d, 1=4.4 Hz), 5.02 (lH, dd, l=I 1.6, 2.4 Hz), 7.23 
(2H,d,l=I2.0Hz), 7.42(2H,d,1=8.0Hz); 13CNMR(CDC13 , 
55 IOO MHz) ll 9.2, I0.7, I2.4, I6.I, I8.I, I8.7, I9.9, 21.1, 21.5, 
29.3, 32.4, 34.8, 36.9, 37.2, 39.2, 45.0, 45.2, 49.3, 50.6, 53.4, 
57.6, 63.3, 65.6, 68.5, 69.0, 70.6, 72.5, 74.2, 76.5, 77.8, 78.I, 
78.2, 80.8, 95.8, I02.5, I20.9, I28.6, I32.0, I33.5, I39.4, 
I75.4; HRMS (ESI) talc for [C46H73N013+H]+ 848.5I55. 
60 found 848.5I8I 
Descladinose-4'-Ethynylbenzylclarithromycin (5) 
A solution of 4'-Ethynylbenzylclarithromycin 4 (27.3 g, 
65 31.2 mmol) in EtOH (200 ml) and IN HCL (200 ml) was 
stirred at room temperature for I 7 h after which TLC analysis 
indicated the absence of starting material. The reaction mix-
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ture was basified with NH40H to about pH 9, added H20 
(250 ml) and EtOAc (350 ml) and separated the two layers. 
The aqueous layer was washed with EtOAc (250 ml) and the 
two organic layers combined and washed with saturated 
brine, then dried over Na2S04 . The crude product was puri- 5 
fied on silica column using gradient elution (12:1, 10:1 and 
8:1 CH2Cl/2/C2 H6CO) to isolate 77% (17.1 g) of 5 as off-
77.1, 77.2, 78.1, 83.9, 101.1, 120.7, 128.5, 132.2, 140.9, 
169.6, 170.0, 205.7, 221.1; HRMS (FAB, nmba) talc for 
[C40H59N01 l+H]+ 730.41664. found 730.41321 
Carbamate Ketolide (8) 
white foam. To a suspension of 7 (1.5 g, 2.06 mmol) in a mixture of 
anhydrous THF (20 ml) and anhydrous DMF (7 ml), was 
added CDI (1.3 g, 8.20 mmol) followed by a solution of 
NaN(TMS)2 1.0 Min THF (2.6 ml, 2.6 mmol) over 75 min 
and stirred at RT for 24 h. The reaction mixture was diluted 
with EtOAc (50 ml), washed with aqueous NaHC03 (20 ml) 
1H-NMR (CDCl3, 400 MHz) ll 0.82 (3H, t, 1=7.6 Hz), 
1.09-1.28 (12H, m), 1.34 (3H, s), 1.40-1.55 (3H, m), 1.70- 10 
1.74 (2H, m), 1.87-1.94 (3H, m), 2.08-2.15 (6H, m), 2.54-
2.66 (2H, m), 2.94-2.98 (3H, m), 3.05 (lH, s), 3.25 (lH, s), 
3.31-3.42 (2H, m), 3.48-3.56 (2H, m), 3.66 (2H, d, 1=10.0 
Hz), 3.82 (lH, s), 3.90 (lH, s), 4.35 (lH, d, 1=7.6 Hz), 5.14 
(lH, dd, 1=10.8, 2.0 Hz), 7.18 (2H, d, 1=8.0 Hz), 7.42 (2H, d, 15 and saturated brine (20 ml) and dried over Na2 S04 . The 
1=8.4 Hz); 13C NMR (CDCl3, 100 MHz) ll 8.4, 10.5, 12.7, 
15.3, 16.3, 17 .8, 18.8, 21.4, 29.2, 35.9, 36.6, 37 .5, 38.7, 44.5, 
45.5, 49.6, 57.8, 65.0, 69.7, 70.1, 70.6, 74.1, 77.9, 78.9, 83.3, 
88.5, 106.5, 121.0, 128.4, 132.1, 139.1, 174.7; HRMS (ESI) 
calc for [C38H59N010+H]+ 690.4212. found 690.4259 
Synthesis of compound (6) (Acetylation) 
To a solution of descladinose-4'-ethynylbenzylclarithro-
mycin 5 (3.8 g, 5.5 mmol) in acetone (20 ml), Ac20 (0.62 g, 
6.0 mmol) was added and stirred at 40° C. for 36 h. The 
reaction mixture was diluted with EtOAc (100 ml) and 
washed with aqueous NaHC03 (70 ml) and saturated brine 
(70 ml). Purification on silica colunm (6:1 CH2Cliacetone) 
afforded 2.8 g (70%) of the title compound as a yellowish 
solid. 
solvent was evaporated and purified on silica colunm (3 :2:0.1 
Et0Ac/Hexane/Et3N) to yield 42% (0.7 g) of the title com-
pound. NMR (CDCl3, 400 MHz) ll 0.91 (3H, t, 7.6 Hz), 1.09 
20 
(3H, d, 1=7.2 Hz), 1.14-1.50 (9H, m), 1.80 (3H, s), 1.83 (3H, 
s), 1.56-1.94 (7H, m), 2.00 (3H, s), 2.05 (3H, s), 2.12 (3H, s), 
2.64-2.80 (lH, m), 3.02 (3H, s), 2.95-3.70 (4H, m), 3.73 (lH, 
q, 1=14.0, 6.8 Hz), 4.10-4.06 (2H, m), 4.30 (lH, d, 1=7.6 Hz), 
4.77-4.80 (lH, m), 5.68 (lH, dd, 1=11.2, 2.0 Hz), 6.77 (lH, s), 
25 7.03 (lH, s), 7.16 (2H, d, 1=7.6 Hz), 7.36 (3H, m), 8.06 (lH, 
s); 13C NMR (CDCl3, 100 MHz) ll 10.7, 13.5, 14.4, 15.2, 
19.1, 20.4, 21.1, 21.2, 21.5, 22.8, 31.2, 36.8, 47.6, 50.5, 51.2, 
58.5, 60.6, 62.8, 69.3, 71.6, 78.7, 83.9, 84.7, 117.3, 120.7, 
30 128.4, 131.1, 132.2, 137.3, 138.8, 140.9, 146.2, 169.1, 169.8; 
HRMS (FAB, nmba) calc for [C44H59N30ll+H]+ 
806.42279. found 806.42103 1 H NMR (CDCl3, 400 MHz) ll 0.80 (3H, t, 1=7 .2 Hz), 0.90 
(3H, d, 1=7.2 Hz), 1.08-1.47 (12H, m), 1.58 (6H, s), 1.63-2.05 
(7H, m), 2.08 (3H, s), 2.16 (3H, s), 2.42-2.80 (3H, m), 2.92 
(3H, s), 2.94-3.00 (lH, m), 3.03-3.68 (3H, m), 3.79 (2H, s), 35 
3.94 (lH, s), 4.08 (lH, m), 4.54 (lH, d, 1=8.0 Hz), 4.80 (lH, 
m), 5.15 (lH, dd, 1=11.6, 2.4 Hz), 7.17 (2H, d, 1=8.4 Hz), 7.38 
(2H, d, 1=8.0 Hz); 13C NMR (CDCl3, 100 MHz) ll 8.0, 10.7, 
12.8, 15.5, 16.4, 18.1, 19.5, 21.3, 21.5, 21.6, 31.1, 31.9, 36.0, 
37.0, 37.5, 38.7, 44.3, 45.7, 50.0, 58.4, 62.5, 68.9, 69.8, 71.6, 40 
74.4, 76.9, 77.0, 77.8, 78.1, 81.3, 83.9, 99.9, 120.7, 128.4, 
132.2, 141.1, 170.1, 174.9, 221.2; HRMS (FAB, nmba) calc 
for [C40H61N011+H]+ 732.43229. found 732.43105 
Tricyclic Ketolide (9) 
To a solutionof8 (0.6 g, 0.74mmol)inCH3CN (!Om!) and 
H2 0 (1 ml), was added ethylenediamine (0.44 g, 7.40 mmol) 
and heated in a sealed tube at 50-55° C. for 24 h. The solvent 
was evaporated off and the reaction mixture partitioned 
between H2 0 (15 ml) and CH2 Cl2 (20 ml) and separated. The 
organic layer was washed with saturated brine (20 ml), dried 
over Na2S04 , and the solvent evaporated. The crude product 
Synthesis of Compound (7) (Oxidation) 
Methyl sulfide (1.42 g, 22.8 mmol), was added to a mixture 
ofN-chlorosuccinimide (2.61g,19.5 mmol) andCH2 Cl2 (10 
ml) while maintaining the temperature at -15° C. Compound 
6 (10.0 g, 13.7 mmol) dissolvedinCH2 Cl2 (50ml)was added 
to the reaction flask, followed by Et3N (1.56 g, 15.4 mmol) 
and stirred at -15° C. for 4.5 h. The reaction mixture was 
poured into EtOAc (350 ml) and 0.5 N aqueous NaOH (250 
ml). The organic layer was separated and washed with satu-
rated brine (250 ml), dried over Na2S04 , evaporated solvent 
and purified on silica colunm (2:3:0.1 Et0Ac/Hexane/Et3N) 
to afford 9.54 g (96%) of the title compound as off-white 
solid. 
1H NMR (CDCl3, 400 MHz) ll 0.80-0.86 (6H, m), 1.09-
1.57 (12H, m), 1.58 (6H, s), 1.62-2.02 (7H, m), 2.05 (3H, s), 
2.15 (3H, s), 2.44-2.80 (2H, m), 2.92 (3H, s), 2.95-3.00 (lH, 
m), 3.05-3.66 (4H, m), 3.80 (lH, q, 1=14.0, 6.8 Hz), 3.89 (lH, 
s), 4.12 (lH, m), 4.38 (lH, d, 1=8.0 Hz), 4.79-4.83 (lH, m), 
5.14 (lH, dd, 1=11.2, 2.0 Hz), 7.16 (2H, d, 1=7.6 Hz), 7.38 
(2H, d, 1=7.6 Hz); 13C NMR (CDCl3, 100 MHz) ll 10.8, 12.4, 
14.4, 14.5, 16.5, 17.9, 19.6, 21.3, 21.5, 31.3, 36.9, 37.6, 39.2, 
45.1, 46.3, 49.7, 51.1, 58.5, 62.5, 69.2, 69.6, 71.5, 74.1, 77.0, 
45 was dissolved in anhydrous MeOH (15 ml) andheated at 90° 
C. in a sealed tube for 24 h. MeOH was evaporated and the 
product purified on silica colunm (Et0Ac/Et3N 12:0.1). 
EtOH (6 ml) followed by AcOH (0.043 g, 0.71 mmol) were 
added to the pure product (0.27 g, 0.34 mmol) and heated at 
50 95° C. in a sealed tube for 20 h. The reaction mixture was 
suspended in dilute NH4 0H (10 ml) and CH2Cl2 (15 ml) and 
separated the organic layer, washed with saturated brine (10 
ml), and dried over Na2S04 . Purification on silica column 
(EtOAc/MeOH/Et3N 10:0.5:0.05) afforded 0.24 g (57%) of 
55 compound 9. 
1HNMR (CDCl3, 400MHz) ll0.80 (3H, t, 1=7.2 Hz), 1.00 
(3H, d, 1=6.8 Hz), 1.14-1.55 (12H, m), 1.30 (3H, s), 1.43 (3H, 
s), 1.60-1.96 (6H, m), 2.12 (3H, s), 2.45-2.95 (6H, m), 3.03 
(3H, s) 3.23-3.43 (4H, m), 3.64-3.78 (4H, m), 3.94 (lH, m), 
60 4.16 (lH, d, 1=8.4 Hz), 4.25 (lH, d, 1=7.6 Hz), 4.90 (lH, d, 
1=10.0 Hz), 7.18 (2H, d, 1=8.0 Hz), 7.39 (2H, d, 1=7.2 Hz); 
13C NMR (CDCl3, 100 MHz) ll 10.6, 11.1, 13.0, 14.6, 16.6, 
19.3, 19.8, 21.4, 22.3, 29.7, 36.5, 37.1, 38.7, 42.5, 43.0, 48.3, 
49.3, 49.7, 51.4, 57.6, 60.1, 65.6, 69.7, 70.5, 76.7, 78.7, 79.4, 
65 81.7, 83.6, 104.0, 121.0, 128.8, 132.4, 140.0, 156.3, 169.8, 
181.5, 204.4; HRMS (FAB, nmba) talc for [C41H59N309+ 
H]+ 738.43296. found 738.43318 
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Azidoalkyl-0-trityl Hydroxamate Derivatives 
(lOa-e) 
Method A 
Tricyclic Ketolide-N-benzy ltriazolylhexa-N-Otrityl 
(1 la) 
142 
2.73 (6H, m), 2.87-2.97 (lH, m), 3.03-3.10 (lH, m), 3.28-
3.S7 (3H, m), 3.70-3.82 (SH, m), 3.93-3.97 (lH, m), 4.21 (lH, 
d, 1=8.4 Hz), 4.27-4.34 (3H, m), 4.94 (lH, dd, 1=12.8, 2.4 
Hz), 7.2S-7.42 (17H, m), 7.71 (lH, s), 7.76 (2H, d, 1=8.0 Hz); 
5 13C NMR (CDCl3, 100 MHz) ll 10.7, 11.1, 13.1, 14.6, 16.6, 
19.3, 19.9, 21.4, 22.3, 26.4, 28.8, 29.6, 30.4, 36.6, 37.0, 38.8, 
42.S, 42.9, 48.3, 49.3, 49.7, S0.6, Sl.4, S3.7, S7.7, 60.1, 6S.S, 
69.8, 70.S, 76.7, 78.7, 79.4, 81.8, 93.8, 104.1, 119.6, 126.0, 
127.7, 128.3, 128.8, 129.2, 129.4, 130.0, 132.7, 138.9, 141.3, General Procedure: 4'-Ethynylbenzyl tricyclic ketolide 9 
(O.lOS g, 0.142 mmol) and 6-azidohexa-o-trityl hydroxamic 
acid lOa (O.OS8 g, 0.142 mmol) were dissolved in anhydrous 
THF (7 mL) and stirred under argon at room temperature. 
Copper (I) iodide (0.012 g, 0.063 mmol) and Hunig's base 
(0.6 mL) were added to the reaction mixture, and stirring 
continued for 24 h. The reaction mixture was diluted with 1 :4 15 
NH4 0H/saturated NH4Cl (SO mL) and extracted with 10% 
MeOH/CH2 Cl2 (3x30 mL). The organic layers were com-
bined, dried over Na2 S04 and concentrated in vacuo. The 
crude product was purified by prep TLC (silica, 12:1:0.1 
CH2 Cl2 /MeOH/conc. NH4 0H) to give 127 mg (78%) of 1 la 20 
as a yellowish solid. 
10 147.7, 1S6.3, 169.8, 177.0, 182.4, 204.4; HRMS (ESI) calc 
for [C68H89N701l+H]+1180.6692. found ll80.6637 
Tricyclic Ketolide-N-benzyltriazolylnona-N-Otrityl 
(1 ld) 
Reaction of 4'-ethynylbenzyl tricyclic ketolide 9 (0.07S g, 
0.102 mmol) and 6-azidonona-o-trityl hydroxamic acid lOd 
(0.046 g, 0.102 mmol) in anhydrous THF (S ml) within 20 h 
as described for the synthesis and purification of 1 la gave 93 
mg (76%) of lid as a yellowish solid. 1H NMR (CDC13, 400 
MHz) ll 0.8S (3H, t, 1=8.0 Hz), I .OS (3H, d, 1=6.8 Hz), 
1.16-1.44 (23H, m), l.4S-l.96 (!SH, m), 2.20 (3H, m), 2.S7-
2.78 (6H, m), 2.90-2.99 (lH, m), 3.02-3.12 (lH, m), 3.30-
3.S7 (3H, m), 3.72-3.84 (SH, m), 3.96-4.00 (lH, m), 4.29 (lH, 
d, 1=8.4 Hz), 4.31 (lH, d, 1=7.2 Hz), 4.37 (2H, 1=7.2 Hz), 
4.9S (lH, dd, 1=12.8, 2.4 Hz), 7.19-7.4S (17H, m), 7.72 (lH, 
s), 7.78 (2H, d, 1=8.0 Hz); 13C NMR (CDC13, 100 MHz) ll 
10.7, 11.1, 13.1, 14.6, 16.6, 19.3, 19.9,21.4,22.3,26.6,28.9, 
29.2, 29.6, 29.9, 30.S, 36.S, 37.0, 37.1, 38.8, 42.S, 43.0, 48.3, 
49.3, 49.7, S0.6, Sl.4, S7.7, 60.1, 6S.S, 6S.6, 69.7, 70.S, 76.7, 
78.7, 79.4, 81.8, 94.3, 104.1, ll9.6, 126.0, 128.3, 128.8, 
129.0, 129.2, 129.4, 130.0, 132.3, 138.9, 141.3, 147.6, 1S6.3, 
169.8, 178.0, 181.S, 204.S; HRMS (ESI) calc for 
[C69H91N7011+H]+ 1194.6849. found ll94.6838 
1H NMR (CDC13, 400 MHz) ll 0.8S (3H, t, 1=7.6 Hz), 1.1 
(3H, d, 1=6.8 Hz), 1.20-1.39 (17H, m), 1.46-2.00 (1 SH, m), 
2.19 (3H, s), 2.S8-2.80 (6H, m), 2.84-3.00 (lH, m), 3.02-3.17 
(lH, m), 3.31-3.60 (3H, m), 3.64-3.87 (SH, m), 3.96-4.0 (lH, 25 
m), 4.22 (lH, d, 1=8.4 Hz), 4.29-4.32 (3H, m), 4.93 (lH, dd, 
1=10.0, 1.6 Hz), 7.23-7.4S (17H, m), 7.71 (lH, s), 7.79 (2H, 
d, 1=8.0Hz); 13CNMR(CDC13, 100 MHz) ll 10.7, 11.1, 13.1, 
14.6, 16.7, 19.3, 19.9, 21.4, 22.3, 22.8, 26.0, 29.6, 30.2, 31.0, 
36.S, 37.0, 38.8, 42.S, 43.0, 48.3, 49.3, 49.7, S0.2, Sl.4, S3.7, 30 
S7.7, 60.1, 6S.6, 69.8, 70.S, 76.7, 78.7, 79.4, 81.8, 93.1, 104.1, 
119.7, 126.0, 128.2, 128.4, 129.2, 129.4, 130.0, 138.9, 141.2, 
147.6, 1S6.3, 169.8, 177.0, 181.S,204.S;HRMS(ESI)talcfor 
[C66H8SN701l+H]+11S2.6379. found 11S2.6367 
Tricyclic Ketolide-N-benzyltriazolylhepta-N-Otrityl 
(1 lb) 
Reaction of 4'-ethynylbenzyl tricyclic ketolide 9 (0.102 g, 
0.138 mmol) and 6-azidohepta-o-trityl hydroxamic acid !Ob 
(O.OS9 g, 0.138 mmol) within 24 has described for the syn-
thesis and purification of 11 a gave 133 mg (83%) of 11 b as a 
yellowish solid. 
1 H NMR (CDC13, 400 MHz) ll 0.8S (3H, t, 1=7 .6 Hz), 1.06 
(3H, d, 1=6.8 Hz), 1.20-1.42 (19H, m), 1.4S-1.98 (1 SH, m), 
2.20 (3H, s), 2.S7-2.79 (6H, m), 2.8S-3.00 (lH, m), 3.03-3.17 
(lH, m), 3.30-3.S7 (3H, m), 3.72-3.83 (SH, m), 3.96-4.00 
(lH, m), 4.22 (lH, d, 1=8.8 Hz), 4.29-4.3S (3H, m), 4.9S (lH, 
dd, 1=10.4, 2.4 Hz), 7.22-7.4S (17H, m), 7.71 (lH, s), 7.78 
(2H, d, 1=8.4 Hz); 13C NMR (CDC13, 100 MHz) ll 10.7, 11.1, 
13.1, 14.6, 16.6, 19.3, 19.9, 21.4, 22.3, 26.3, 29.6, 30.2, 36.S, 
37.0, 38.8, 42.S, 43.0, 48.3, 49.3, 49.7, S0.4, Sl.4, S3.7, S7.7, 
60.1, 6S.S, 69.7, 70.S, 76.7, 78.7, 79.4, 81.8, 92.8, 104.1, 
119.7, 126.0, 128.4, 129.2, 129.4, 130.0, 132.3, 138.9, 141.3, 
147.6, 1S6.3, 169.8, 177.6, 182.S, 204.S; HRMS (ESI) calc 
for [C67H87N7011+H]+ 1166.6S36. found 1166.6478 
Tricyclic Ketolide-N-benzyltriazolylocta-N-Otrityl 
(lie) 
Reaction of 4'-ethynylbenzyl tricyclic ketolide 9 (0.07S g, 
0.102 mmol) and 6-azidoocta-o-trityl hydroxamic acid lOc 
(0.04S g, 0.102 mmol) in anhydrous THF (S ml) within 22 h 
as described for the synthesis and purification of 1 la gave 94 
mg (79%) of 1 lc as a yellowish solid. 1H NMR (CDC13, 400 
MHz) ll 0.83 (3H, t, 1=7.2 Hz), 1.04 (3H, d, 1=7.2 Hz), 
1.lS-1.41 (21H, m), l.4S-l.9S (!SH, m), 2.18 (3H, s), 2.SS-
35 
Tricyclic Ketolide-N-benzyltriazolyldeca-N-Otrityl 
(1 le) 
Reaction of 4'-ethynylbenzyl tricyclic ketolide 9 (0.07S g, 
40 0.102 mmol) and 6-azidodeca-o-trityl hydroxamic acid lOe 
(0.048 g, 0.102 mmol) in anhydrous THF (S ml) within 20 h 
as described for the synthesis and purification of 1 la gave 98 
mg (80%) of 1 le as a yellowish solid. 1H NMR (CDC13, 400 
MHz) ll 0.83 (3H, t, 1=6.8 Hz), 1.03 (3H, d, 1=7.2 Hz), 
45 1.lS-1.40 (2SH, m), 1.44-1.96 (!SH, m), 2.17 (3H, s), 2.S7-
2.78 (6H, m), 2.87-2.9S (lH, m), 3.03-3.08 (lH, m), 3.28-
3.S3 (3H, m), 3.70-3.82 (SH, m), 3.92-3.96 (lH, m), 4.20 (lH, 
d, 1=8.4 Hz), 4.29 (lH, d, 1=6.8 Hz), 4.33 (2H, t, 1=7.2 Hz), 
4.93 (lH, d, 1=10.0 Hz), 7.26-7.43 (17H, m), 7.73 (lH, s), 
50 7.76 (2H, d, 1=8.0 Hz); 13C NMR (CDC13, 100 MHz) ll 10.7, 
11.1, 13.1, 14.6, 16.6, 19.3, 19.8, 21.4, 22.3, 26.6, 29.1, 29.3, 
29.6, 29.9, 30.S, 36.6, 37.0, 38.8, 42.S, 43.0, 48.3, 49.3, 49.7, 
S0.6, Sl.4, S7.7, 60.1, 6S.S, 69.7, 70.S, 76.7, 78.7, 79.4, 81.8, 
93.4, 104.1, 199.6, 126.0, 128.3, 129.2, 129.4, 130.0, 138.9, 
55 147.6, 1S6.3, 169.8, 177.6, 182.0, 204.S; HRMS (ESI) calc 
for [C70H93N701l+H]+1208.700S. found 1208.6888 
60 
Tricyclic Ketolide-N-benzyltriazolylhexahydroxamic 
acid (S6a) 
Protocol B: To a solution of tricyclic ketolide-N-benzyl-
triazolylhexa-N-Otrityl 1 la (0.120 g, O.lOS mmol) in meth-
ylene chloride (1 ml) at 0° C., was added thioanisole (0.2 ml) 
and TFA (0.2 ml) dropwise. Stirring was continued at 0° C. 
65 for 2 h after which TLC analysis indicated completion of 
reaction. Excess TFA and solvent were evaporated off and 
immediately placed back in the ice-bath followed by addition 
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of PBS buffer (10 ml). Saturated NaHC03 was added drop-
wise until the pH was neutral. Extraction with 20% MeOH/ 
CH2 Cl2 (10 mlx3), drying over Na2S04 , and evaporation of 
solvent afforded liquid crude product which was then purified 
byprepTLC(silica, 12:1:0.1 CH2CliMeOH/conc.NH4 0H) 5 
to afford 47 mg (SO%) of S6a as a yellowish solid. 
Protocol C: To a mixture of tricyclic ketolide-N-benzyl-
triazolylhexa-N-Otrityl 1 la (0.136 g, 0.118 mmol) in 
CH2 Cl2 /MeOH (2 ml: 2 ml) was added BF3 .0Et2 (0.033 g, 
0.236 mmol) and stirred at room temperature for 4S min. 10 
Dilute NaHC03 (20 ml) was added until pH=8, and then 
extracted with 10% MeOH/CH2 Cl2 (10 mlx4), dried over 
Na2S04 and concentrated in vacuo. The crude product was 
purified by prep TLC (silica, 12:1:0.1 CH2 Cl2 /MeOH/conc. 
NH4 0H) to give 64 mg (60%) of S6a as a yellowish solid. 15 
Protocol D: 4'-Ethynylbenzyl tricyclic ketolide 9 (O.OSO g, 
0.06S mmol) and 6-azidohexahydroxamic acid 13a (0.02S g, 
O.l4S mmol) were dissolved in anhydrous THF (7 mL) and 
stirred under argon at room temperature. Copper (I) iodide 
(0.007 g, 0.036mmol) andHunig's base (O.S mL)wereadded 20 
to the reaction mixture, and stirring continued for 12 h. The 
reaction mixture was diluted with 10% MeOH/CH2Cl2 (20 
mL) and washed with 1:4 NH40H/saturated NH4Cl (3x10 
mL) and saturated NH4Cl (10 mL). The organic layer was 
dried over Na2S04 and concentrated in vacuo. The crude 25 
product was purified by prep TLC (silica, 12: 1:0.1 CH2Cl2/ 
MeO H/conc. NH 40 H) to give 20 mg (34 % ) of S6a as a brown 
solid. 
1 H NMR (CDC13 , 400 MHz) ll 0.8S (3H, t, 1=8.0 Hz), I .OS 
(3H, d, 1=7.2 Hz), 1.20-2.00 (30H, m), 2.13-2.18 (2H, m), 30 
2.20 (3H, s), 2.S8-2.72 (6H, m), 2.92-2.98 (lH, m), 3.0S-3.09 
(lH, m), 3.30-3.SS (3H, m), 3.70-3.84 (SH, m), 3.9S-3.98 
(lH, m), 4.22 (lH, d, 1=8.0Hz), 4.31-4.38 (3H, m), 4.9S (lH, 
d, 1=8.8 Hz), 7 .33 (2H, d, 1=8.0 Hz), 7 .77 (3H, m); 13C NMR 
(CDC13 , 100 MHz) ll 10.6, 11.1, 13.1, 14.6, 16.S, 19.3, 19.8, 35 
21.4, 22.3, 24.7, 2S.9, 29.7, 29.9, 30.0, 36.6, 37.1, 38.8, 42.S, 
42.8, 49.4, 49.6, S0.3, Sl.4, S3.7, S7.7, 60.1, 6S.S, 69.7, 70.S, 
76.7, 78.7, 79.3, 81.8, 104.1, 120.1, 126.0, 129.S, 129.7, 
139.1, 147.7, 1S6.3, 169.8, 171.1, 182.3, 204.S; HRMS 
(EST) talc for [C47H71N7011+H]+ 910.S284. found 40 
910.S279; Melting point 127-130° C. 
Tricyclic 
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120.0, 126.0, 129.4, 129.8, 139.1, 147.7, 1S6.3, 169.8, 171.2, 
182.4, 204.S; HRMS (ESI) calc for [C48H73N7011+H]+ 
924.S440. found 924.S422; Melting point 128-131° C. 
Tricyclic Ketolide-N-benzyltriazolyloctahydroxamic 
acid(S6c) 
Reaction of l lc (0.092 mg, 0.079 mmol) in CH2Cl2 (1 ml), 
thioanisole (0.2 ml) and TFA (0.2 ml) according to protocol B 
afforded 3 7 mg ( S l % ) of S6c as a yellowish solid. 
1 H NMR (CDC13 , 400 MHz) ll 0.83 (3H, t, 1=6.4 Hz), 1.03 
(3H, d, l=S.6 Hz), 1.18-1.60 (21H, m), 1.66-2.1 (lSH, m), 
2.18 (3H, s), 2.S6-2.70 (6H, m), 290-2.98 (lH, m), 3.02-3.07 
(lH, m), 3.28-3.S8 (3H, m), 3.70-3.81 (SH, m), 3.94-3.97 
(lH, m), 4.20 (lH, d, 1=7.2 Hz), 4.28 (lH, d, 1=6.0 Hz), 4.3S 
(2H, m), 4.93 (lH, d, 1=10.4 Hz), 7.30 (2H, d, 1=7.2 Hz), 
7.73-7.76(3H,m); 13CNMR(CDC13 , lOOMHz)ll 10.6, 11.1, 
13.1, 14.4, 14.6, 16.S, 19.3, 19.8, 21.3, 21.4, 22.3, 2S.2, 26.1, 
28.3, 29.7, 29.9, 30.2, 32.9, 36.6, 37.1, 38.8, 42.S, 42.7, 48.2, 
49.4, 49.S, SO.S, Sl.4, S7.7, 60.1, 60.6, 6S.S, 69.7, 70.S, 76.7, 
78.7, 79.3, 81.8, 104.0, 119.9, 126.0, 129.S, 129.8, 139.0, 
147.7, 1S6.3, 169.8, 171.7, 182.4, 204.S; HRMS (ESI) calc 
for [C49H7SN701 l+H]+ 938.SS97. found 938.SSS6; Melt-
ing point 113-l 1S° C. 
Tricyclic Ketolide-N-benzy ltriazolylnonahydroxamic 
acid (S6d) 
Reaction ofl ld (0.091 mg, 0.077 mmol) in CH2 Cl2 (1 ml), 
thioanisole (0.2 ml) and TFA (0.2 ml) according to protocol B 
afforded 43 mg ( 60%) of S6d as a yellowish solid. 
1HNMR (CDC13 , 400MHz) ll0.83 (3H, t, 1=7.2 Hz), 1.03 
(3H, d, 1=7.2 Hz), 1.17-1.60 (23H, m), 1.66-2.14 (lSH, m), 
2.17 (3H, s), 2.S8-2.73 (6H, m), 2.87-2.9S (lH, m), 3.00-3.07 
(lH, m), 3.27-3.SS (3H, m), 3.70-3.82 (SH, m), 3.93-3.97 
(lH, m), 4.20 (lH, d, 1=8.8 Hz), 4.28 (lH, d, 7.2 Hz), 4.3S 
(2H, t, 1=6.8 Hz), 4.92 (lH, dd, 1=10.0, 1.2 Hz), 7.30 (2H, d, 
1=8.0Hz), 7.7S (3H,m); 13CNMR(CDC13 , lOOMHz) ll 10.7, 
11.1, 13.1, 14.6, 16.S, 19.3, 19.8, 21.4, 22.3, 2S.4, 26.3, 28.6, 
28.8, 28.9, 29.6, 29.9, 30.3, 32.9, 36.6, 37.1, 38.8, 42.S, 42.8, 
48.2, 49.3, 49.6, S0.6, Sl.4, S7.7, 60.1, 6S.S, 69.7, 70.S, 76.7, 
78.7, 79.3, 81.8, 104.1, 119.8, 126.0, 129.S, 129.8, 139.0, 
147.7, 1S6.3, 169.8, 171.3, 182.9, 204.S; HRMS (ESI) calc Ketolide-N-benzy ltriazolylheptahydroxamic acid 
(S6b) 45 for [CSOH77N701 l+H]+ 9S2.S7S3. found 9S2.S728; Melt-
ing point 112-11S° C. 
According to protocol B, reaction of 11 b (0.132 g, 0.113 
mmol) in CH2Cl2 (1 ml), thioanisole (0.3 ml) and TFA (0.3 
ml) for 3 h afforded S6 mg (SS%) of S6b as a yellowish solid. 
According to protocol C, reaction of llb (O.lS g, 0.127 50 
mmol) and BF3 .0Et2 (0.037 g, 0.2S7 mmol) afforded 6S mg 
(SS%) ofS6b as a yellowish solid. 
Reaction of 4'-ethynylbenzyl tricyclic ketolide 9 (0.048 g, 
0.063 mmol) and 7-azidoheptahydroxamic acid 13b (0.020 g, 
0.107 mmol) within 12 h, according to the protocol D 55 
described for the synthesis of compound S6a, gave 22 mg 
(38%) of S6b as a brown solid. 
1 H NMR (CDC13 , 400 MHz) ll 0.83 (3H, t, 1=7 .6 Hz), 1.03 
(3H, d, 1=6.4 Hz), 1.18-1.90 (32H, m), 2.10-2.13 (2H, m), 
2.17 (3H, s), 2.S8-2.73 (6H, m), 2.93-2.98 (lH, m), 3.03-3.07 60 
(lH, m), 3.28-3.60 (3H, m), 3.70-3.81 (SH, m), 3.98 (lH, m), 
4.20 (lH, d, 1=8.4 Hz), 4.29-4.38 (3H, m), 4.93 (lH, d, 1=10.4 
Hz), 7.30 (2H, d, 1=7.6 Hz), 7.7S (2H, d, 1=7.6 Hz), 7.78 (lH, 
s); 13C NMR (CDC13 , 100 MHz) ll 10.6, 11.1, 13.1, 14.6, 
16.S, 19.3, 19.8, 21.4, 22.3, 2S.2, 26.0, 28.2, 29.7, 29.9, 30.1, 65 
36.6, 37.0, 38.8, 42.S, 42.7, 48.2, 49.3, 49.S, S0.4, Sl.4, S3.7, 
S7.7, 60.1, 6S.S, 69.7, 70.S, 76.7, 78.7, 79.3, 81.8, 104.0, 
Tricyclic Ketolide-N-benzyltriazolyldecahydroxamic 
acid(S6e) 
Reaction of I le (0.097 mg, 0.081 mmol) inCH2Cl2 (1 ml), 
thioanisole (0.2 ml) and TFA (0.2 ml) according to protocol B 
afforded 42 mg (SS%) of S6e as a yellowish solid. 
1HNMR (CDC13 , 400MHz) ll0.83 (3H, t, 1=7.2 Hz), 1.03 
(3H, d, 1=6.4 Hz), 1.18-1.61 (2SH, m), 1.66-2.14 (lSH, m), 
2.18 (3H, s), 2.S9-2.73 (6H, m), 2.89-2.94 (lH, m), 3.01-3.07 
(lH, m), 3.28-3.S4 (3H, m), 3.70-8.83 (SH, m), 3.93-3.97 
(lH, m), 4.20 (lH, d, 1=8.4 Hz), 4.28 (lH, d, 1=6.8 Hz), 4.36 
(2H, t, 1=7.2 Hz), 4.92 (lH, dd, 1=10.4, 1.6 Hz), 7.30 (2H, d, 
1=8.0Hz), 7.76 (3H,m); 13CNMR(CDC13 , lOOMHz) ll 10.7, 
11.1, 13.1, 14.4, 14.6, 16.S, 19.3, 19.9,21.4,22.3,2S.S,26.3, 
28.7, 28.9, 29.0, 29.6, 29.9, 30.3, 33.1, 36.6, 37.1, 38.8, 42.S, 
42.7, 48.2, 49.4, 49.S, S0.6, Sl.4, S7.7, 60.1, 60.6, 6S.S, 69.7, 
70.S, 76.7, 78.7, 79.3, 81.8, 104.0, 119.8, 126.0, 129.S, 129.8, 
139.0, 147.7, 1S6.3, 169.8, 171.7, 182.9, 204.S; HRMS (ESI) 
calc for [CS1H79N701 l+H]+ 966.S910. found 966.S919; 
Melting point 123-126° C. 
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Example 5 
Anti-HDAC Activity ofNonpeptide Macrocyclic 
HDAC Inhibitors 
Inhibition ofHeLa nuclear extract HDACl/2 and HDAC8 
by compounds 7-14, 23-30, 36, and 38 was evaluated in a 
Fluor de Lys assay according to the manufacture's protocol. 
Each IC50 value was obtained by averaging three independent 
experiments. This data is shown in Table 4. The compounds 10 
displayed both linker-length and macrolide-type dependent 
HDAC inhibition activities with IC50 in low nanomolar range. 
146 
HDAC8. Compared to SAHA, compounds 56a and 56b are 
more selective for HDACl/2 with selectivity indices compa-
rable to those of their 14-membered macrolide congeners. 
Compounds 56c-e are less selective for either HDAC isoform 
compared to 56a-b. However, 56c-e have improved HDAC6 
and comparable HDAC8 isoform selectivity relative to 
SAHA (Table 5). 
Example 6 
Evaluating in Vitro Anti-Cancer Activity of HDAC 
Inhibitors 
TABLE4 
Inhibitory activity ofHDAC inhibitors 
Compound HDAC 1/2 (nM) HDAC 8 (nM) 
7 91.6 4,730 
The potency of compounds in Table 5 were investigated by 
15 determining the drug concentrations necessary for 50% inhi-
bition of cell viability (IC50) in SKMES 1, NCI-1169, DU 145 
cells, lung fibroblasts, and HMEC. Drug concentrations nec-
essary for 50% inhibition of cell viability (EC50) were quan-
titatively measured using trypan blue exclusion according to 
20 literature protocol (Mosmami, T. (1983). J. Immunol. Meth-
ods 65: 55; Chen et al. (2008) Bioorg. Med. Chem. 16: 4839). 
Table 6 shows the EC50 values for each compound. All com-
pounds inhibit the proliferation of the transformed cells stud-
ied with EC50 in low micromolar range. Most importantly, 
88.8 3,740 
9 13.85 994 
10 10.56 1,020 
11 58.88 7,130 
12 72.44 6,780 
13 145.50 11,050 
14 226.73 
23 36.98 
24 44.26 
N.D. 
3,990 
4,750 
25 these compounds are less toxic to untransformed cell-lines 
(lung fibroblast and HMEC) that we have studied to date. 
25 4.09 1,890 
26 1.87 1,390 
27 55.59 5,880 
28 123.03 4,420 30 
29 169.80 10,550 
30 223.36 N.D 
36 107.1 6,680 
38 109.8 2,320 
The ketolides 56 were also evaluated for their HDAC 35 
inhibitory activity against HDACs 1 and 2 from HeLa cell 
nuclear extract, HDAC6, and HDAC8 using the Fluor de Lys 
assay. The results are shown in Table 5. 
TABLES 
HDAC inhibition activity (IC50) and Isoform Selectivity oftricyclic 
ketolide-based HDAC inhibitors 
HDAC8: HDAC6: 
Nuclear Nuclear 
Nuclear Extract Extract 
Extract HDAC !so form HDAC !so form 
Com pd n (nM) 8 (nM) Selectivity 6(nM) Selectivity 
40 
45 
TABLE6 
Cell growth inhibitory data 
Lung 
SKMES 1 NCI-H69 DU-145 fibroblast HMEC 
Compound (uM) (uM) (uM) (uM) (uM) 
7 1.79 1.92 1.45 >10 >10 
1.68 1.77 1.24 >10 >10 
9 2.33 3.45 1.88 >10 >10 
10 2.56 3.01 1.97 >10 >10 
11 4.89 4.56 5.89 >10 >10 
12 4.67 3.99 5.68 >10 >10 
13 7.54 8.45 >10 >10 >10 
23 2.15 2.67 2.98 >10 >10 
24 1.95 1.92 3.29 >10 >10 
25 1.33 1.45 1.12 >10 >10 
26 1.28 1.49 1.05 >10 >10 
27 4.89 5.67 6.97 >10 >10 
28 4.45 5.09 5.78 >10 >10 
29 7.12 7.29 8.14 >10 >10 
The effect of compounds 56a-e on cancer cell lines: pros-
tate (DU-145), lung (A549), and breast cancer (MCF-7) and 
56a 7.77 796.2 
56b 2 1.03 544.6 
56c 104.2 1909.3 
56d 4 163.6 2859.9 
56e 208.2 4557.8 
102.5 1180.1 
528.7 728.7 
18.3 1709.8 
17.5 1916.9 
21.9 3203.1 
151.9 
707.5 
16.4 
11.7 
15.4 
50 a non-transformed cell, human lung fibroblast cell (Hsi .Lu) 
were also evaluated. Drug concentrations necessary for 50% 
inhibition of cell viability (EC50) were quantitatively mea-
sured using MTS colorimetric assay as described above. 
Results show a linker-dependent anti-HDAC activity 55 
which peaked with compound 56b, an analog having 6 meth-
ylene spacers separating the triazole ring from the zinc bind-
ing hydroxamic acid group (Table 5). Compound 56b 
potently inhibits the deacetylase activity of HDACs 1 and 2 
with a single digit nanomolar IC50 . Compounds 56c-e, ana-
logs having longer methylene spacers than those of 56b, show 
60 
a progressive reduction in anti-HDAC activity with increase 
in methylene spacer length. The HDAC inhibition profiles of 
these triketolide-derived HDACi paralleled those we previ-
ously reported for the macrolide-derived HDACi. 
To obtain evidence for the HDAC isoform selectivity, the 
triketolide HDAC inhibitors were tested against HDAC6 and 
65 
Table 7 shows the EC50 values of each compound. 
TABLE 7 
Anti-proliferative activity (µM) oftricyclic ketolide-based HDAC 
inhibitors 
DU-145 A549 MCF-7 Hsi.Lu Normal Lung 
Com pd n (µM) (µM) (µM) Fibroblast (µM) 
56a 1.64 1.17 1.26 N.D. 
56b 2 0.82 0.66 0.75 N.D. 
56c 3.70 1.64 1.35 N.D. 
56d 4 3.89 2.48 2.56 N.D. 
56e 4.83 2.81 3.68 N.D. 
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Compounds 56a-e inhibit the proliferation of all trans-
formed cells studied with anti-proliferative activity that 
closely matched their in vitro ant-HDAC activity. Specifi-
cally, compound 56b has the most potent anti-proliferative 
activity with high nanomolar efficacy against all three cancer 
cell lines. Moreover, none of the compound shows any dis-
cernible toxicity against normal Hsi .Lu cells at drug concen-
trations in excess of 10 µM (Table 7). These data showed that 
the triketolide hydroxamates reported here are selectively 
toxic to the transformed cells. 
Example 7 
Antiparasitic Activity of Non-Peptide Macrocyclic 
Histone Deacetylase Inhibitors 
Macrocyclic histone deacetylase inhibitors were evaluated 
for parasitic activity against Plasmodium falciparum and 
Leismania donovani. P. falciparum and L. donovani are the 
causative parasites of malaria and leishmaniasis, two human 
148 
diseases which constitute a serious threat to public health in 
tropical and sub-tropical countries. Antimalarial activity was 
evaluated in vitro using chloroquine-sensitive (D6, Sierra 
Leone) and chloroquine-resistant (W2, Indochina) strains of 
P.falciparum. Antileishmanial activity was evaluated in vitro 
against the promastigote stage of L. donovani. 
Plasmodium growth inhibition was determined by a para-
site lactate dehydrogenase assay using Malstat reagent. Inhi-
bition of viability of the promastigote stage of L. donovani 
10 
was determined using standard Alamar blue assay, modified 
to a fluorometric assay. Amphotericin B and pentamidine, 
standard antileishmanial agents; chloroquine and artimisinin, 
standard antimalarial; and suberoylanilide hydroxamic acid 
15 (SAHA), standard HDACi were all used as positive controls. 
To determine selective toxicity index, all compounds were 
tested against nontransformed mammalian cell lines namely, 
monkey kidney fibroblasts (Vero) and murine macrophages 
(1774.1) using Neutral Red assay. The results are shown in 
Table 8. 
TABLES 
Corn pd R 
2 
Antiparasitic activity of non-peptide HDAC inhibitors 
HDAC Antimalarial Activity Cyto-
Inhibi- Antileshrnanial Plasmodium Plasmodium toxicity 
lion activity falciparum falciparum (VERO) S.I. 
IC50 IC90 (D6 clone) (W2 clone) 
n (µg/ml) (µg/ml) IC50 (µg/ml) IC50 (µg/ml) 
37.0 NA NA 0.90 0.93 
44.3 NA NA 1.20 1.40 
91.6 NA NA 1.20 1.60 
ICso 
(µg/ml) 
NC 
NC 
NC 
D6 
(W2) 
>5.3 
(>5.1) 
>4.0 
(>3.4) 
>4.0 
(>3.0) 
Corn pd 
4 
0 
7 
149 
R 
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TABLE 8 . 
. -contmued 
Antmarasitic activity f o non-peptide HDAC 'nh' . 1 ib1tors 
HDAC 
Inhibi-
ti on 
ICso 
n (nM)" 
88.8 
4.1 
1.9 
Antileshmanial 
activity 
IC so IC90 
(µg/ml) (µg/ml) 
NA NA 
18 NA 
NA NA 
OH~,N~ 
HO, 
.. ,,,, '· 
"''o 0 
13.9 NA NA 
"''O'Q; 
OH 
0-
10.6 NA NA 
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Antimalarial Act' . lVlty 
Plasmodium Plasm odium 
falciparum falciparum 
(D6 clone) (W2 clone) 
ICso (µg/ml) ICso (µg/ml) 
1.30 1.70 
0.27 0.31 
0.18 0.25 
0.23 0.10 
0.16 0.17 
Cyto-
toxicity 
(VERO) 
ICso 
(µg/ml) 
NC 
NC 
NC 
NC 
NC 
S.I. 
D6 
(W2) 
>3.7 
(>2.8) 
>17.6 
(>15.4) 
>26.4 
(>19.0 
>20.7 
(>47.6) 
>29.8 
(>28.0 
Corn pd 
9 
0 
10 
0 
11 
12 
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TABLE 8 . -contmued 
Anti par::.:.:::=-~...:.:=:: _____ _ 
as1tlc activity of no . 
n-pept1de HDAC. . . ------------
mh1b1tors 
HDAC 
Inhibi- Antileshmanial 
ti on activity 
IC so IC90 
R n (µg/ml) (µg/ml) 
20 34 
' N~ 7 (,:~I, 
55.6 
'''o~ 
' OJ-
0 
........ 
'N~ 7 123.0 ~~,:~I' 
NA NA 
7 58.9 NA NA 
7 72.4 NA NA 
Antimalarial Act' . !Vlty 
Plasmodium Plasm odium 
falciparum falciparum 
(D6 clone) (W2 clone) 
ICso (µg/ml) ICso (µg/ml) 
2.50 2.00 
3.00 2.70 
2.40 2.30 
3.50 3,20 
Cyto-
toxicity 
(VERO) 
ICso 
(µg/ml) 
NC 
NC 
NC 
NC 
S.I. 
D6 
(W2) 
>1.9 
(>2.4) 
>1.6 
(>1.8) 
>2.0 
(>2.1) 
>1.4 
(>1.5) 
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TABLE 8-continued 
Antiparasitic activity of non-peptide HDAC inhibitors 
HDAC 
Inhibi- Antileshmanial 
ti on activity 
ICso IC so IC90 
Corn pd R n (nM)" (µg/ml) (µg/ml) 
13 'N~ 169.8 3.40 7.00 ~-0:0:1 # 
_,,,o o 
14 'N~ 
o~ H-01, ... ,,, . 
"''10 0 
145.5 20 35 
0 ""'O'Q; .. 
• '
101-
b-
15 9 223.4 3.40 7.00 
154 
Antimalarial Activity 
Plasmodium Plasm odium 
falciparum falciparum 
(D6 clone) (W2 clone) 
ICso (µg/ml) ICso (µg/ml) 
1.70 1.00 
1.10 0.83 
1.40 0.80 
Cyto-
toxicity 
(VERO) 
ICso 
(µg/ml) 
NC 
NC 
NC 
S.I. 
D6 
(W2) 
>2.8 
(>4.8) 
>4.3 
(>5.7) 
>3.4 
(6.0) 
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TABLE 8-continued 
Antiparasitic activity of non-peptide HDAC inhibitors 
HDAC Antimalarial Activity Cyto-
Inhibi- Antileshmanial Plasmodium Plasmodium toxicity 
lion activity falciparum falciparum (VERO) S.I. 
Corn pd R n 
16 
" N 1-o~OH 
0 '-N~9 
H-0~, ... ,,, . 
,,· 
o' ''''·· 
"''10 0 
,,· 0 
\ 
0 ""'O'Q; .. 
• '
101-
b-
Chloroquine 
Artetnisinin 
Pentarnidine 
Amphotericine B 
SAHA 
NA= Not active up to the highest concentration tested 
NC= Not cytotoxic up to the highest concentration tested 
NT = Not tested 
226.7 
NT 
NT 
NT 
NT 
65 
The non-peptide macrocyclic HDAC inhibitors potently 40 
inhibited the proliferation of both the sensitive and resistant 
strains of P.falciparum with IC50 ranging from 0.1 µg/mL to 
3.5 µg/mL (Table 1). In particular, compounds 5-8 in Table 8, 
derived from either the 14- or 15-membered macrolide ana- 45 
logs macrolides and having 6 methylene spacers separating 
the triazole ring from the zinc-binding hydroxamic acid 
group (n=6), have the most potent antimalarial activities in 
this series. These compounds are equipotent or >4-fold more 50 
potent than the control compound SAHA. Moreover, they are 
several folds more selectively toxic to either strains of P. 
falciparum compared to SAHA. The antimalarial activities of 
IC50 IC90 (D6 clone) (W2 clone) 
(µg/ml) (µg/ml) IC50 (µg/ml) IC50 (µg/ml) 
3.50 7.00 0.84 0.88 
NT NT 0.017 0.125 
NT NT 0.004 0.006 
0.90 1.70 NT NT 
0.18 0.32 NT NT 
22 50 0.25 0.47 
ICso 
(µg/ml) 
NC 
NT 
NT 
NT 
NT 
1.20 
D6 
(W2) 
>5.7 
(>5.4) 
NT 
NT 
NT 
NT 
4.8 
(2.5) 
rocyclic rings. 14-Membered compound 13 is 5- to 6-fold 
more potent than its 15-membered congener 14. However, 
this disparity dissipates after a single methylene group exten-
sion (n=9), as compounds 15 and 16 have virtually indistin-
guishable antileishmanial activities. Comparatively, com-
pounds 13, 15 and 16, analogs with the most potent 
antileishmanial activities, are about 7- to 10-fold more potent 
than SAHA and approximately 3-fold less potent than penta-
midine. 
Since these non-peptide macrocyclic HDACi have nano-
molar anti-HDAC activities, the observed disparity in the 
trend of their antimalarial and antileishmanial activities may 
these macrocyclic HDACi followed a similar trend as their have implication in the organization of the active sites of the 
55 
anti-HDAC activity against HDACl/2 from HeLa nuclear relevant P. falciparum and L. donovani HDAC isozymes. 
extract, suggesting that parasite HDACs could be an intrac-
ellular target of the these compounds. 
Compounds 5 and 9 exhibited modest activity against the 
promastigote stage of L. donovani. This result is contrary to 
previous data on simple aryltriazolylhydroxamates which 
have antimalarial and antileishmanial activities that followed 
a similar trend. 
60 
A comparison of the antileishmanial activities of com- 65 
pounds 13 and 14, analogs with n=8, revealed an interesting 
disparity between the activity of 14- and 15-membered mac-
These observations provide additional evidence of the suit-
ability of HDAC inhibition as a viable therapeutic option to 
curb infections caused by apicomplexan protozoans and try-
panosomatids (1, 5, 6, 14) and could facilitate the identifica-
tion of other HDACi that are more selective for either para-
site. 
The antiparasitic activity ofketolides 56 were also evalu-
ated against P. falciparum and L. donovani. The results are 
shown in Table 9. 
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TABLE9 
Anti12arasitic activi\y ofketolide non-12e12tide HDAC inhibitors 
Antimalarial Activi\y 
Antilieshmanial Plasmodium Plasmodium Cytotoxicity 
Activi\y falciparum falciparum (VERO) S.I. 
ICso IC90 (D6 clone) (W2 clone) ICso D6 
Compound n (µg/ml) (µg/ml) IC so (µg/ml) IC50 (µg/ml) (µg/ml)" (W2) 
56a NA NA 0.96 1.80 NC 
56b 2 NA NA 0.14 0.12 NC 
56c 19 36 1.20 1.50 NC 
56d 4 14 32 1.20 1.30 NC 
56e 4.8 23 1.20 0.84 NC 
Chloroquine NT NT 0.011 0.14 NT 
Artemisinin NT NT 0.006 0.009 NT 
Pentarnidine 1.4 6.0 NT NT NT 
Arnphotericine 0.08 0.3 NT NT NT 
B 
SAHA 22 50 0.25 0.47 1.20 
Compounds 56a-e potently inhibit the proliferation of both 
the sensitive and resistant strains of P. falciparum with IC50 
ranging from 0.12 µg/mL to 1.5 µg/mL (Table 9). 56b has the 
most potent antimalarial activity which is between 2- to 25 
4-fold more potent than the control compound SAHA. More-
over, 56b is several folds more selectively toxic to either 
strains of P. falciparum compared to SAHA. Compounds 
56c-e have a moderate to good antileishmanial activity 
against the promastigote stage of L. donovani activity which 30 
peaks with 56e, the analog with the longest methylene spacers 
in the series. This result is in contrast to the antimalarial 
activity that mirrors compound anti-HDAC activity and it 
may have implications in the organization of the active sites 35 
of the relevant P. falciparum and L. donovani HDAC 
isozymes. We have observed a similar methylene spacer-
length dependence in the antileishmanial activity of macro-
cyclic HDACi 14- and 15-memberedmacrolides as shown in 
Table 8. The foregoing observations further support the suit- 40 
ability of HDAC inhibition as a viable therapeutic strategy to 
curb infections caused by apicomplexan protozoans and try-
panosomatids. 
>5 .0 (no value) 
>34 (>39.7) 
>4.0 (>3.2) 
>4.0 (>3.7) 
>4.0 (>5.7) 
NT 
NT 
NT 
NT 
4.8 (2.5) 
are expected to bind more tightly with Zn2 + metal ion than 
their carbonyl counterparts, thereby improving binding 
energy. 
nNH 
K 
HO S 
S~NH 
r 
HO 
3-hydroxy pyridine-2-thione 3-hydroxy pyridine-4-thione 
Q 
HO S 
!-hydroxy pyridine-2-thione 
These fragments were docked against class I HDAC 
enzymes HDACl and HDACS and structurally distinct 
HDAC6 which belongs to class II. These isoforms have dis-
tinct structural differences at the Zn2+ active site. Any evi-
dence of isoform selectivity against any one of them should 
Example 8 
3-Hydroxypyridine-2-thiones as Zinc Binding 
Groups for HDAC Inhibition 
45 establish a broader isoform profile. The HD ACS crystal struc-
ture (PDB code: lVKG) has been solved, while HDACl and 
HDAC6 homology model were built from human HDAC2 
(PDB code: 3MAX) and HDACS (PDB code: 3FOR) X-ray 
structure coordinates respectively. These were used to obtain 
In Silica Analysis of Pyridinone Zinc Binding 
Groups 
50 in silica data for fragment interaction at the active sites. 
Preliminary docking analysis against HDAC isoforms 
revealed that 3-hydroxypyridine-2-thione (3-HPT), 3-hy-
droxypyridine-4-thiones, and l-hydroxypyridine-2-thione 
bind to the vicinity of Zn2+ ion at the active sites of HDACl, 
To evaluate the feasibility of pyridinone fragments in 
HDACi design, fragments were docked against HDAC crys-
55 HDAC6 and HDACS. This suggests that pyridinones can 
serve as effective ZBGs in HDACi design. 
tal structures using validated molecular dock program (Au-
toDock 4.2). Three representative pyridinone fragments-3-
hydroxypyridine-2-thione (3-HPT), 3-hydroxypyridine-4-
thiones, and l-hydroxypyridine-2-thione, the structures of 
which are shown below, were docked against HDAC macro-
molecules. It is noted that the N-1 position of3-hydroxypy-
ridine-2-thione and 3-hydroxypyridine-4-thione could be 
modified, as required, to include a prototypical HDACi linker 
region coupled to a surface recognition cap group. Small 
fragments tend to have lower binding energy and non-specific 
interaction at the surface. These problems were addressed by: 65 
i) selecting compact grid size around the Zn2 + active site; and 
ii) selecting thione analogs of pyridinone fragments which 
Closer analyses of the docked structures revealed that the 
orientation ofN-1 position of 3-hydroxypyridine-4-thione is 
pointing towards the base of the active site pocket instead of 
pointing toward the surface as seen with 3-HPT. In order to 
60 evaluate ZBGs other than hydroxamic acid, 3-hydroxypyri-
dine-2-ones were selected for further investigation. 
In vitro analysis of3-hydroxypyridine-2-ones as 
ZBGs 
To verify the in silica findings, an HDAC inhibition assay 
using 3-hydroxypyridine-2-ones was performed to determine 
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their effect on enzyme activity. HDAC inhibition was assayed 
initially using cell free assay (Fluor de Lys) as described 
above. 
There is precedence that fluorescently labeled substrates 
can perturb enzyme activity and the effect of inhibitors. 
Indeed, many recommended Fluor de Lys substrates have 
been shown not to be active toward their corresponding 
enzymes, including HDAC8, in the absence of fluorophore. 
Additionally, 3-hydroxypyridine-2-ones are highly colored 
solids and might lead to false positive signals. Mindful of 
these facts, a label-free SAMDI (self-assembled monolayers 
for MALDI) mass spectrometry assay was also used to assess 
HDAC inhibition. 
The SAMDI technique, wherein self-assembled monolay-
160 
group of docked l-methyl-3-hydroxypyridine-2-thione's 
structure. Similarly, the hydrophobic tunnel which joins the 
ZBG active site of HDAC8 to the surface consists of amino 
acid(AA)residues Phe152, Phe208, Tyr306, Trp141, His180, 
5 Asp267. Hydrophobic aromatic AA residues Phe152, 
Phe208, Tyr306, Trp141 are in close proximity ofN-methyl 
group of docked l-methyl-3-hydroxypyridine-2-thione's 
structure. As a consequence, aromatic linkers containing, for 
example, phenyl, biphenyl or triazole rings, might contribute 
10 to pi-stacking interactions with aromatic AA, thereby 
enhancing binding energy and improve compounds' affinity 
for HDAC6 and HDAC8. 
Compounds 138-140, 3-hydroxypyridine-2-thiones con-
15 taining aromatic substituents attached to the N-1 nitrogen, 
were investigated in silica. ers (SAM) of alkanethiolates on gold are analyzed by matrix 
assisted laser desorption/ionization (MALDI) mass spec-
trometry, has been widely used to characterize many bio-
chemical activities, including the deacetylase enzyme family. 
The SAMDI assay was used to measure the inhibition con-
stant (K 1 ) of fragments against HDAC 1, HDAC6 and HDAC8 20 
using a previously identified preferred HDAC substrate. 
3-hydroxypyridine-2-one was found to be inactive against the 
three HDAC isoforms. However, the thione derivative 
(3-HPT) showed low micromolar IC50 values against the 
HDAC6 and HDAC8 isoform and inactive against HDACl 25 
(Table 10). 
138 
139 
s HOD TABLE 10 
Activity of3-hydroxypyridine-2-one and 3-hydroxypyridine-2-
thione as determined by SAMDI analysis. 
IC nM 
Compounds HDACl HDAC6 HDAC8 
NI 
NI 681 ± 110 3675 ± 1201 
NI - No significant Inhibition (below 20% Inhibition); 
% inhibitions of the compounds at 10 µMare given if the IC50 was above 10 µM. 
Analysis of substituted 3-hydroxypyridine-2-thiones 
After promising results which demonstrated the activity of 
3-hydroxypyridine-2-thione and suggested potential isoform 
selectivity, 3-HPT analogues substituted at the N-1 nitrogen 
were investigated to determine if linker substitution at this 
position can be tolerated. Accordingly, l-methyl-3-hydroxy-
pyridine-2-thione was docked against HDAC6 and HDAC8. 
Substitution with N-methyl group didn't alter the docked 
pose of 3-HPT fragment. The amino acid residues surround-
ing the docked structure of l-methyl-3-hydroxypyridine-2-
thiones were analyzed to further refine the design of the linker 
region. The hydrophobic tunnel which joins the ZBG active 
site of HDAC6 to the surface consists of amino acid (AA) 
residues Leu74, Pro501, Asp567, Gly619, Phe620, Phe680, 
Pro748, Tyr782. Hydrophobic aromatic Phe620, Phe680, 
Tyr782 AA residues are in close proximity to the N-methyl 
30 
35 
40 
I N 
.,,::::; 
140 
Analysis of HDAC6 docking with compound 138 reveals 
hydrophobic interaction between the compound 138 phenyl 
ring and AA residues Phe620 and Pro501. However, upon 
addition of a rd phenyl ring, as in compound 139, the com-
45 pound adopts a higher energy confirmation which loses 
hydrophobic interaction as seen in compound 138. 
In the case of HDAC8 docking, analysis of compounds 
138, 139, and 140 revealed that the phenyl ring and the tria-
zole group participated in pi-stacking interactions with aro-
50 maticAA Trp141 inHDAC8. In compound 139, containing a 
biphenyl substitution, the 1st phenyl ring adjacent to ZBG 
maintained its pi-stacking interaction with Trpl 41 and the 2nd 
phenyl ring orients in deep subpocket near the active site, 
albeit without any significant interaction. However, it is inter-
55 esting to note that the rd phenyl ring of compound 139 is 
surrounded by amino acids which can potentially contribute 
to a low energy conformation by exploiting hydrogen bond-
ing and hydrophobic interaction surrounding it. Similarly, 
Pro7 4 and Leu7 49 surround the 2nd phenyl ring of compound 
60 139 in HDAC6 docked conformation. This suggests that sub-
stitution of the 2nd phenyl ring with hydrogen bonding or 
hydrophobic groups will potentially lower binding energy 
and improve potency. 
To investigate the effect of incorporation of functional 
65 groups on the rd phenyl group of the 3-hydroxypyridine-2-
thiones, compounds possessing varied substituents on the 
second phenyl ring were evaluated. The proposed modifica-
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tions allow the 3-hydroxypyridine-2-thiones to participate in 
hydrogen bonding as well as hydrophobic interactions with 
AA residues surrounding the rd phenyl group of 139. The 
compounds chosen for initial investigation are shown below 
x~o, s 
x 
"oYvl~ u ~R 
R~ t-Q-rn t-drn tb 
t-0- t-d K> 
10 
15 
x~o, s 
Y~H, 
Y = dimethyamino 
162 
-continued 
Initial fragments 142a-142c and 144a-144c were synthe-
sized in 2 to 3 steps as indicated in Scheme 17. Synthesis 
involved coupling of methyl iodide and corresponding benzyl 
20 bromides with commercially available 3-methoxypyridine-2-
one to give the 0-methy 1 protected intermediates 141 a-141 c. 
Thione intermediates were synthesized from their carbonyl 
precursors using Lawesson's reagent chemistry. Finally, 
25 deprotection of 0-methyl group by lewis acid BBr3 gave the 
desired products 142a-142c and 144a-144c. 
Scheme 17. Synthesis of142a-142c and 144a-144c. 
a 
--
R~H, 141a 
R ~phenyl, 14lb 
R ~ 1,1'-biphenyl, 141c 
0 
HOD/'-.... I N R 
# 
R~H,142a 
R ~phenyl, 142b 
R~ 1,1'-biphenyl, 142c 
b 
-- --
R~H,143a R~H, 144a 
R ~phenyl, 143b R ~phenyl, 144b 
R ~ 1,1'-biphenyl, 143c R ~ 1,1'-biphenyl, 144c 
For 141a a) MeI, KOH, MeOH; For 14lb, 14lc; a)R-CH2Br, K2C03, DMF, 100° C. b) Lawesson's reagent, toluene, reflux. c) BBr3, CH2Cb 
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The proposed routes to the biphenyl fragments require 
crucial intermediate 145 which was obtained by coupling of 
4-bromobenzylbromide with 3-methoxypyridine-2-ones 
(Scheme 18). Standard Suzuki coupling with corresponding 
boronic acids gave intermediates 146a-146i. Similarly, 5 
Lawesson's chemistry was used to prepare thione intermedi-
ates. Deprotection of the 0-methyl group yielded the final 
biphenyl compounds 148a-148i and 149a-149i (Scheme 18). 
-continued 
0 s 
HO+N~ HO+N~ u~Ru~R 
148a-148i 149a-149i 
R~ CN 
K}-rn t--0 
Scheme 18. Synthesis of148a-148i and 149a-149i. 
I a ov~ 
I a OY'N~ u ~Br 
b 
-
145 
I o O'{N~ u ~R 
146a-146i 
-
I s O'{N~ u ~R 
147a-147i 
10 
15 
20 
h 
a) 4-bromobenzylbromide, K2C03, THF, reflux, b) R -B(OH)2, 
25 
Pd(PPh3)4, K2C03, toluene:ethanol:H20; 80° C. c) Lawesson's reaget, toluene, reflux; 
d) BBr3, CH2Cl2 
Synthesis of triazole based compounds 153a-153b and 
154a-154b is shown in Scheme 18. It involves the interme-
30 diacy of terminal alkyne 150, by N-alkylation reaction of 
3-methoxypyridine-2-one with propargyl bromide. Cu(I)-
catalyzed Huisgen cycloaddition gave the cyclized product 
151a-151b. Lawesson's chemistry was again used to gain 
access to thiolated analogs. Deprotection of 0-methyl group 
was achieved by reaction with BBr3 (Scheme 19). 
Scheme 19. Synthesis of153a-153b and 154a-154b. 
a 
-
X~H, 154a 
150 
X ~ dimethyamino, 154b 
a) propargyl bromide, K2C03, THF, reflux 
c 
-
X~H, 151a 
X ~ dimethyamino, 151b 
c 
-
X~H, 153a 
X ~ dimethyamino, 153b 
b) azido intermediates (phenyl azide, 4-azido-N, N-dimethylaniline), CuI, DIPEA, THF; 
c) BBr3, CH2Cl2; 
d) Lawessons' reagent, Toluene, reflux 
X~H, 152a 
X ~ dimethyamino, 152b 
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The activity of these compounds was evaluated using 
SAMDI analysis as described above. There is clear distinc-
tion in the HDAC inhibition activities of the carbonyl and 
thione analogs with the latter showing higher potency (Table 
11). The enhanced anti-HDAC activity of the thione analogs 5 
could be attributed to thiophilicity which favors Zn2 + binding. 
Most of the compounds in this series showed more selectivity 
towards HDAC6 andHDACS compared to HDACl .Ahead to 
head comparison of HDAC6 inhibition showed that com-
pound 144 b which contains one phenyl ring has better activity 10 
than biphenyl compound 144e. Similarly, for HDACS com-
pound 144b showed 2 fold superior activity when compared 
to 144e. This observation is consistent with the docking result 
as the 2nd phenyl ring doesn't take part in any meaningful 15 
interactions with residues on HDAC6 and HD ACS outer rims. 
However, replacement of the rd phenyl ring of compound 
144c with a 4-pyridyl ring results in slightly better activity 
against HDACS, however this substitution wasn't tolerated 
very well against HDAC6 resulting in 4-fold diminished 20 
activity when compared to 144b. 
Substitution of 2nd phenyl ring with electron donating N,N-
dimethylamino group at para position (149g) has similar 
effect as 4-pyridyl substitution (149i) for HDACS. Impor-
tantly, it resulted in loss of activity against HDAC6, making it 25 
distinctively selective for HDACS (Table 11). On the con-
trary, combination of pyridine and N,N-dimethylamine sub-
stitutions as seen in compound 149h resulted in HDAC6 
166 
selectivity as compared to HDACl and HDACS. Incorpora-
tion of methyl group, another electron donating group, 
revealed an interesting paradigm of selectivity for HDAC6 
and HDACS. In case ofHDAC6, ortho-substitution found to 
be more favored, followed by meta and then para. Conversely, 
for HDACS, trend for potency was reversed with para-substi-
tution showing the best IC50 values (comparing compounds 
149d, 149e, 149fin Table 11). Ortho-cyano substitution was 
also tolerated very well for electron withdrawing cyano group 
in case ofHDAC6 with IC50 value of372 nM, followed by 
para-substitution. Meta-cyano substitution was least toler-
ated. In case ofHDACS, changing substitution pattern didn't 
change IC50 values significantly showing approximately 2 
µM activity (comparing compounds 149a, 149b, 149c in 
Table 11 ). Interestingly, triazole substituted compounds 154a 
was found to be more active than corresponding biphenyl 
compound 144c for HDACS inhibition. However, a para-N, 
N-dimethylamino substitution of 154a which resulted in 
compound 154b was not beneficial. This is contrary to the 
effect of a similar substitution on the biphenyl compound 
(Table 11, comparing 144c and 149g; 154a and 154b) where 
para-N,N-dimethylamino substitution showed enhancement 
of activity. In case ofHDAC6 inhibition, bi phenyl compound 
144c showed superior activity when compared to triazole 
compound 154a which was also not surpassed by a para-N, 
N-dimethylamino substitution as seen in 154b. This SAR 
provided selective inhibitors of HDAC6 and HDACS, albeit 
with lower micromolar activity. 
TABLE 11 
In-vitro HDAC inhibition of3-hydroxypyridine-2-thiones 
COMPOUNDS 
rr/ 
~o 
OH 
142a 
HO-p 0 NLQ 
142b 
144b 
IC50 (nM)* 
HDACl HDAC6 HDAC8 
NI NI 8% 
NI NI 8% 
NI 457 ± 27 1272 ± 200 
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TABLE 11-continued 
In-vitro HDAC inhibition of3-hydroxypyridine-2-thiones 
IC50 (nM)* 
COMPOUNDS HDACl HDAC6 HDAC8 
HO-p 0 N"---0---0 
NI NI 8% 
142c 
NI 847 ± 188 4283 ± 1548 
144c 
NI NI 16% 
148a 
NI 957 ± 159 2075 ± 459 
149a 
HO-p 
0 
NI NI 9% 
CN 
148b 
HO-p NI 44% 1701 ±717 
s 
CN 
149b 
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TABLE 11-continued 
In-vitro HDAC inhibition of3-hydroxypyridine-2-thiones 
IC50 (nM)* 
COMPOUNDS HDACl HDAC6 HDAC8 
HO--Q 
0 
NI 5% 9% 
NC 
148c 
HO--Q NI 372 ± 35 1907 ± 771 
s 
NC 
149c 
HO--Q NI NI 25% 
ON~ 
148d 
HO--Q NI 454 ± 42 800 ± 304 
SN~ 
149d 
HO--Q 
0 
NI NI NI 
148e 
HO--Q NI 812 ± 286 2496 ± 1180 
s 
149e 
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TABLE 11-continued 
In-vitro HDAC inhibition of3-hydroxypyridine-2-thiones 
IC50 (nM)* 
COMPOUNDS HDACl HDAC6 HDAC8 
HO-Q 
0 
NI NI 9% 
148f 
NI 306 ± 69 3105 ± 1649 
149f 
HO-Q NI 11% 35% 
ON~< 
148g 
HO-Q NI NI 2858 ± 944 
SN~< 
149g 
HO-Q NI NI 37% 
ON~! 
N \ 
148h 
HO-Q NI 2390 ± 458 34% 
SN~/ 
N \ 
149h 
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TABLE 11-contmue 
------. AC inhibition of3- y 
'd'ne-2-thiones :~~~~'.::'....'.:~h~d~ro~x.:::::_w~~1 _1 _~~ Jn-vitro HD ( M)* ~~~~- ~~~ 
IC so ,,,n.:_:::_ _ _ 
c~ro~M~P~OUN~D~S~-----~~-~NI 
= NI 
HDACl HDAC6 
-----
HDAC8 
---r-\ HOO}-~N 
16% 
148i 
149i 
~hb 
0 f 
-= 
OH 
152a 
~hb 
s f 
-= 
OH 
154a 
~h'Q 
0 f 
-= -
OH N 
I 
152b 
NI 
NI 
NI 
NI 
2780 ± 323 2204 ± 355 
NI 17% 
41% 1570 ± 1067 
NI 8% 
174 
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TABLE 11-continued 
In-vitro HDAC inhibition of3-hydroxypyridine-2-thiones 
IC 50 (nM)* 
COMPOUNDS HDACl HDAC6 HDAC8 
~~h NI 1023 ± 99 1868 ± 723 
OH ' 'Q 
N-
I 
154b 
SAHA 38 +/- 2 95% 232 ± 19 
SAHA wass used for a positive control; 
NI - No significant Inhibition (below 20% Inhibition); 
% inhibitions of the compounds at 10 µMare given if the IC50 was above 10 µM. 
Synthetic Procedures 
Bromoalkanoic acid, benzyl bromide, 4-bromobenzylbro-
mide, 4-(bromomethyl)-1, 1'-biphenyl,3-methoxy-2(1H)-py-
ridone, propargyl bromide, phenylacetylene and representa-
tive boronic acids were purchased from either Sigma-Aldrich 
25 3.28 (s, 3H). 13C NMR (100 MHz, CDC13 ) o 1S8.01, 149.S6, 
128.81, 111.91, 104.31, SS.44, 37.10. 
or Alfa-Aesar. Anhydrous solvents and other reagents were 30 
purchased and used without further purification. Analtech 
silica gel plates (60 F254) were used for analytical TLC, and 
Analtech preparative TLC plates (UV 2S4, 2000 µm) were 
used for purification. UV light was used to examine the spots. 
Silica gel (200-400 Mesh) was used in colunm chromatogra- 35 
phy. NMR spectra were recorded on a Varian-Gemini 400 
magnetic resonance spectrometer. 1 H NMR spectra were 
recorded in parts per million (ppm) relative to the peak of 
CDC13 , (7.24 ppm), CD3 0D (3.31 ppm), or DMSO-d6 (2.49 
ppm). 13C spectra were recorded relative to the central peak of 40 
the CDC13 triplet (77.0 ppm), CD3 0D (49.0 ppm), or the 
DMSO-d6 septet (39.7 ppm), and were recorded with com-
plete heterodecoupling. Multiplicities are described using the 
abbreviation s, singlet; d, doublet, t, triplet; q, quartet; m, 
multiplet; and app, apparent. High-resolution mass spectra 45 
were recorded at the Georgia Institute of Technology mass 
spectrometry facility in Atlanta. Synthesis of 138a was 
adapted from literature protocol. Azidoalkanols (138a-138f) 
were prepared according to literature protocols and was used 
without further purification. Synthesis of phenyl azide and 50 
4-azido-N,N-dimethylaniline were adapted from literature 
protocols. 
l-Benzyl-3-methoxypyridine-2-one (141 b) 
To a stirring reaction mixture of3-methoxypyridine-2-one 
(0.2 g, 1.6 mmol) and K2C03 (0.66 g, 4.8 mmol) in DMF (8 
mL) was added benzyl bromide (0.33 g, 1.92 mmol) dropwise 
in a condenser equipped round bottom flask. Reaction mix-
ture was then heated to 100° C. After overnight stirring, 
reaction mixture was cooled down and diluted with water ( 40 
mL) and CHC13 (SO mL). Organic layer was washed with 
water (3x40 mL), brine (lx30 mL) and dried over Na2 S04 
and solvent was evaporated in vacuo to yield pure 141 b (0.26 
g, 7S%) as a colorless oil without any further purification 
needed. 1H NMR (400 MHz, CDC13 ) o 7.26 (m, SH), 6.8S 
( dd, J=6.9, 1.7 Hz, lH), 6.S4 ( dd, J=7 .S, 1.6 Hz, lH), 6.03 (m, 
lH), S.13 (s, 2H), 3.76 (s, 3H). 13C NMR (100 MHz, CDC13 ) 
0 1S7.94, ISO.OS, 136.31, 128.S6, 128.01, 127.74, 127.70, 
111.82, 104.83, 104.81, SS.64, Sl.64. 
1-(1, 1 '-Biphenylmethyl)-3-methoxypyridine-2-one 
(141c) 
Reaction of 3-methoxypyridine-2-one (0.2 g, 1.6 mmol), 
K2 C03 (0.66 g, 4.8 mmol), (4-bromomethyl)-1,1'-biphenyl 
(0.47 g, 1.92 mmol) in DMF (8 mL) according to method 
described for synthesis of 141b followed by colunm chroma-
tography with CH2 Cl2 , acetone (0-1S% gradient), MeOH 
(O-S% gradient) afforded pure 14 k (0.3S g, 76%) as a color-Synthesis of 1-methy 1-3-methoxypyridine-2-one 
(141a) 55 less oil. 1H NMR (400 MHz, CDC13 ) 7.48 (dd, J=2S.9, 20.6 
Hz, 4H), 7.32 (m, SH), 6.88 (m, lH), 6.S4 (d, J=7.2 Hz, lH), 
6.04 (t, J=7.1 Hz, lH), S.16 (s, 2H), 3.76 (s, 3H). 13C NMR 
(100 MHz, CDC13 ) o 1S7.86, 149.97, 140.Sl, 140.24, 13S.28, 
128.Sl, 128.40, 127.71, 127.16, 127.13, 126.74, 111.82, 
To a stirring reaction mixture of3-methoxypyridine-2-one 
(0.2 g, 1.6 mmol) and KOH (0.18 g, 3.2 mmol) in methanol 
was added Mel (0.68 g, 4.8 mmol) dropwise in condenser 
equipped round bottom flask. After overnight stirring at room 
temperature revealed quantitative formation of product. 
Reaction mixture was then diluted with water (3S mL) and 
CHC13 (40mL). Organic layer was washed with water (lx3S 
mL ), brine (1 x30 mL) and dried over Na2S04 and solvent was 
evaporated in vacua to yield pure 141a (0.20 g, 89%) as a 65 
colorless oil. 1H NMR (400 MHz, CDC13 ) o 6.66 (m, lH), 
6.3S (d, J=7.4 Hz, lH), S.83 (t, J=7.1 Hz, lH), 3.S2 (s, 3H), 
60 104.80, SS.S6, Sl.36. 
l-Methyl-3-hydroxypyridine-2-one (142a) 
To a solution of 141a (0.1 g, 0.68 mmol) in dry CH2Cl2 (8 
mL) was slowly added IM BBr3 (0.82 mL) at -30° C. under 
inert atmosphere. The reaction mixture was stirred for 48 hat 
room temperature. The mixture was again cooled to -30° C. 
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& thenMeOH (5 mL) was slowly added to the mixture. After 
evaporation of solvent, the residue was adjusted to pH 7 with 
IM NaOH and then extracted with CHCl3 (3x30 mL). The 
combined organic layer dried over Na2 SO 4 . After evaporation 
178 
of solvent, the residue was purified by prep-TLC with 5 
CH2 Cl2 :Acetone:MeOH (IO:l:0.2) to give 6I mg (72%) of 
pure off white solid. 1H NMR (400 MHz, CDCl3 ) o 7.92 (s, 
lH), 6.78 (dd, J=Il.1, 7.I Hz, 2H), 6.IO (t, J=7.0 Hz, lH), 
3.57 (s, 3H). 13C NMR (100 MHz, CDCl3 ) o I58.82, I46.67, 
I27.63, I I4.36, I06.68, 37.28. HRMS (EI) calcd for 
10 C6H7N02 [Mt I25.0477. found 125.0477. 
I42a afforded pure I44b (0.034 g, 72%) as olive green solid. 
1H NMR (400 MHz, cd3 od) o 7.34 (m, 3H), 6.84 (m, lH), 
5.83 (d, J=49.5 Hz, lH). 13C NMR (100 MHz, CD3 0D) o 
I28.I2, I27.6I, I27.27, I26.94, I 13.77. HRMS (EI) calcdfor 
C12H11NOS [Mt 2I7.0561. found2I7.0762. 
I -(I, I'-Bipheny lmethy 1)-3-hydroxypyridine-2-thione 
(I44c) 
Reactionof143c (O.IO g, 0.32 mmol) with IM BBr3 (0.48 
mL) in dry CH2 Cl2 ( 5 mL) within 48 h according to procedure 
I42a afforded pure I44c (0.074 g, 90%) as olive green solid. 
1H NMR (400 MHz, cd3 od) o 7.39 (m, 9H), 6.88 (m, 3H), 
5.86 (s, 2H). 13C NMR (IOI MHz, cd3 od) o I41.33, I40.2I, 
I28.7I, I28.52, I27.49, I27.45, I26.89. HRMS (EI) calcdfor 
I-Benzyl-3-hydroxypyridine-2-one (I42b) 
15 C18H15NOS [Mt 293.0874. found 293.0873. 
Reactionof14Ib (O.I5 g, 0.55 mmol) with IM BBr3 (0.66 
mL) in dry CH2 Cl2 ( 5 mL) within 48 h according to procedure 
I42a afforded pure I42b (O.I3 g, 90%) as slightly brownish 
solid. 1H NMR (400 MHz, CDCl3 ) o 7.3.I (m, SH), 6.83 (m, 
3H), 6.I4 (t, J=7.I Hz, lH), 5.I9 (s, 2H). 13C NMR (100 
MHz, CDCl3 ) o I58.62, I46.78, 135.82, I28.74, I27.97, 
I26.53, I 13.94, I06.95, 52.I8. HRMS (EI) calcd for 20 
C12H11 N02 [Mt 20I .0792. found 20I .0790. 
I -( 4-Bromo benzyl )-3-methoxypyridine-2 (I H)-one 
(I45) 
To a stirring reaction mixture of3-methoxypyridine-2-one 
(2.00 g, I6 mmol) and K2C03 (4.42 g, 32 mmol) in THF was 
added 4-bromobenzyl bromide (5.20 g, 20.8 mmol) slowly. 
Reaction mixture was the heated to reflux and stirring con-
tinued overnight. Reaction mixture was then cooled down and 
I -(I, I '-Bipheny !methyl )-3-hydroxypyridine-2-one 
(I42c) 
Reaction of I4 k (O.I3 g, 0.43 mmol) with IM BBr3 (0.5I 
mL) in dry CH2 Cl2 (7 mL) within 48 h according to procedure 
I42a afforded pure I42c (O.I g, 82%) as slightly brownish 
solid. 1HNMR(400 MHz, DMSO-d6) o 9.06 (s, lH), 7.6I (d, 
J=7.5 Hz, 4H), 7.36 (m, 6H), 6.70 (d, J=6.5 Hz, lH), 6.I2 (t, 
1=6.9 Hz, lH), 5.I6 (s, 2H). 13CNMR (IOOMHz, DMSO-d6 ) 
0 I47.02, 139.77, I39.46, I36.58, I28.93, I28.35, I28.I5, 
I27.49, I26.86, I26.66, II4.75, IOS.64, 51.07. HRMS (EI) 
calcd for C18H15N02 [Mt 277.I IOl. found 277.I I03. 
I-Benzyl-3-methoxypyridine-2-thione (I43b) 
A suspension of I4Ib (0.060 g, 0.28 mmol) and Lawes-
son's reagent (0.067 g, O.I 7 mmol) in toluene (IO mL) was 
heated to reflux overnight. Reaction mixture was then cooled 
25 separated into organic and aqueous layer by adding CH2Cl2 
(I20mL) and water (60mL). Organic layer was separated and 
subsequently washed with water (2x60 mL), brine (Ix40 
mL). Organic layer was dried on Na2S04 and solvent was 
evaporated in vacuo. Crude yellowish solid was triturated 
30 with hexanes to give pure white solid I45 (3.49 g, 74%) 
without further purification. 1 H NMR ( 400 MHz, CDCl3 ) o 
7.25 (m, 2H), 7.04 (m, 2H), 6.78 (dd, J=6.8, 1.2 Hz, lH), 6.45 
(dd, J=7.2, 1.6 Hz, lH), 5.94 (t, J=7.2 Hz, lH), 4.95 (s, 2H), 
3.64 (s, 3H). 13C NMR (100 MHz, CDCl3 ) o I57.7I, I49.9I, 
35 I35.29, I3I .49, I29.59, I27.53, I21.57, 111.82, I04.98, 
55.54, 51.10. HRMS (EI) calcd for C13H12BrN02 [Mt 
293.0051. found 293.0051. 
to room temperature. Toluene was evaporated in vacuo and 40 
resulting crude solid was directly loaded on prep-TLC. Elu-
tion withCH2Cl2 :Acetone:MeOH (5:1:0.2) gave I43b 53 mg 
(82%) of yellow solid. 
I-( 4-Cyano-(I, I '-biphenylmethyl))-3-methoxyoxy-
pyridine-2-one (I46a) 
I45 (0.26 g, 0.86 mmol), ( 4-cyanophenyl)boronic acid 
(O.I4 g, 0.95 mmol), 2M aq. K2 C03 (0.24 g, 1.73 mmol), 
toluene (8 mL), EtOH (4 mL) and water (4 mL) were added 
into reaction flask equipped with magnetic stirrer and water 
condenser. The resulting suspension was degassed for I 0 min 
1 H NMR ( 400 MHz, CDCl3 ) o 7 .30 (m, 6H), 6.65 ( d, J=7 .7 
Hz, lH), 6.54 (t, J=7.0 Hz, lH), 5.89 (s, 2H), 3.88 (s, 3H). 13C 45 
NMR (100 MHz, CDCl3 ) o I73.I8, I59.0I, I35.I8, I31.70, 
I28.72, I28.03, I27.98, 111.57, I09.63, 58.79, 56.61. HRMS 
(EI) calcd for C13H13NOS [Mt 231.07I8. found 231.07I6. 
by sparging with argon gas. Pd(PPh3 ) 4 (2.5 mo!%) was added 
and the reaction mixture was heated to reflux overnight under 
argon atmosphere. After cooling to room temperature, 
I-(I, I '-Biphenylmethyl)-3-methoxypyridine-2-
thione (I43c) 
Reaction of I41c (O.I3 g, 0.44 mmol) and Lawesson's 
reagent (O. I I g, 0.27 mmol) in toluene according to method 
described for synthesis of I43b afforded I22 mg of I43c 
(88%) of yellow solid. 1HNMR (400 MHz, CDCl3 ) 7.52 (m, 
lH), 7.35 (m, 2H), 6.66 (dd, J=7.8, 1.3 Hz, lH), 6.55 (dd, 
J=7.8, 6.6 Hz, lH), 5.93 (s, lH), 3.89 (s, lH). 13C NMR (100 
MHz, CDCl3 ) o I73.08, I58.99, I40.8I, I40.20, I34.I4, 
I31.72, I28.6I, I28.42, I27.35, I27.28, I26.83, IIl.62, 
I09.67, I04.80, 58.52, 56.58. HRMS (EI) calcd for 
C19H17NOS [Mt 307.I031. found 307.I029. 
I-Benzyl-3-hydroxypyridine-2-thione (I44b) 
Reactionof143b (0.050 g, 0.2I mmol)with IMBBr3 (0.66 
mL) in dry CH2 Cl2 ( 5 mL) within 48 h according to procedure 
50 CH2Cl2 was added (50mL) & washed with water(Ix40mL), 
brine (Ix20 mL) and dried on Na2S04 . Column chromatog-
raphy using gradient CHCl3 :Acetone:MeOH (with 5%-20% 
of acetone and I %-8% MeOH gradual increase) gave pure off 
white solid I46a (0.42 g, 78% ). 1 H NMR (CDCl3 , 400 MHz) 
55 o 7.60 (m, 4H), 7.40 (m, 4H), 6.90 (dd, J=6.8, 1.6 Hz, lH), 
6.55 (dd, J=7.6, 1.6 Hz, lH), 6.07 (t, J=7.2 Hz, lH), 5.I6 (s, 
2H), 3.75 (s, 3H). 13C NMR (100 MHz, CDCl3 ) o I58.08, 
I50.28, I44.96, I38.62, I37.I3, 132.56, 131.96, I28.85, 
I28.55, I28.43, I27.96, I27.60, I27.53, 118.88, 112.II, 
60 I I0.88, I05.24, 56.20, 51.80. HRMS (EI) calcd for 
C20H6N2 0 2 [Mt 3I6.I2I2. found 3I6.I2IO. 
65 
I-(3-Cyano-(I, I '-biphenylmethyl))-3-methoxyoxy-
pyridine-2-one (I46b) 
Reaction of I40 (0.25 g, 0.85 mmol), (3-cyanophenyl) 
boronicacid(O.I4 g, 0.93mmol), 2Maq. K2C03 (0.23 g, 1.69 
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mmol) and Pd(PPh3 ) 4 (2.5 mo! %) according to method 
described for synthesis of 146a within 18 h afforded 17 5 mg 
of 146b ( 66%) of white solid. 1 H NMR ( 400 MHz, CDCl3 ) o 
7.70 (m, 2H), 7.48 (m, 6H), 6.92(dd,1=6.9, 1.6 Hz, lH), 6.57 
(dd, 1=7.4, 1.4 Hz, lH), 6.08(t,1=7.2 Hz, lH), 5.16 (s, 2H), 5 
3.76 (s, 3H). 13C NMR (100 MHz, CDCl3 ) o 158.09, 150.24, 
141.70, 138.33, 136.81, 131.38, 130.76, 130.45, 129.66, 
128.87, 127.96, 127.36, 118.76, 112.82, 112.14, 105.26, 
55.84, 51.66. HRMS (EI) calcd for C20H16N20 2 [Mt 
316.1212. found 332.1216. 10 
of white solid. 1HNMR(400MHz, cdcl3 ) 07.31(d,1=7.9Hz, 
lH), 7.17 (m, 2H), 6.93 (m, lH), 6.56(dd,1=7.4, 1.6 Hz, lH), 
6.06(t,1=7.2 Hz, lH), 5.18 (s, lH), 3.76 (s, lH), 2.20 (s, lH). 
13C NMR (101 MHz, cdcl3 ) o 158.13, 150.23, 141.51, 
141.26, 135.23, 135.00, 130.33, 129.68, 129.51, 128.13, 
127.85, 127.34, 125.77, 112.13, 105.07, 55.82, 51.79, 20.45. 
HRMS (EI) calcd for C20H19N02 [Mt 305.1416. found 
305.1419. 
1-(2-Cyano-(1, 1 '-biphenylmethyl)-3-methoxyoxypy-
ridine-2-one (146c) 
Reaction of 140 (0.15 g, 0.50 mmol), (2-cyanophenyl) 
boronicacid(0.09 g, 0.60mmol), 2Maq. K2 C03 (0.14 g, 1.69 
mmol) and Pd(PPh3 ) 4 (2.5 mo! %) according to method 
described for synthesis of 146a within 18 h afforded 118 mg 
1-( 4-Dimethylamino-(1,l '-biphenylmethyl))-3-meth-
oxyoxypyridine-2-one (146g) 
Reaction of 145 (0.25 g, 0.85 mmol), (4-(dimethylamino) 
phenyl)boronic acid (0.17 g, 1.02 mmol), 2M aq. K2 C03 
15 (0.23 g, 1.69 mmol), Pd(PPh3 ) 4 (2.5 mo! %) according to 
method described for synthesis of 146a within 18 h afforded 
230 mg of 146 g (81 % ) as white solid. 1 H NMR ( 400 MHz, 
CDCl3 ) o 7.46 (m, 4H), 7.29 (m, 2H), 6.86(dd,1=7.2, 2.0Hz, 
lH), 7.73 (m, 2H), 6.52(dd,1=7.2, 1.6 Hz, lH), 6.01(t,1=7.2 of 146c (75%) of white solid. 1H NMR (400 MHz, cdcl3 ) o 
7.72 (m, lH), 7.60 (m, lH), 7.45 (m, 2H), 6.94(dd,1=6.9, 1.7 
Hz, lH), 6.60(dd,1=7.4, 1.6 Hz, lH), 6.10(t,1=7.2 Hz, lH), 
5.21 (s, lH), 3.80 (s, lH). 13C NMR (100 MHz, cdcl3 ) o 
158.01, 150.18, 144.70, 137.56, 136.94, 133.61, 132.78, 
129.91, 129.01, 128.31, 127.92, 127.55, 118.54, 112.01, 
110.94, 105.13, 55.74, 51.60. HRMS (EI) calcd for 25 
C20H16N2 0 2 [Mt 316.1212. found 316.1201. 
20 Hz, lH), 5.13 (s, 2H), 3.76 (s, 3H), 2.93 (s, 6H). 13C NMR 
(100 MHz, CDCl3 ) o 157.86, 149.90, 149.73, 140.55, 133.81, 
128.43, 128.04, 127.68, 127.28, 126.16, 112.40, 111.77, 
104.69, 55.53, 51.31, 40.18. HRMS (EI) calcd for 
C21 H22N2 0 2 [Mt 334.1681. found 334.1684. 
1-( 4-(6-(Dimethylamino )pyridine-3-yl)benzyl))-3-
methoxyoxypyridine-2-one (146h) 
1-( 4-Methyl-(1,l '-biphenylmethyl))-3-methoxyoxy-
pyridine-2-one (146d) 
Reaction of 145 (0.25 g, 0.85 mmol), p-tolylboronic acid 
(0.14 g, 1.02 mmol), 2M aq. K2C03 (0.23 g, 1.69 mmol), 
Pd(PPh3 ) 4 (2.5 mo! %) according to method described for 
synthesis ofl 46a within 18 h afforded 259 mg ofl 46d ( quan-
titative) of white solid. 1 H NMR ( 400 MHz, CDCl3 ) o 7.49 ( d, 
1=8.1Hz,2H), 7.42(d,1=8.1Hz,2H), 7.33(d,1=8.1Hz,2H), 
7.19(d,1=8.0 Hz, 2H), 6.88(dd,1=6.9, 1.6 Hz, lH), 6.54 (dd, 
1=7.4, 1.4 Hz, lH), 6.03 (t, 1=7.2 Hz, lH), 5.15 (s, 2H), 3.76 
(s, 3H), 2.34 (s, 3H). 13C NMR (100 MHz, CDCl3 ) o 157.81, 
149.88, 140.39, 137.29, 136.87, 134.93, 129.21, 128.35, 
127.66, 126.91, 126.53, 111.75, 104.78, 55.51, 51.31, 20.80. 
HRMS (EI) calcd for C20H19N02 [Mt 305.1416. found 
305.1422. 
1-(3-Methyl-(1, 1 '-biphenylmethyl) )-3-methoxyoxy-
pyridine-2-one (146e) 
Reaction of 140 (0.20 g, 0.68 mmol), m-tolylboronic acid 
(0.11g,0.82 mmol), 2M aq. K2 C03 (0.19 g, 1.36 mmol) and 
Pd(PPh3 ) 4 (2.5 mo! %) according to method described for 
synthesis of146a within 18 hafforded259 mg of146e (quan-
titative) of white solid. 1H NMR (400 MHz, cdcl3 ) o 7.49 (m, 
lH), 7.29 (m, 2H), 7.11(d,1=7.2 Hz, lH), 6.88(dd,1=6.9, 1.7 
Hz, lH), 6.53(dd,1=7.4, 1.6 Hz, lH), 6.03(t,1=7.2 Hz, lH), 
5.15 (s, 1lH),3.75 (s, lH), 2.35 (s, lH). 13CNMR(lOOMHz, 
cdcl3 ) o 157.81, 149.86, 140.58, 140.16, 137.99, 135.11, 
128.37, 128.29, 127.83, 127.66, 127.46, 127.10, 123.80, 
111.81, 104.80, 55.48, 51.30, 21.19. HRMS (EI) calcd for 
C20H19N02 [Mt 305.1416. found 305.1415. 
1-(2-Methyl-(1, 1 '-biphenylmethyl) )-3-methoxyoxy-
pyridine-2-one (146f) 
Reaction of 140 (0.20 g, 0.68 mmol), 0-tolylboronic acid 
(0.11g,0.82 mmol), 2M aq. K2 C03 (0.19 g, 1.36 mmol) and 
Pd(PPh3 ) 4 (2.5 mo! %) according to method described for 
synthesis of 146a within 18 h afforded 243 mg of 146f (98%) 
Reaction of 145 (0.43 g, 1.44 mmol), (6-(dimethylamino) 
30 pyridine-3-yl)boronic acid (0.2 g, 1.20 mmol), 2M aq. K2 C03 
(0.33 g, 2.41 mmol), Pd(PPh3 ) 4 (2.5 mo! %) according to 
method described for synthesis of 146a within 18 h afforded 
335 mg of 146h (83%) of white solid. 1H NMR (400 MHz, 
CDCl3 ) o 8.28 ( d, 1=2.3 Hz, lH), 7 .51 ( dd, 1=8.8, 2.5 Hz, lH), 
35 7.33 (d, 1=8.2 Hz, 2H), 7.22 (d, 1=8.2 Hz, 2H), 6.80 (dd, 
1=6.9, 1.6 Hz, lH), 6.44 (m, 2H), 5.94(t,1=7.2 Hz, lH), 5.04 
(s, 2H), 3.66 (s, 3H), 2.97 (s, 6H). 13C NMR (100 MHz, 
CDCl3 ) o 158.12, 157.61, 149.68, 145.49, 137.75, 135.14, 
134.20, 128.35, 127.54, 125.69, 123.15, 111.62, 105.23, 
40 104.62, 55.36, 51.16, 37.66. HRMS (EI) calcd for 
C20H21N3 0 2 [Mt 335.1634. found 335.1635. 
45 
1-( 4-(Pyridin-4-yl)benzyl)-3-methoxy-pyridine-2-
one (146i) 
Reaction of 145 (0.25 g, 0.85 mmol), pyrdin-4-ylboronic 
acid (0.12 g, 1.02 mmol), 2M aq. K2 C03 (0.23 g, 1.69 mmol), 
Pd(PPh3 ) 4 (2.5 mo! %) according to method described for 
synthesis of 146a within 18 h afforded 203 mg of 146i (82%) 
50 of white solid. 1HNMR(400MHz, CDCl3 ) o 8.54(dd,1=4.5, 
1.6 Hz, 2H), 7.48 (m, 2H), 7.36 (m, 4H), 6.87(dd,1=6.9, 1.7 
Hz, lH), 6.53(dd,1=7.4, 1.6 Hz, lH), 6.03 (t, 1=7.2 Hz, lH), 
5.13 (s, 2H), 3.72 (s, 3H). 13C NMR (100 MHz, CDCl3 ) o 
157.82, 150.32, 150.01, 149.90, 147.40, 137.31, 137.28, 
55 128.57, 127.68, 127.04, 121.22, 111.90, 104.98, 55.57, 
51.42. HRMS (EI) calcd for C18H16N20 2 [Mt 292.1212. 
found 292.1205. 
1-( 4-Cyano-(1, 1 '-biphenylmethyl))-3-methoxyoxy-
60 pyridine-2-thione (147a) 
A suspension of146a (0.13 g, 0.42 mmol) and Lawesson's 
reagent (0.10 g, 0.25 mmol) in toluene (10 mL) was heated to 
reflux overnight. Reaction mixture was then cooled to room 
65 temperature. Toluene was evaporated off under vacuo and 
resulting crude solid was directly loaded on prep-TLC. Elu-
tion with CHCl3 :Acetone:EtOH (12: 1:0.2) gave 147a 123 mg 
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1-(2-Methyl-(1, 1 '-biphenylmethyl)-3-methoxyoxy-
pyridine-2-thione (147f) 
Reaction of 146f (0.14 g, OAS mmol) and Lawesson's 
(88%) of yellow solid. 1H NMR (CDCl3, 400 MHz) o 7.60 
(m, 4H), 7.40 (m, 4H), 6.90(dd,1=6.8, 1.6 Hz, lH), 6.SS (dd, 
1=7.6, 1.6 Hz, lH), 6.07 (t, 1=7.2 Hz, lH), S.16 (s, 2H), 3.7S 
(s, 3H). 13C NMR (100 MHz, CDCl3) o 1S8.08, lS0.28, 
144.96, 138.62, 137.13, 132.S6, 131.96, 128.8S, 128.SS, 
128.43, 127.96, 127.60, 127.S3, 118.88, 112.11, 110.88, 
lOS.24, S6.20, Sl.80HRMS (EI)calcdforC20H16N2 0S [Mt 
332.0983. found 332.0987. 
5 reagent (0.11 g, 0.27 mmol) in toluene according to method 
described for synthesis of 147a afforded 118 mg of 147f 
(86%) as yellow solid. 1 H NMR ( 400 MHz, cdcl3) o 7.42 ( dd, 
1=6.6, 1.0 Hz, lH), 7 .22 (m, 3H), 6.68 ( d, 1=7 .3 Hz, lH), 6.S9 
(m, lH), S.96 (s, lH), 3.90 (s, lH), 2.22 (s, lH). 13C NMR 
10 (101 MHz, cdcl3) o 1S8.97, 141.S4, 140.93, l3S.02, l33.S9, 
131.79, 130.13, 129.46, 129.42, 127.6S, 127.18, l2S.S7, 
111.62, 109.67, S8.S6, S6.S7, 20.2S. HRMS (EI) calcd for 
C20H19NOS [Mt 30S.1187. found 321.1189. 
1-(3-Cyano-(1, 1 '-biphenylmethyl) )-3-methoxypyri-
dine-2-thione (147b) 
Reaction of 146b (0.11 g, 0.36 mmol) and Lawesson's 
reagent (0.09 g, 0.22 mmol) in toluene according to method 
described for synthesis of 147a afforded 113 mg of 147b 15 
(9S%)ofyellow solid. 1HNMR(400MHz, DMSO-d6) o 7.92 
(m, 3H), 7.84 (m, 2H), 7.71(d,1=8.4 Hz, 2H), 7.36 (d, 1=8.8 
Hz, 2H), 7.00 (m, lH), 6.80 (m, lH), S.9S (s, 2H), 3.78 (s, 
3H). 13C NMR (100 MHz, CDCl3) o 173.39, 1S9.26, 144.82, 
138.81, 13S.79, 132.SS, 131.81, 128.6S, 127.S8, 127.SO, 20 
118.77, 111.80, 110.98, 109.69, S8.63, S6.74. HRMS (EI) 
calcd for C20H16N20S [Mt 332.0983. found 332.0984. 
1-( 4-Dimethylamino-(1,l '-biphenylmethyl))-3-meth-
oxyoxypyridine-2-thione (147g) 
Reaction of 146 g (0.22 g, 0.67 mmol) and Lawesson's 
reagent (0.16 g, 0.40 mmol) in toluene according to method 
described for synthesis of 147a afforded 172 mg of 147 g 
(73%) as yellow solid. 1 H NMR ( 400 MHz, CDCl3) 7 .39 (m, 
SH), 7.22 (m, 2H), 6.69 (m, 3H), 6.6S (m, lH), S.82 (s, 2H), 
3.82 (s, 3H), 2.88 (s, 6H). 13C NMR (100 MHz, CDCl3) o 
172.36, 1S8.73, 149.92, 140.89, 132.48, 131.84, 128.44, 1-(2-Cyano-(1, 1 '-biphenylmethyl)-3-methoxyoxypy-
ridine-2-thione (147c) 
Reaction of 146c (0.09 g, 0.28 mmol) and Lawesson's 
reagent (0.07 g, 0.17 mmol) in toluene according to method 
described for synthesis ofl 4 7 a afforded 72 mg ofl 4 7 c (77%) 
25 128.20, 127.29, 126.32, 112.69, 112.02, 110.17, S8.68, 
S6.3l, 40.24. HRMS (EI) calcd for C21H22N2 0S [Mt 
3SO.l4S3. found 3S0.14Sl. 
of yellow solid. 1H NMR (400 MHz, cdcl3) o 7.74 (m, lH), 30 
7.63(td,1=7.7, 1.4 Hz, lH), 7.4S (m, 2H), 6.71(dd,1=7.8, 1.3 
Hz, lH), 6.62 (dd, 1=7.8, 6.6 Hz, lH), 6.00 (s, lH), S.28 (s, 
lH), 3.93 (s, lH). 13C NMR (101 MHz, cdcl3) o 173.38, 
lS9.22, 144.68, 137.79, 13S.80, 133.67, 132.86, 131.9S, 
129.97, 129.17, 128.2S, 127.66, 118.S9, 111.84, 111.01, 35 
109.76, S8.63, S6.74. HRMS (EI) calcd for C20H16N20S 
[Mt 332.0983. found 332.0981. 
1-( 4-( 6-(Dimethylamino )pyridin-3-yl)benzyl) )-3-
methoxyoxypyridine-2-thione (14 7h) 
Reaction of 146h (0.14 g, 0.42 mmol) and Lawesson's 
reagent (0.10 g, 0.2S mmol) in toluene according to method 
described for synthesis of 147a afforded 130 mg of 147h 
(88%) of yellow solid. 1HNMR (400 MHz, CDCl3) o 8.32 (d, 
1=2.3 Hz, lH), 7.S6(dd,1=8.6, 2.1 Hz, lH), 7.36(dd,1=19.8, 
7.3 Hz, 3H), 7.26 (d, 1=8.0 Hz, 2H), 6.61 (d, 1=7.8 Hz, lH), 
6.SO (m, 2H), S.8S (s, 2H), 3.83 (s, 3H), 3.03 (s, 6H). 13C 
NMR (100 MHz, CDCl3) o 172.74, 1S8.80, 1S8.31, l4S.6S, 1-( 4-Methyl-(1,l '-biphenylmethyl))-3-methoxyoxy-
pyridine-2-thione (147d) 40 138.13, 13S.32, 133.08, 131.66, 128.46, l2S.9S, 123.21, 
111.S7, 109.64, lOS.42, S8.42, S6.47, 37.86. HRMS (EI) 
calcd for C20H21N30S [Mt 3Sl.l40S. found 3Sl.l40S. Reaction of 146d (0.12 g, 0.39 mmol) and Lawesson's 
reagent (0.09 g, 0.23 mmol) in toluene according to method 
described for synthesis of 147a afforded 117 mg of 147d 
(94%) as yellow solid. 1H NMR (400 MHz, CDCl3) o 7.Sl 45 
(m, 2H), 7.42 (m, 2H), 7.34 (m, 3H), 7.21(dd,1=8.4, 0.6 Hz, 
2H), 6.66 (dd, 1=7.8, 1.2 Hz, lH), 6.SS (dd, 1=7.8, 6.6 Hz, 
lH), S.92 (s, 2H), 3.89 (s, 3H), 2.36 (s, 3H). 13C NMR (100 
MHz, CDCl3) o 173.0S, 1S8.97, 140.74, 137.30, 137.08, 
133.81, 131.70, 129.33, 128.42, 127.12, 126,64, 111.S9, 50 
l09.6S, S8.S2, S6.S7, 20.91. HRMS (EI) calcd for 
C20H19NOS [Mt 321.1187. found 321.1192. 
1-( 4-(Pyridin-4-yl)benzyl)-3-methoxypyridine-2-
thione (147i) 
Reaction of 146i (0.13 g, OAS mmol) and Lawesson's 
reagent (0.11 g, 0.27 mmol) in toluene according to method 
described for synthesis of 147a afforded 104 mg of 147i 
(76%) as yellow solid with greenish tinge. 1H NMR (400 
MHz, CDCl3) o 8.S9 (d, l=S.9 Hz, 2H), 7.SS (d, 1=8.3 Hz, 
2H), 7.39 (m, SH), 6.67 (dd, 1=7.8, 1.1 Hz, lH), 6.S8 (dd, 
1=73, 6.7 Hz, lH), S.9S (s, 2H), 3.89 (s, 3H). 13C NMR (100 
MHz, CDCl3) o 173.29, lS9.lS, lS0.11, 147.43, 137.67, 1-(3-Methyl-(1, 1 '-biphenylmethyl) )-3-methoxyoxy-
pyridine-2-thione (147e) 55 136.17, 131.78, 128.S8, 127.28, 121.3S, 111.72, 109.67, 
S8.S4, S6.66. HRMS (EI) calcd for C18H16N2 0S [Mt 
308.0983. found 308.097S. Reaction of 146e (0.12 g, 0.37 mmol) and Lawesson's 
reagent (0.09 g, 0.23 mmol) in toluene according to method 
described for synthesis of 147a afforded 112 mg of 147e 
(93%) as yellow solid. 1H NMR (400 MHz, cdcl3) o 7.S3 (m, 60 
lH), 7.33 (m, 2H), 7.14 (dd, 1=7.1, 0.6 Hz, lH), 6.67 (dd, 
1=7.8, 1.2 Hz, lH), 6.S6 (m, lH), S.94 (s, lH), 3.91 (s, lH), 
2.39 (s, lH). 13C NMR (101 MHz, cdcl3) o 173.21, 1S9.07, 
141.06, 140.28, 138.24, 134.07, 131.72, 128.S7, 128.48, 
128.09, 127.69, 127.44, 124.01, 111.62, 109.66, S8.60, 65 
S6.63, 21.39. HRMS (EI) calcd for C20H19NOS [Mt 
30S.1187. found321.1188. 
1-( 4-Cyano-( 1, 1 '-bipheny !methyl )-3-hydroxyoxypy-
ridine-2-one (148a) 
To a solution of 146a (0.1 g, 0.32 mmol) in dry CH2Cl2 (8 
mL) was slowly added IM BBr3 (0.3S mL) at -30° C. under 
argon atmosphere. The reaction mixture was stirred for 32 hat 
room temperature. The mixture was again cooled to -30 & 
then MeOH (S mL) was slowly added to the mixture. After 
evaporation of solvent, the residue was adjusted to pH 7 with 
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IM NaOH and then extracted with CHC13 (3x30 mL). The 
combined organic layer dried over Na2SO 4. After evaporation 
of solvent, the residue was purified by prep-TLC with CHC13: 
Acetone:EtOH (IO:l:0.2) to give 89 mg of I48a (94%) as 
pure slightly brownish solid. 1 H NMR ( 400 MHz, DMSO) o 5 
9.08 (s, lH), 7.87(dd,1=24.8, 7.9 Hz, 4H), 7.7I (d, 1=7.6 Hz, 
2H), 7.40 (d, 1=7.7 Hz, 2H), 7.29 (d, 1=6.7 Hz, lH), 6.70 (d, 
1=6.7 Hz, lH), 6.13(t,1=6.8 Hz, lH), 5.I8 (s, 2H). 13C NMR 
(100 MHz, CDC13) o I47.I I, I45.I3, I39.24, 136.77, I32.87, 
I28.95, I27.97, I27.89, I27.06, II9.08, II4.I5, IIl.35, lO 
I07.55, 52.48, 29.93. HRMS (ESI) calcd for C19H15N20 2 
[M+Ht 303.I I28. found 303.I I24. 
184 
(s, lH). 13C NMR (IOI MHz, cdcl3) o I46.7I, I41.19, 
I40.38, I38.32, I34.70, I28.63, I28.4I, I28.I6, I27.79, 
I27.56, I26.60, I24.I I, I I3.66, I06.98, 52.IO, 2I .45. HRMS 
(EI) calcd for C19H17N02 [Mt 29I .I259. found 29I .I263. 
I-(2-Methyl-(I, I '-biphenylmethyl) )-3-hydroxyoxy-
pyridine-2-one (I48f) 
I-(3-Cyano-(I, I '-biphenylmethyl))-3-hydroxyoxypy-
ridine-2-one (I48b) 
Reactionof146b (0.05 g, O.I5 mmol) with IM BBr3 (0.26 
mL) in dry CH2Cl2 within 48 h according to procedure I48a 
afforded pure I 48b ( 44 mg, quantitative) as slightly brownish 
solid. 1 H NMR ( 400 MHz, DMSO-d6) o 9.08 (s, lH), 8.I I (s, 20 
lH), 7.98 (d, 1=7.8 Hz, lH), 7.70 (m, 4H), 7.40 (d, 1=7.7 Hz, 
2H), 7.28 (d, 1=6.2 Hz, lH), 6.70 (d, 1=6.8 Hz, lH), 6.I3 (t, 
1=6.7 Hz, lH), 5.I 7 (s, 2H). 13C NMR (IOI MHz, CDC13) o 
I46.78, I41.62, I38.62, I36.I3, I31.3I, I30.82, I30.5I, 
I29.62, I28.7I, I27.49, I26.66, I I8.66, I 13.90, I I2.96, 25 
I07.26, 52.25. HRMS (EI) calcd for C19H14N20 2 [M+Ht 
302.I055. found 302.I055. 
Reactionof146f(0.077 g, 0.25 mmol) with IM BBr3 (0.38 
mL) indry CH2Cl2 (5 mL) within48 haccordingto procedure 
I 48a afforded pure I 48f ( 65 mg, 90%) as slightly brownish 
solid. 1H NMR (400 MHz, cdcl3) o 7.28 (m, 3H), 6.87 (dd, 
1=3I.4, 6.8 Hz, lH), 6.I8 (t, 1=6.9 Hz, lH), 5.27 (d, l=I6.7 
Hz, lH), 2.26 (s, lH). 13C NMR (IOI MHz, cdcl3) o I46.73, 15 I41.8I, I41.14, I35.24, I34.30, 130.3I, I29.66, I27.68, 
I27.37, I26.73, I25.75, I I3.59, I06.99, 52.2I, 20.40. HRMS 
(EI) calcd for C19H17N02 [Mt 29I .I259. found 29I .I260. 
I-( 4-Dimethylamino-(I, I '-biphenylmethyl) )-3-hy-
droxyoxypyridine-2-one (I48g) 
Reactionof146g (O.IO g, 0.30mmol) with IMBBr3 (0.45 
mL) in dry CH2Cl2 (8 mL) within 48 h according to procedure 
I48a afforded pure I48g (84 mg, 87%) as slightly brownish 
solid. 1HNMR (400MHz, DMSO-d6) o 9.06 (s, lH), 7.52 (d, 
1=8.0 Hz, 3H), 7.28 (m, 4H), 6.76 (m, 2H), 6.IO (t, 1=5.8 Hz, 
lH), 5.I2 (s, 2H), 2.90 (s, 6H). 13C NMR (100 MHz, CDC13) 
0 I58.7I, I49.98, I46.62, I41.07, I35.8I, I33.29, I28.83, 
I28.47, I28.2I, I28.07, I27.98, I27.55, I26.57, 113.48, I-(2-Cyano-(I, I '-biphenylmethyl))-3-hydroxyoxypy-
ridine-2-one (I48c) 30 I I2.60, I 06.89, 52.11, 40.44. HRMS (EI) calcd for 
C20H20N20 2 [Mt 320.I524. found 320.I5I2. 
Reactionof146e (0.072g, O.I5 mmol)with IMBBr3 (0.34 
mL) in dry CH2Cl2 within 48 h according to procedure I48a 
afforded pure I48c (6I mg, 90%) as slightly brownish solid. 
1H NMR (400 MHz, cdcl3) o 7.75 (d, 1=7.6 Hz, lH), 7.63 (t, 35 
1=7.7 Hz, lH), 7.53(d,1=7.3 Hz, lH), 7.43 (m, 2H), 7.I2 (m, 
lH), 6.86 (dd, 1=28.2, 6.6 Hz, lH), 6.I9 (t, 1=6.I Hz, lH), 
5.25 (s, lH). 13C NMR (IOI MHz, cdcl3) o I44.67, I37.88, 
I3642, I33.7I, 132.85, I29.95, I29.23, I28.20, I27.69, 
II8.56, IIl.08, I07.I7, 52.I3. HRMS (EI) calcd for 40 
C19H14N202 [M+Ht 302.I055. found 302.I053. 
I-( 4-Methyl-(I, I '-biphenylmethyl) )-3-hydroxyoxy-
pyridine-2-one (I48d) 
I-( 4-(6-(Dimethylamino )pyridine-3-yl)benzyl))-3-
hydroxyoxypyridine-2-one (I48h) 
Reactionof146h (O.IO g, 0.29 mmol) with IMBBr3 (0.45 
mL) in dry CH2Cl2 (7 mL) within 48 h according to procedure 
I48a afforded pure I48h (67 mg, 83%) as slightly brownish 
solid. 1H NMR (400 MHz, CDC13) o 8.40 (s, lH), 7.66 (d, 
1=8.0Hz, lH), 7.49(d,1=7.7 Hz, 2H), 7.33(d,1=7.7 Hz, 2H), 
6.84(dd,1=27.3, 6.8 Hz, 3H), 6.57(d,1=8.7 Hz, lH), 6.I5 (t, 
1=7.0 Hz, lH), 5.20 (s, 2H), 3.I2 (s, 6H). 13C NMR (100 
MHz, CDC13) o I58.47, I46.67, I45.66, 138.3I, 135.79, 
I33.89, I31.95, I28.49, I26.79, I26.28, I23.6I, 114.I6, 
45 I07.I9, IOS.94, 52.13, 38.I5. HRMS (EI) calcd for 
C19H19N30 2 [Mt 321.1477. found 321.1479. Reaction of I46d (0.06 g, 0.20 mmol) with IM BBr3 (0.30 
mL) in dry CH2 Cl2 ( 5 mL) within 48 h according to procedure 
I48a afforded pure I48d (57 mg, quantitative) as slightly 
brownish solid. 1H NMR (400 MHz, DMSO-d6 ) o 9.07 (s, 
lH), 7.57 (m, 2H), 7.50 (d, 1=8.I Hz, 2H), 7.34 (d, 1=6.8 Hz, 50 
2H), 7.25 (dd, l=I4.8, 7.I Hz, 3H), 6.69 (d, 1=7.4 Hz, lH), 
6.II (t, 1=7.I Hz, lH), 5.I4 (s, 2H), 2.30 (s, 3H). 13C NMR 
(100 MHz, DMSO-d6 ) o I39.8I, I37.29, I37.22, I36.68, 
I29.94, I28.77, I27.00, I26.89, 51.69, 21.10. Even after 
repeated cycles, quaternary carbons couldn't be visualized. 55 
(No improvement with relaxation delay of 2 sec). HRMS (EI) 
calcd for C19H17N02 [Mt 291.1259. found 291.1250. 
I-(3-Methyl-(I, I '-biphenylmethyl) )-3-hydroxyoxy-
pyridine-2-one (I48e) 60 
Reactionof146e (0.064 g, 0.20 mmol) with IMBBr3 (0.30 
mL) in dry CH2 Cl2 ( 5 mL) within 48 h according to procedure 
I48a afforded pure I48e (60 mg, quantitative) as slightly 
brownish solid. 1H NMR (400 MHz, cdcl3) o 7.56 (d, 1=7.5 65 
Hz, lH), 7.33 (m, 2H), 7.I7 (d, 1=7.2 Hz, lH), 6.85 (dd, 
1=22.2, 6.4 Hz, lH), 6.I6(t,1=6.5 Hz, lH), 5.23 (s, lH), 2.42 
I-( 4-(Pyridine-4-yl)benzyl)-3-hydroxypyridine-2-
one (I48i) 
Reaction of I46i (O.IO g, 0.34 mmol) with IM BBr3 (0.5I 
mL) in dry CH2Cl2 within 48 h according to procedure I48a 
afforded pure I48i (79 mg, 83%) as slightly brownish solid. 
1HNMR (400MHz, CDC13) o 8.65 (s, 2H), 7.46 (s, 2H), 7.39 
(d, 1=7.9 Hz, 2H), 6.83(dd,1=22.5, 7.0 Hz, 2H), 6.I6(t,1=7.0 
Hz, lH), 5.22 (s, 2H). 13C NMR(IOOMHz, CDC13) o I50.23, 
I47.62, I46.76, I37.98, I36.87, I28.66, I27.5I, I26.64, 
I21.58, I13.66, I07.I3, 52.I9. HRMS (FAB) calcd for 
C17H15N202 [M+Ht 279.II33. found279.1147. 
I-( 4-Cyano-(I ,I '-biphenylmethyl))-3-hydroxyoxypy-
ridine-2-thione (I49a) 
Reactionof147a (O.IO g, 0.30mmol) with IM BBr3 (0.33 
mL) in dry CH2Cl2 (8 mL) within 48 h according to procedure 
I48a afforded pure I49a (84 mg, 88%) as olive green color 
solid. 1H NMR (400 MHz, DMSO-d6 ) o 7.87 (m, SH), 7.74 
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3H), 6.98 (m, lH), 6.70 (m, lH), S.83 (s, lH), 2.I9 (s, lH). 
13C NMR (I01 MHz, cd3od) o I42.I4, I40.99, l3S.OS, 
I30.2I, I29.S8, I29.48, I27.76, I27.33, I2S.66, 20.02. 
HRMS (EI) calcd for C19H17NOS [Mt 307.I031. found 
(d, J=S.I Hz, 2H), 7.37 (d, J=S.I Hz, 2H), 7.04 (m, lH), 6.90 
(d, J=S.I Hz, lH), S.87 (s, 2H). 13C NMR (100 MHz, CDC13 ) 
0 I64.47, I44.66, I39.24, I34.64, 132.60, I28.S6, I27.74, 
I27.62, II8.7S, IIl.lS, 61.79, 29.64. HRMS (EI) calcd for 
C19H15N2 0S [Mt 3I8.0827. found 3I8.0828. 5 307.I034. 
I-(3-Cyano-(I, I '-biphenylmethyl))-3-hydroxyoxypy-
ridine-2-thione (I49b) 
I-( 4-Dimethylamino-(I, I '-biphenylmethyl) )-3-hy-
droxyoxypyridine-2-thione (I49g) 
Reaction of I47g (O.I I g, 0.33 mmol) with IM BBr3 (0.39 
mL) in dry CH2 Cl2 ( S mL) within 48 h according to procedure 
I48a afforded pure I49g (68 mg, 62%) as olive green color 
solid. 1 H NMR ( 400 MHz, CDC13 ) o 8.S7 ( d, J=S.S Hz, lH), 
Reaction of147b (0.07 g, 0.2I mmol) with IM BBr3 (0.32 10 
mL) in dry CH2 Cl2 ( S mL) within 48 h according to procedure 
I48a afforded pure I49b (S3 mg, 79%) as olive green color 
solid. 1H NMR (400 MHz, CD3 0D) o 7.89 (m, 2H), 7.6S (m, 
SH), 7.44 (d, J=S.2 Hz, 2H), 7.02 (d, J=7.7 Hz, 2H), 6.77 (m, 
lH), S.90 (s, 2H). 13C NMR (100 MHz, CD30D) o I42.99, 
I40.04, I32.82, I32.I8, I31.69, I31.12, I30.03, I29.97, 
I29.89, I28.69, I28.S9, I I9.83, I I3.94, I06.40, S4.78. 
HRMS (EI) calcd for C19H14N20 2 [M+Ht 3I8.0827. found 
3I8.0827 
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7.S3 (d, J=S.2 Hz, 2H), 7.46 (m, 2H), 7.33 (d, J=S.O Hz, 3H), 
6.97 (d, J=6.8 Hz, lH), 6.77 (d, J=S.8 Hz, 2H), 6.62 (m, lH), 
S.79 (s, 2H), 2.98 (s, 6H). 13C NMR (100 MHz, CDC13 ) o 
I69.7I, ISS.I4, ISO.OS, I41.SI, 131.92, 130.80, I29.00, 
I28.83, I27.99, I27.S8, I26.68, 113.SS, 112.62, 111.90, 
I-(2-Cyano-(I, I '-biphenylmethyl))-3-hydroxyoxypy-
ridine-2-thione (I49c) 
20 60.11, 40.4S. HRMS (EI) calcd for C20H20N2 0S [Mt 
336.I296. found 336.I29S. 
Reactionof147c (0.042g, 0.2I mmol)with IMBBr3 (O.I9 
mL) in dry CH2 Cl2 ( S mL) within 48 h according to procedure 25 
I48a afforded pure I49c (3I mg, 78%) as olive green color 
solid. 1H NMR (400 MHz, cd3od) o 7.77 (dd, J=7.7, 0.9 Hz, 
lH), 7.67 (m, 2H), 7.48 (m, 4H), 7.0I (d, J=I3.I Hz, lH), 6.70 
(m, I 1.1), S.90 (s, lH). 13C NMR (IOI MHz, cd3 od) o I4S.34, 
I38.90, I34.40, I33.88, I30.7S, I29.88, I28.90, I28.62, 30 
II9.I7, 11S.I2, IIl.38. HRMS (EI) calcd for C19H14N2 0 2 
[M+Ht 3I8.0821. found 3I8.0827 
I-( 4-( 6-(Dimethylamino )pyridin-3-yl)benzyl) )-3-
hydroxyoxypyridine-2-thione (I49h) 
Reactionof147h(0.064 g, O.I8mmol)with IMBBr3 (0.27 
mL) in dry CH2 Cl2 ( S mL) within 48 h according to procedure 
I48a afforded pure I49h ( 48 mg, 79%) as olive green color 
solid. 1H NMR (400 MHz, CDC13 ) o 8.30 (s, lH), 7.70 (d, 
J=S.9 Hz, lH), 7.46 (s, 2H), 7.3I (t, J=7.6 Hz, 3H), 6.98 (d, 
J=7.8 Hz, lH), 6.67 (m, 2H), S.7S (s, 2H), 3.I I (s, SH). 13C 
NMR (100 MHz, CDC13 ) o IS7.02, I43.4S, I42.I8, 137.74, 
I36.98, I32.8I, I28.7S, I27.S6, I26.37, I23.70, 114.43, 
I07.03, 38.48, 29.S4. HRMS (EI) calcd for C19H19N30S I-( 4-Methyl-(I, I '-biphenylmethyl) )-3-hydroxyoxy-
pyridine-2-thione (I49d) 35 [Mt 337.I249. found 337.I2Sl. 
Reaction of I47d (0.06 g, 0.20 mmol) with IM BBr3 (0.30 
mL) in dry CH2 Cl2 ( S mL) within 48 h according to procedure 
I48a afforded pure I49d ( 4S mg, 73%) as olive green color 
solid. 1H -NMR (400 MHz, CD3 0D) o 7.70 (d, J=l.1 Hz, 40 
lH), 7.63 (d, J=6.3 Hz, lH), 7.SS (d, J=S.2 Hz, 2H), 7.40 (m, 
3H), 7.2I (d, J=S.I Hz, 2H), 7.03 (dd, J=I4.9, 7.8 Hz, 2H), 
6.7S (t, J=7.0 Hz, lH), S.87 (s, 2H), 2.3S (s, 3H). Even after 
repeated cycles, quaternary carbons couldn't be visualized. 
(No improvement with relaxation delay of2 see). HRMS (EI) 45 
calcd for C19H17NOS [Mt 307.I031. found 307.I022. 
I-( 4-(Pyridin-4-yl)benzyl)-3-hydroxypyridine-2-
thione (I49i) 
Reaction of I47i (0.08 g, 0.2S mmol) with IM BBr3 (0.38 
mL) in dry CH2 Cl2 ( S mL) within 48 h according to procedure 
I48a afforded pure I49i (6S mg, 88%) as olive green color 
solid. 1H NMR (400 MHz, CDC13 ) o 8.6S (d, J=S.3 Hz, 2H), 
8.SS (s, lH), 7.62 (d, J=S.O Hz, 2H), 7.42 (m, SH), 6.99 (d, 
1=7.S Hz, lH), 6.67 (t, J=7.0 Hz, lH), S.SS (s, 2H). 13C NMR 
(IOO MHz, CDC13 ) o I 70.0S, ISS.32, IS0.2S, I47.44, 138.22, 
I3S.48, I30.9I, I28.80, I27.SS, I2I.48, 113.73, 111.94, 
S9.9l. HRMS (EI) calcd for C17H14N20S [Mt 294.0827. 
I-(3-Methyl-(I, I '-biphenylmethyl) )-3-hydroxyoxy-
pyridine-2-thione (I49e) 
50 found 294.0823. 
Reaction of I47e (0.08 g, 0.20 mmol) with IM BBr3 (0.36 
mL) in dry CH2 Cl2 ( S mL) within 48 h according to procedure 
I48a afforded pure I49e (SI mg, 70%) as olive green color 
solid. 1H NMR (400 MHz, cd3od) o 7.S3 (m, lH), 7.30 (m, 
2H), 7.I2 (d, J=7.2 Hz, lH), 6.97 (m, lH), 6.68 (m, lH), S.SI 55 
(s, lH), 2.36 (s, lH). 13C NMR (I01 MHz, cd3od) o I41.S3, 
I40.2I, I38.34, I28.62, I28.48, I28.2I, I27.69, I27.S4, 
I24.03, 21.19. HRMS (EI) calcd for C19H17NOS [Mt 
307.I031. found 307.I031. 
I -Propargy 1-3-methoxypyridine-2-one (I SO) 
To a stirring solution of 3-methoxy-2-pyridinone (I .00 g, 
8.00 mmol) in DMF (2S mL), was added propargyl bromide 
(80 wt% solution in toluene, l.S equiv) and K2 C03 (3.3I3 g, 
24 mmol). Reaction mixture was heated to I00° C. After 
overnight reaction, reaction mixture was partitioned between 
EtOAc (I20 mL) and water (100 mL). Organic layer was 
I-(2-Methyl-(I, I '-biphenylmethyl) )-3-hydroxyoxy-
pyridine-2-thione (I49f) 
Reaction of I47f (0.08 g, 0.20 mmol) with IM BBr3 (0.36 
mL) in dry CH2 Cl2 ( S mL) within 48 h according to procedure 
I48a afforded pure I49f (49 mg, 67%) as olive green color 
solid. 1H NMR (400 MHz, cd3od) o 7.S4 (m, lH), 7.I9 (m, 
60 separated and washed repeatedly with water (7 x I 00 mL) and 
brine (Ix60 mL). Organic layer was dried on Na2 S04 and 
evaporated under vacuo to yield dark brown crude product. 
Colunm chromatography using gradient CH2Cl2 :Acetone 
(max 20%) gave pure ISO (0.79 g, 60%) as a slightly brownish 
65 solid. 1 H NMR (CDC13 , 400 MHz) o 2.36 (lH, t, J=2.8), 3.67 
(3H, m), 4.66 (lH, d, J=2.8), 6.0S (lH, t, J=7 .2), 6.SO (lH, dd, 
J=l.6, 7.2), 7.I I (lH, dd, J=l.6, 6.8); 13C NMR (CDC13 , IOO 
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MHz) o 37.2, 55.5, 74.6, 77.3, I04.8, 112.0, I26.3, I49.4, 
I57.1. HRMS (EI) calcdforC9H9N02 [Mt I63.0633. found 
I63.0636 
188 
I -Pheny ltriazoly lmethyl-3-methoxypyridine-2-thione 
(I53a) 
Reaction of I5Ia (0.295 g, 1.04 mmol) and Lawesson's 
I -Pheny ltriazolylmethy 1-3-methoxypyridine-2-one 
(I5Ia) 
I50 (0.32 g, I .95 I mmol) and phenylazide (0.348 g, 2.926 
mmol) were dissolved in anhydrous THF (IO mL) and stirred 
under argon at room temperature. Copper (I) iodide (0.01 I g, 
0.07 mmol) andHunig's base (O.I mL) were then added to the 
reaction mixture, and stirring continued for 4 h. The reaction 
mixture was diluted with CH2Cl2 ( 40 mL) and washed with 
5 reagent (0.252 g, 0.624 mmol) in toluene (I5 mL) within I2 
has described forthe synthesis of I47a gave compound I53a 
(0.29I g, 94%) as yellow solid. 1H NMR (CDC13 , 400 MHz) 
o 3.90 (3H, s ), 6.04 (2H, s), 6.62-6.68 (2H, m), 7 .38-7.42 (lH, 
m), 7.48 (2H, t, 1=7.2), 7.68 (2H, d, 1=8.0), 7.82 (lH, d, 
10 1=4.8), 8.53 (lH, s); 13C NMR (CDC13 , IOO MHz) o 50.9, 
56.4, I IO.O, I I2.0, I20.2, I22.4, I28.5, I29.3, 132.2, I36.4, 
I41.9, I58.7, I 71.5 HRMS (EI) calcd for C15H14N4 0 2 [Mt 
282.III7. found 282.11I5. HRMS (EI) calcd for 
15 C15H14N4 0S [Mt 298.0888. found 298.0888. I :4 NH40H/saturated NH4 Cl (3x30 mL) and saturated NH4 Cl (30 mL). The organic layer was dried over Na2 S04 
and concentrated in vacuo. The crude product was triturated 
with hexanes to give 5IO mg (92%) of white solid I5Ia. 1H 
NMR (CDC13 , 400 MHz) o 3.58 (3H, s), 5.I I (2H, s), 5.93 
(lH, t, 1=7.6), 6.42 (lH, d, 1=7.2), 7.07 (lH, d, 1=6.4), 7.I6- 20 
7.20 (lH, m), 7.26 (2H, t, 1=7.6), 7.49 (2H, d, 1=8.0); 13C 
NMR (CDC13 , IOO MHz) o 44.2, 55.2, I04.7, I I2.0, 119.7, 
I21.8, I27.9, I28.I, I29.0, 136.2, I42.8, I49.3, I57.2. 
HRMS (EI) calcd for C15H14N4 0 2 [Mt 282.11I7. found 
282.11I5. 
I-( 4-Dimethylamino )phenylltriazolylmethyl-3-meth-
oxypyridine-2-thione (I 53b) 
Reaction of I5Ib (0.078 g, 0.248 mmol) and Lawesson's 
reagent (0.06 g, O.I5 mmol) in toluene (8 mL) within I2 has 
described for the synthesis of I47a gave compound I53b 
(0.07 g, 84%) as yellow solid. 1H NMR (400 MHz, cdcl3 ) o 
8.36 (s, lH), 7.8I (dd, 1=6.4, 1.5 Hz, lH), 7.46 (m, 2H), 6.66 
I-( 4-Dimethylamino )phenylltriazolylmethyl-3-meth-
oxypyridine-2-one (I 5 I b) 
25 (m, 4H), 6.0I (s, 2H), 3.87 (s, 3H), 2.97 (s, 6H). 13C NMR 
(IOO MHz, CDC13 ) o I 71.82, I58.93, I50.44, I41.54, 132.44, 
I26.29, I22.49, I21.77, I I2.IO, I I2.03, I IO.I4, 56.65, 
51.20, 40.29. HRMS (EI) calcd for C17H19N5 0S [Mt 
3I4.I3IO. found 3I4.I304. 
Reaction of 4-azido-N,N-dimethylaniline (0.09 g, 0.6I 30 
mmol) and I50 (O.IO g, 0.6I mmol) within 4 has described 
for synthesis of I5Ia gave compound I5I b (0.13 g, 68%) as 
awhitesolid. 1HNMR(400MHz,cdcl3)o8.04(s, IH), 7.4I 
(m, 2H), 7.I5(dd,1=6.9, 1.7 Hz, lH), 6.62 (m, 2H), 6.5I (dd, 
1=7.5, 1.6 Hz, lH), 6.03 (m, lH), 5.I9 (s, 2H), 3.70 (s, 3H), 35 
2.89 (s, 6H). 13C NMR (100 MHz, CDC13 ) o I57.54, I50.I8, 
I49.65, I42.60, I28.I 7, I26.I8, I21.90, I2I .43, I I2.20, 
IIl.84, I04.93, 55.55, 44.54, 40.08. HRMS (EI) calcd for 
C17H19N5 0 2 [Mt 325.I539. found 325.I544. 
I -Pheny ltriazoly lmethyl-3-hydroxypyridine-2-thione 
(I54a) 
Reaction of I53a (0.28 g, 0.93 mmol) and IM BBr3 in 
CH2Cl2 (I .5 equiv) within 48 has described for the synthesis 
of I48a gave compound I54a (O.I 78 g, 67%) as olive green 
solid. 1HNMR (400MHz, CDC13 ) o 8.43 (d, l=I6.6 Hz, lH), 
8.39 (s, lH), 7.79(dd,1=6.6, 1.3 Hz, lH), 7.69 (m, 2H), 7.46 
(m, 3H), 6.97(dd,1=7.7, 1.2 Hz, lH), 6.69(dd,1=7.6, 6.8 Hz, 
I -Pheny ltriazolylmethyl-3-hydroxypyridine-2-one 
(I52a) 
40 lH), 5.94 (s, 2H). 13C NMR (100 MHz, CDC3 ) o I68.59, 
I55.I2, I41.60, I36.66, I31.65, I29.69, I28.99, I22.57, 
I20.60, 114.04, 112.47, 77.30, 76.99, 76.67, 52.08. HRMS 
(EI) calcd for C14H12N4 0S [Mt 284.0730. found 284.0732. 
Reaction of I5Ia (0.2I2 g, 0.75 mmol) and IM BBr3 in 
CH2 Cl2 (1.5 equiv) within 48 has described for the synthesis 45 
of I48a gave compound I52a (O.I23 g, 6I %) as light brown 
solid. 1H NMR (DMSO-d6 , 400 MHz) o 5.27 (2H, s), 6.13 
(lH, t, 1=6.4), 6.67 (lH, d, 1=7.2), 7.30 (lH, d, 1=5.6), 7.45-
7.49 (lH, m), 7.57 (2H, t, 1=7.6), 7.87 (2H, d, 1=8.0), 8.73 
(lH, s), 9.08 (lH, s); 13C NMR (I01 MHz, CDC13 ) o I36.59, 50 
I29.60, I28.94, I22.29, I20.62, I07.99, 29.29. (quaternary 
carbons were not seen). HRMS (EI) calcd for C14H12N4 0 2 
[Mt 268.0960. found 268.0967. 
I-( 4-Dimethylamino )phenylltriazolylmethyl-3-hy-
droxypyridine-2-thione (I54b) 
Reaction of I53b (0.07 g, 0.2I2 mmol) and IM BBr3 in 
CH2Cl2 (0.64 mL, I .5 equiv) within 48 has described forthe 
synthesis of I48a gave compound I54b (0.032 g, 48%) as 
olive green solid. 1HNMR (400MHz, CDC13 ) o 8.42 (s, lH), 
8.29(d,l=Il.5Hz, lH), 7.79(d,1=6.4Hz, lH), 7.50(m,2H), 
6.98 (dd, 1=36.5, 28.9 Hz, 2H), 6.72 (m, 3H), 5.94 (s, 2H), 
3.0I (d, 1=2.7 Hz, 6H). 13C NMR (100 MHz, CDC13 ) o 
I-( 4-Dimethylamino )phenylltriazolylmethyl-3-hy-
droxypyridine-2-one (I 52b) 
55 I55.09, I50.66, I41.13, I31.72, I27.68, I26.27, I22.45, 
I21.97, 114.04, 112.52, 112.I6, 52.2I, 40.41. HRMS (EI) 
calcd for C16H17N5 0S [Mt 327.I I54. found 327.I I54. 
Reaction of I5Ib (0.045 g, O.I4 mmol) and IM BBr3 in 
CH2 Cl2 (0.22 mL, I .5 equiv) within 48 has described for the 
synthesis of I48a gave compound I52b (0.033 g, 77%) as 60 
light brown solid. 1 H NMR ( 400 MHz, cdcl3 ) o 8.08 (s, lH), 
7.48 (dd, l=I9.9, 8.4 Hz, 2H), 7.I8 (d, 1=6.7 Hz, lH), 6.69 
(ddd, 1=25.8, 24.8, 7.5 Hz, 4H), 6.I6 (t, 1=6.9 Hz, lH), 5.3I 
(s, 2H), 2.98 (m, 6H). 13C NMR (I 01 MHz, CDC13 ) o I 58.35, 
I50.52, I46.68, I42.48, I27.IO, I26.44, I22.06, I21.88, 65 
I21.76, II2.I2, I07.I4, 44.66, 40.33. HRMS (EI) calcd for 
C16H17N5 0 2 [Mt 3I 1.1382. found 3Il.1386. 
Example 9 
2nd Generation 3-Hydroxypyridine-2-thione-based 
HDAC Inhibitors 
Compounds with variable methylene group linker lengths; 
from one (as seen in compound I54a) to seven (as seen in 
SAHA) were synthesized and evaluated for their activity as 
HDAC inhibitors. 
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The synthesis of rd generation 3-HPT-based compounds 
is depicted in Scheme 20. The crucial azidoalkyl methane-
sulfonates are synthesized in two steps. The reaction of cor-
responding bromoalkanols with sodium azide furnished azi-
doalkanols 155a-l 55f which were subsequently mesylated to 
give methanesulfonate intermediates 156a-156f in almost 
quantitative yields. As described earlier, N-alkylation of 
0-methyl or 0-benzyl protected 3-hydroxypyridine-2-one 
with the mesylate intermediates gave azido intermediates 
157a-l 57f in moderate to good yields. Aromatic surface rec- 10 
ognition cap group was linked to these azido intermediates 
via 1,2,3-triazole ring. Cu(I)-catalyzed Huisgen cycloaddi-
tion between phenylacetylene and azido intermediates 157a-
190 
157f, followed by deprotection of methyl ether by Lewis acid 
BBr3 furnished the desired compounds in good to excellent 
yields. All the higher linker thione compounds were synthe-
sized from their carbonyl counterparts by using P 4 S10 chem-
istry as previously reported. However, methylene linker com-
pound 159a did not tolerate the rigorous temperature 
conditions and was degraded to complex reaction mixture 
within 2 hrs. Therefore the synthetic scheme shown in 
Scheme 20 was modified. Incorporation of 0-methyl pro-
tected intermediate 158a permitted the use of milder Lawes-
son's reaction chemistry to access thione compound 161 
(Scheme 20). 
Scheme 20. Synthesis of 2nd generation 3-HPT based HDACis. 
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n ~ 2; 159b 
n~3; 159c 
n ~ 4; 159d 
n~5; 159e 
n~6;159f 
n ~ 2; 162b 
n~3; 162c 
n ~ 4; 162d 
n~5; 162e 
n~6; 162f 
a) NaN3, DMF, 75° C. (b) methanesulfonyl chloride, Et3N, THF; (c) 3-methocypridine-2-one, K2C03, THF/DMF, reflux (d) Phenylacetylene, CuI, DIPEA, THF/DMSO; (e) for 22a-
BBr3, DCM; for 22b-f-H2' Pd.IC, THF; (f) Lawesson's reagent, toluene, reflux; (g) BBr3, DCM; (h) P4S10, 175° C., neat. 
Activities of rd generation compounds also were consis-
tent for HDAC6 and HDACS selectivity over HDACl and 
thione compounds always outperformed their corresponding 
carbonyl compounds. It is interesting to note that very similar 20 
trend was observed for HDAC6 and HDACS activities 
pound 162d, IC50=911 nM for HDAC6; IC50=917 nM for 
HDAS). However, one additional carbon linker again results 
in drop of activity (Table 12; comparing 162d and 162e). 
Interestingly, 7-carbon linker compound 1621 showed supe-
rior activity than 162e however it still didn't surpass the 
activity of 162d. according to variation in linker length. For thione analogs, 
increase in methylene spacer by I-carbon to compound 154a 
shows significant loss of activity (comparing 154a and 161 in 
Table 11 and Table 12). Gradual increase in methylene spacer 
length from 3-carbon to 5-carbon shows improvement in 
activity with 5-carbon linker shows optimum activity (com-
This suggests that 5-carbon methylene chain is optimum 
linker in HDACi design containing 3-HPT as ZBG. In addi-
25 ti on to five methylene spacer, one and seven methylene spacer 
showed comparable activities and should be viable leads as 
well. 
TABLE 12 
In vitro HDAC Inhibition of 2ndGeneration Compounds 
COMPOUND 
HODO ~%:)--Q I N 
# 
159a 
161 
159b 
162b 
HDACl HDAC6 
12% NI 
21% 14% 
8% 41% 
27% 3628 ± 1363 
HDAC8 
15% 
56% 
47% 
63% 
US 8,871,728 B2 
193 
TABLE 12-continued 
In vitro HDAC Inhibition of 2nd Generation Compounds 
COMPOUND 
159c 
162c 
0 
~N- ......_,, ......_,, 'N \ -HOD_,,...__,,,....._,,,....._ 
I# h:)----0 
159d 
162d 
HODO ~ZJ-0 I N 
# 
159c 
HODS ~ZJ-0 I N 
# 
162e 
159f 
IC,0 (nM) 
HDACl HDAC6 HDAC8 
15% NI 10% 
ND 1085 ± 333 3303 ± 260 
43% NI 30% 
30% 911±173 917+/-139 
12% NI 5% 
23% 22% 6791 ± 910 
34% 42% 
s 35% 955 ± 150 232 ± 19 
H00N~N~ u h._N~ 
162f 
SAHA 38 +/- 2 95% 232 ± 19 
SAHA was used for a positive control; 
NI - No significant Inhibition (below 20% Inhibition); 
% inhibitions of the compounds at 10 µMare given if the IC50 was above 10 µM. 
194 
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Synthetic Procedures 
2-Azidoethyl methanesulfonate (1S6a) 
To a solution of compound 2-azidoethanol (1.00 g, 11.49 5 
mmol) in THF (2S mL) and triethylamine (Et3N) (2.418 mL, 
17.24 mmol) was added mesyl chloride (1.328 mL, 17.24 
mmol) at 0° C., and the mixture was allowed to warm to room 
temperature. Stirring continued for 3 h, during which TLC 
10 
revealed a quantitative conversion into a higher Rf product. 
CH2Cl2 (70 mL) and saturated sodium bicarbonate (SO mL) 
were added, and the two layers were separated. The organic 
layer was washed with sodium bicarbonate (2xSO mL), satu-
rated brine (4S mL) and dried over Na2S04. Solvent was 15 
evaporated off to give crude compound 1S6a (1.70 g) as a 
colorless oil, which was used for next step without further 
purification. 
2-Azidopropyl methanesulfonate (1 S6b) 
Reaction of 3-azidopropanol (1.00 g, 9.90 mmol) and 
mesyl chloride (1.14 mL, 14.8S mmol) within 3 h as 
described for synthesis of1S6a gave compound 1S6b (1.18 g) 
as a crude colorless oil. 
20 
196 
2H). 13C NMR (100 MHz, CDCl3) o 1S7.39, 149.41, 128.61, 
112.16, 104.37, SS.36, 49.00, 48.91. HRMS (EI) calcd for 
C8H10N402 [Mt 194.0804. found 194.0816. 
(3-Azidopropyl)-3-benzyloxypyridine-2-one (1 S7b) 
Reaction of 3-benzyloxypyridine-2-one (0.40 g, 1.99 
mmol) and 1S6b (O.S3 g, 2.98mmol)within 16 has described 
for synthesis of 1S7a gave compound 1S7b (0.30 g, S3%) as 
a colorless oil. 1 H NMR (300 MHz, CDC13) 7 .28 (m, SH), 
6.84 (dd, J=6.9, 1.6 Hz, lH), 6.60 (dd, J=7.4, l.S Hz, lH), 
S.98 (t, J=7.1 Hz, lH), 3.97 (t, J=6.8 Hz, 2H), 3.28 (t, 1=6.S 
Hz, 2H), 1.98 (p, J=6.7 Hz, 2H). 13C NMR (7S MHz, CDC13) 
0 1S7.78, 148.6S, 13S.93, 128.8S, 128.24, 127.69, 127.03, 
1lS.16,104.S3, 70.39, 48.14, 47.06, 27.66. HRMS (EI) calcd 
for C15H16N40 2 [Mt 284.1273. found 284.1271. 
1-( 4-Azidobutyl)-3-benzyloxypyridine-2-one (1 S7 c) 
Reaction of 3-benzyloxypyridine-2-one (0.40 g, 1.99 
mmol) and 1 S6c (O.S8 g, 2.98 mmol) within 16 has described 
for synthesis of1S7a gave compound 1S7c (0.36 g, 62%) as a 
colorless oil. 1H NMR (400 MHz, CDC13) o 7.22 (m, SH), 
6.78 (dd, J=6.9, 1.7 Hz, lH), 6.S4 (dd, J=7.4, 1.7 Hz, lH), 
2-Azidobutyl methanesulfonate (1S6c) 
Reaction of 4-azidobutanol (0.80 g, 6.9S mmol) and mesyl 
chloride (1.48 mL, 10.43 mmol) within 3 has described for 
synthesis of 1S6a gave compound 1S6c (1.33 g) as a crude 
colorless oil. 
25 S.91 (m, lH), 4.96 (s, 2H), 3.8S (t, J=7.2 Hz, 2H), 3.17 (t, 
J=6.8 Hz, 2H), 1.71 (m, 2H), 1.48 (m, 2H). 13C NMR (100 
MHz, CDC13) o lS7.S2, 148.27, 13S.78, 128.37, 127.98, 
127.42, 126.82, 114.92, 104.32, 70.09, S0.43, 48.46, 2S.83, 
2S.42. HRMS (EI) calcd for C16H18N40 2 [Mt 298.1430. 
2-Azidopentyl methanesulfonate (1 S6d) 
30 found 298.1446. 
l-(S-Azidopentyl)-3-benzyloxypyridine-2-one 
(1S7d) 
Reaction of S-azidopentanol (1.1 g, 8.S3 mmol) and mesyl 35 
chloride (0.98 mL, 12.79 mmol) within 3 has described for 
synthesis of 1S6a gave compound 1S6d (l.S4 g) as a crude 
colorless oil. 
Reaction of 3-benzyloxypyridine-2-one (O.SO g, 2.49 
mmol) and 1S6d(0.62 g, 2.98mmol)within 16 has described 
for synthesis of 1S7a gave compound 1S7d (0.49 g, 63%) as 
a colorless oil. 1 H NMR ( 400 MHz, CDC13) o 7 .3S ( d, J=8.0 
Hz, 2H), 7.23 (m, 3H), 6.81 (m, lH), 6.S6 (m, lH), S.94 (m, 
2-Azidohexyl methanesulfonate (1S6e) 
Reaction of 6-azidohexanol (0. 7 4 g, S .22 mmol) and mesyl 
chloride (0.61 mL, 7.83 mmol) within 3 has described for 
synthesis of 1S6a gave compound 1S6e (0.87 g) as a crude 
colorless oil. 
2-Azidoheptyl methanesulfonate (1S6f) 
Reaction of 7-azidoheptanol (O.SS g, 3.49 mmol) and 
mesyl chloride (0.41 mL, S.30 mmol) within 3 has described 
for synthesis of1S6a gave compound 1S61 (0.79 g) as a crude 
colorless oil. 
1-(2-Azidoethyl)-3-methoxypyridine-2-one (1 S7 a) 
3-methoxypyridine-2-one (0.40 g, 3.20 mmol), 1S6a (0.79 
40 lH), S.01 (s, 2H), 3.8S (m, 2H), 3.18 (m, 2H), 1.71 (m, 2H), 
l.S4 (m, 2H), 1.32 (m, 2H). 13C NMR (100 MHz, CDC13) o 
1S7.68, 148.47, 13S.98, 128.60, 128.12, 127.S3, 126.93, 
llS.09, 104.32, 70.27, S0.77, 49.21, 28.19, 28.06, 23.37. 
HRMS (EI) calcd for C17H20N40 2 [Mt 312.1S86. found 
45 312.1S89. 
1-(6-Azidohexyl)-3-benzyloxypyridine-2-one (1S7e) 
Reaction of 3-benzyloxypyridine-2-one (O.SO g, 2.49 
50 mmol) and 1S6d(0.66 g, 2.98mmol)within 16 has described 
for synthesis of1S7a gave compound 1S7e (0.48 g, 60%) as a 
colorless oil. 1H NMR (400 MHz, CDC13) o 7.lS (m, SH), 
6.6S (dd, J=7.4, 1.8 Hz, lH), 6.4S (dd, J=7.4, 1.8 Hz, lH), 
S.81 (t, J=7.1 Hz, lH), 4.92 (s, 2H), 3.76 (t, J=6.8 Hz, 2H), 
55 3.0S (t, J=6.8 Hz, 2H), 1.S8 (m, 2H), 1.40 (m, 2H), 1.90 (m, 
4H). 13C NMR (100 MHz, CDCl3) o lS7.SS, 148.2S, l3S.9S, 
128.60, 128.10, 126.9S, 126.SO, l lS.OS, 104.90, 70.SO, 
SI.OS, 49.20, 28.6S, 28.SO, 26.20, 2S.80. HRMS (FAB) calcd 
for Cl8H23N402 [M+Ht 327.1821. found 327.1848. 
g, 4.80 mmol), and K2C03 (1.32 g, 9.60 mmol) stirred over-
night in THF at reflux temperature. Reaction mixture was 
cooled down to room temperature. Reaction mixture was 
partitioned between CH2Cl2 (60 mL) and water (SO mL). 60 
Organic layer washed with water (2x3S mL), brine (lx30 
mL). Organic layerdriedonNa2S04 and evaporated in vacuo. 
Crude product was purified by flash chromatography with 
stepwise gradient ofCH2Cl2 and acetone (max 1S%) to give 
0.34 mg of 1S7a (SS%) as colorless oil. 1H NMR (400 MHz, 65 
CDC13) o 6.77 (dd, J=6.9, 1.6 Hz, lH), 6.48 (dd, 1=7.S, 1.6 
Hz, lH), S.96 (m, lH), 3.91 (m, 2H), 3.62 (s, 3H), 3.S2 (m, 
1-(7-Azidoheptyl)-3-benzyloxypyridine-2-one (1 S7f) 
Reaction of 3-benzyloxypyridine-2-one (0.79 g, 3.38 
mmol) and 1S6f(0.81g,4.0S mmol)within 16 has described 
for synthesis of 1S7a gave compound 1S7f (O.SS g, 48%) as a 
colorless oil. 1H NMR (400 MHz, CDC13) o 7.42 (dd, J=7.8, 
1.0 Hz, 2H), 7.31(m,3H), 6.8S (dd, J=6.9, 1.7 Hz, lH), 6.61 
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lH), 5.02 (s, 2H), 4.3I (t, 1=7.0 Hz, 2H), 3.S7 (t, 1=7.2 Hz, 
2H), 1.9I (m, 2H), 1.74 (m, 2H), 1.30 (m, 2H). 13CNMR(IOO 
MHz, CDC13) o I57.SO, I4S.57, I47.39, 136.02, 130.44, 
I2S.64, I2S.56, I2S.27, I27.SI, I27.7I, I27.05, I25.40, 
(dd, 1=7.4, 1.7 Hz, lH), 5.99 (m, lH), 5.09 (s, 2H), 3.93 (m, 
2H), 3.23 (t, 1=6.9 Hz, 2H), 1.74 (m, 2H), 1.55 (m, 2H), 1.34 
(m, 6H). 13C NMR (100 MHz, CDC13) o I5S.32, I49.I9, 
I36.63, I29.I5, I2S.74, I2S.I3, I27.52, II5.66, I04.69, 
94.66, 70.96, 51.62, 50.03, 29.22, 2S.9S, 26.77, 26.72. 5 II9.57, 115.I2, I04.49, 70.40, 49.7I, 49.06, 29.42, 2S.03, 
23.05. 
I -Pheny ltriazoly lethyl-3-methoxypyridine-2-one 
(I5Sa) 
Phenylacetylene (O.I67 g, 1.63 mmol) and I57a (0.265 g, 10 
1.36 mmol) were dissolved in anhydrous THF (IO mL) and 
stirred under argon at room temperature. Copper (I) iodide 
(0.01 I g, 0.07 mmol) and Hunig's base (O.I mL) were then 
added to the reaction mixture, and stirring continued for 4 h. 
The reaction mixture was diluted with CH2Cl2 (40 mL) and 15 
washed with I:4 NH40H/saturated NH4Cl (3x30 mL) and 
saturated NH4Cl (30 mL). The organic layer was dried over 
Na2S04 and concentrated in vacuo. The crude product was 
triturated with hexanes to give 366 mg (9I % ) of white solid 
I5Sa. 1H NMR (400 MHz, CDC13) o 7.6S (s, lH), 7.47 (d, 20 
1=7.5 Hz, 2H), 7.I I (m, 3H), 6.43(d,1=7.4 Hz, lH), 6.35 (dd, 
1=6.S, 0.9 Hz, lH), 5.7S (t, 1=7.2 Hz, lH), 4.57 (t, 1=5.7 Hz, 
2H), 4.25 (t, 1=5.6 Hz, 2H), 3.53 (s, 3H). 13C NMR (100 
MHz, CDC13) o I57.70, I49.0S, I47.2I, I29.40, I2S.30, 
I2S.OS, I27.SO, I25.00, I20.9I, I13.02, I05.44, 55.I5, 25 
49.72, 47.44. HRMS (EI) calcd for C16H16N40 2 [Mt 
296.I273. found 296.I26S. 
I-Phenyltriazolylhexyl-3-benzyloxypyridine-2-one 
(I5Se) 
Reactionofphenylacetylene (O.SO g, 0.7S mmol) and I57e 
(0.2I g, 0.65 mmol) within 4 has described for synthesis of 
I5Sa gave compound I5Se (O.I6 g, 56%) as a white solid. 
NMR (400 MHz, CDC13) o 7.66 (m, 3H), 7.20 (m, SH), 6.6S 
(dd, 1=6.9, 1.5 Hz, lH), 6.46(dd,1=7.4, 1.5 Hz, lH), 5.S2 (t, 
1=7.I Hz, lH), 4.92 (s, 2H), 4.IS (t, 1=6.S Hz, 2H), 3.75 (t, 
1=6.S Hz, 2H), 1.76 (m, 2H), 1.56 (m, 2H), 1.19 (m, 4H). 13C 
NMR (100 MHz, CDC13) o I57.64, I4S.46, I47.27, 135.95, 
I30.36, I2S.57, I2S.4S, I2S.I9, I27.72, I27.60, I26.96, 
I25.32, II9.37, 115.02, I04.37 70.45, 50.03, 49.35, 29.90, 
2S.66, 25.S7, 25.7S. HRMS (FAB) calcd for C26H29N40 2 
[M+Ht 429.2290. found 429.229I. 
I -Pheny ltriazoly lheptyl-3-benzy loxypyridine-2-one 
(I5Sf) 
Reaction of phenylacetylene (0.90 g, O.SS mmol) and I57f 
(0.25 g, 0.735 mmol) within 4 has described for synthesis of 
I 5Sa gave compound I 5SI (0.23 g, 63%) as a white solid. 1 H I -Phenyltriazoly lpropyl-3-benzy loxypyridine-2-one 
(I5Sb) 30 NMR (400 MHz, CDC13) o 7.79 (m, 3H), 7.3I (m, SH), 6.S3 
(dd, 1=6.9, 1.7 Hz, lH), 6.60(dd,1=7.4, 1.7 Hz, lH), 5.97 (t, 
1=7.I Hz, lH), 5.07 (s, 2H), 4.35 (t, 1=7.I Hz, 2H), 3.9I (m, 
2H), 1.SS (m, 2H), 1.7I (m, 2H), 1.32 (d, l=IO.O Hz, 6H). 13C 
NMR (100 MHz, CDC13) o I5S.3I, I49.13, I47.92, 136.57, 
Reaction of phenylacetylene (O.I27 g, 1.25 mmol) and 
I57b (0.295 g, 1.04 mmol) within 4 has described for syn-
thesis of I5Sa gave compound I5Sb (0.3I g, 77%) as a white 
solid. 1H NMR (400 MHz, CDC13) o S.00 (s, lH), 7.77 (d, 
1=7.3 Hz, 2H), 7.27 (m, SH), 6.SS (d, 1=5.7 Hz, lH), 6.57 (d, 
1=6.4 Hz, lH), 5.95 (t, 1=7.I Hz, lH), 4.99 (s, 2H), 4.34 (t, 
1=6.4 Hz, 2H), 3.94(t,1=6.4 Hz, 2H), 2.32 (m, 2H). 13C NMR 
(100 MHz, CDC13) o I57.92, I4S.47, I47.30, 135.73, I30.26, 
I2S.SI, I2S.49, I2S.22, I27.76, I27.7I, I27.0I, I25.33, 40 
I20.I6, I I4.95, I04.S3, 70.33, 47.00, 46.4S, 29.30. HRMS 
(EI) calcd for C23H22N40 2 [Mt 3S6.I743. found 3S6.I 734. 
I -Pheny ltriazoly lbuty 1-3-benzy loxypyridine-2-one 
(I5Sc) 
Reaction of phenylacetylene (O.I24 g, 1.2I mmol) and 
I 57c (0.30 g, 1.0I mmol) within 4 has described for synthesis 
of I 5Sa gave compound I 5Sc (0.3 I g, 77%) as a white solid. 
1H NMR (400 MHz, CDC13) o 7.S3 (s, lH), 7.76 (m, 2H), 
7.26 (m, SH), 6.76 (dd, 1=6.9, 1.5 Hz, lH), 6.56 (dd, 1=7.4, 
1.5 Hz, lH), 5.9I (t, 1=7.I Hz, lH), 4.99 (s, 2H), 4.3I (m, 2H), 
3.S9(t,1=7.I Hz, 2H), 1.S5 (m, 2H), 1.67 (m, 2H). 13C NMR 
(100 MHz, CDC13) o I57.7I, I4S.3S, I47.20, 135.S3, I30.29, 
I2S.45, I2S.4I, I2S.I6, I27.6S, I27.63, I26.96, I25.25, 
II9.S7, 114.99, I04.60, 70.26, 49.11, 4S.02, 26.7S, 25.65. 
HRMS (EI) calcd for C24H24N40 2 [Mt 400.IS99. found 
400.ISSS. 
I -Pheny ltriazoly lpentyl-3-benzy loxypyridine-2-one 
(I5Sd) 
Reactionofphenylacetylene (0.04 g, 0.32mmol) and I57d 
(O.IO g, 0.32 mmol) within 4 has described for synthesis of 
35 I30.93, I29.I5, I29.04, I2S.74, I2S.2S, I2S.I5, I27.5I, 
I25.90, I25.S6, I I9.75, 115.60, I04.79, 70.92, 50.52, 49.90, 
30.42, 29.13, 2S.72, 26.53, 26.46. HRMS (FAB) calcd for 
C27H31N402 [M+Ht 443.2447. found 443.2494. 
I -Pheny ltriazoly lethy 1-3-hydroxypyridine-2-one 
(I59a) 
To a solution of I5Sa (O.IO g, 0.33S mmol) in dry CH2Cl2 
(S mL) was slowly added IM BBr3 (1.2 equiv) at -30° C. 
45 under argon atmosphere. The reaction mixture was stirred for 
4S h at room temperature. The mixture was again cooled to 
-30° C. and the MeOH (5 mL) was slowly added to the 
mixture. After evaporation of solvent, the residue was 
adjusted to pH 7 with IM NaOH and then extracted with 
50 CHC13 (30 mLx3). The combined organic layer dried over 
Na2S04 to give 79 mg (S3%) of I59a as slightly brownish 
solid without any further purification required. 1 H NMR ( 400 
MHz, DMSO) o 9.I I (s, lH), S.5I (s, lH), 7.7S (d, 1=7.3 Hz, 
2H), 7.43 (t, 1=7.6 Hz, 2H), 7.3I (t, 1=7.3 Hz, lH), 6.75 (d, 
55 1=5.9 Hz, lH), 6.64 (d, 1=6.0 Hz, lH), 5.95 (t, 1=7.0 Hz, lH), 
4.76(t,1=5.5 Hz, 2H), 4.42 (t, 1=5.6 Hz, 2H). 13C NMR (100 
MHz, DMSO) o I5S.25, I47.I7, I46.77, 131.lI, I29.34, 
I2S.4I, I2S.3I, I25.54, I22.23, I I5.3S, I05.76, 49.42, 
4S.33. HRMS (EI) calcd for C15H14N40 2 [Mt 2S2.I 117. 
60 found 2S2.I I20. 
I -Pheny ltriazoly lpropy 1-3-hydroxypyridine-2-one 
(I59b) 
I 5Sa gave compound I 5Sd (0.092 g, 72%) as a white solid. 1 H 65 
NMR (400 MHz, CDC13) o 7.7S (m, 3H), 7.30 (m, SH), 6.79 
To a solution of I5Sb (0.29 g, 1.0I mmol) in CH2Cl2: 
EtOAc:MeOH (2:2:I, IO mL) was added IO% Pd on carbon 
(I 5 mg). Reaction was stirred under balloon hydrogen pres-(d, 1=6.S Hz, lH), 6.57 (d, 1=7.3 Hz, lH), 5.94 (t, 1=7.I Hz, 
US 8,871,728 B2 
199 
sure for 5 h. Reaction mixture was filtered and solvent was 
evaporated. Column chromatography using gradient CH2Cl2: 
Acetone (max 20%) gave pure 159b (0.19 g, 64%) as a 
slightly brownish solid. 1H NMR (400 MHz, DMSO) o 9.03 
(s, lH), 8.62 (s, lH), 7.82 (d, 1=7.6 Hz, 2H), 7.38 (m, 3H), 5 
7.15 (d, 1=6.6 Hz, lH), 6.68(d,1=6.4 Hz, lH), 6.11(t,1=6.7 
Hz, lH), 4.43 (t, 1=6.4 Hz, 2H), 3.99 (m, 2H), 2.27 (m, 2H). 
13C NMR (100 MHz, CDCl3) 0 147.49, 129.71, 128.52, 
127.99, 125.29, 120.42, 107.98, 66.61, 47.10, 29.27. (ex-
pected aromatic carbons=ll; quaternary carbons can't be 10 
seen even after repeated cycles) HRMS (EI) calcd for 
C16H16N40 2 [Mt 296.1273. found 296.1274. 
200 
130.88, 129.05, 128.30, 127.12, 125.87, 119.83, 114.13, 
107.10, 50.48, 50.05, 30.37, 29.20, 28.67, 26.46, 26.42. 
HRMS (FAB) calcd for C20H25N40 2 [M+Ht 353.1977. 
found 353.1992. 
1-Phenyltriazoly lethy 1-3-methoxypyridine-2-thione 
(160) 
To a stirring solutionofLawesson'sreagent (0.075 g, 0.185 
mmol) in toluene (10 mL), was added starting material 158a 
(0.10 g, 0.33 mmol). Reaction mixture was heated to reflux 
temperature. After overnight reaction, solvent was evapo-
rated under reduced pressure. Crude product was dissolved in 
small amount of CH2Cl2 to load onto preparative-TLC and 1-Pheny ltriazolylbutyl-3-hydroxypyridine-2-one 
(159c) 15 eluted with CHCl3:Acetone:EtOH (10:1:0.2) to give pure 
yellow solid 160 (0.07 g, 68%). 1H NMR (400 MHz, CDC13) 
o 7.69(d,1=7.4 Hz, 2H), 7.56 (s, lH), 7.35 (t, 1=7.5 Hz, 2H), 
7.28 (m, lH), 6.97(d,1=6.6 Hz, lH), 6.62(d,1=7.8 Hz, lH), 
6.37 (m, lH), 5.13 (t, 1=5.6 Hz, 2H), 5.03 (t, 1=5.6 Hz, 2H), 
Reaction ofl 58c (0.25 g, 0.62 mmol) in anhydrous THF as 
described for synthesis of 159b gave 159c (0.12 g, 63%) of 
pure product. 1H NMR (400 MHz, CDC13) o 7.79 (m, 3H), 
7.41 (t, 1=7.6 Hz, 2H), 7.32 (t, 1=7.4 Hz, lH), 6.76 (m, 3H), 
6.13 (t, 1=7.2 Hz, lH), 4.45 (t, 1=6.8 Hz, 2H), 4.02 (t, 1=7.l 
Hz, 2H), 1.99 (m, 2H), 1.82 (m, 2H). 13C NMR (100 MHz, 
CDC13) o 158.47, 147.63, 146.62, 130.41, 128.69, 127.99, 
126.60, 125.53, 119.80, 114.15, 107.10, 49.38, 48.57, 27.02, 
26.01. HRMS (EI) calcd for C17H18N40 2 [Mt 310.1430. 25 
found 310.1425. 
20 3.86 (s, 3H). 13C NMR (100 MHz, CDC13) o 171.92, 158.94, 
147.52, 132.68, 129.92, 128.69, 128.14, 125.43, 120.96, 
111.72, 110.22, 56.72, 56.63, 46.38. HRMS (EI) calcd for 
C16H16N40S [Mt 312.104. found 312.1039. 
1-Pheny ltriazoly lpenty 1-3-hydroxypyridine-2-one 
(159d) 
1-Phenyltriazoly lethy 1-3-hydroxypyridine-2-thione 
(161) 
Reaction of 160 (0.062 g, 0.198 mmol) and IM BBr3 in 
CH2Cl2 (0.218 mmol) within 48 has described for synthesis 
Reaction of 158d (0.085 g, 0.20 mmol) in anhydrous THF 
as described for synthesis of 159b gave 159d (0.045 g, 68%) 
30 of 148a gave compound 161 (0.055 g, 93%) as a dark violet 
solid. 1H NMR (400 MHz, CDC13) o 8.40 (s, lH), 7.73 (d, 
1=7.3 Hz, 2H), 7.51 (s, lH), 7.40 (t, 1=7.5 Hz, 2H), 7.33 (t, 
1=7.3 Hz, lH), 6.95 (dd, 1=9.2, 7.2 Hz, 2H), 6.46 (m, lH), of pure product. 1H NMR (400 MHz, DMSO) o 8.56 (s, lH), 
7.82 (d, 1=8.1 Hz, 2H), 7.43 (t, 1=7.7 Hz, 2H), 7.32 (t, 1=7.4 
Hz, lH), 7.10(dd,1=6.8, 1.6 Hz, lH), 6.65(dd,1=7.2, 1.5 Hz, 35 
lH), 6.05 (1, 1=7.0 Hz, lH), 4.38 (t, 1=7.0 Hz, 2H), 3.89 (t, 
1=7.2 Hz, 2H), 1.89 (m, 2H), 1.67 (m, 2H), 1.25 (m, 2H). 13C 
NMR (100 MHz, CDC13) o 158.44, 147.67, 146.61, 130.51, 
128.72, 128.01, 126.71, 125.57, 119.54, 113.81, 106.86, 
49.86, 49.38, 29.58, 28.31, 23.19. HRMS (FAB) calcd for 40 
Cl8H21N402 [M+Ht 325.1664. found 325.1683. 
5.08 (m, 4H). 13CNMR (lOOMHz, CDC13) o 168.47, 155.10, 
147.75, 132.00, 129.82, 128.77, 128.30, 125.53, 120.90, 
113.66, 112.61, 57.45, 46.41. HRMS (EI) calcd for 
C15H14N40S [Mt 298.088. found 298.0888. 
1-Pheny ltriazoly lpropy 1-3-hydroxypyridine-2-thione 
(162b) 
1-Phenyltriazoly lhexy 1-3-hydroxypyridine-2-one 
(159e) 
159b (0.062 g, 0.21 mmol)was ground togetherwithP4S10 
(0.047 g, 0.105 mmol) in mortar and pestle to form grey 
powder. The powder was stirred under argon in a flask fitted 
45 with condenser and heated to 175° C. for 2 h. The reaction 
Reactionof158e (0.15 g, 0.35 mmol) in anhydrous THF as 
described for synthesis of 159b gave 159e (0.081 g, 69%) of 
pure product. 1H NMR (400 MHz, CDC13) o 7.81 (m, 3H), 
7.42 (m, 2H), 7.32 (m, lH), 6.77 (m, 2H), 6.12 (t, 1=7.l Hz, 
lH), 4.38(t,1=7.l Hz, 2H), 3.95 (m, 2H), 1.95 (m, 2H), 1.76 50 
( d, 1=7 .0 Hz, 2H), 1.39 (m, 4H). 13C NMR (100 MHz, CDC13) 
flask was covered with aluminum foil during reaction. After 2 
h of reaction, flask was cooled down to room temperature. 25 
mL ofCH2Cl2:MeOH (10%) mixtures was added and stirred 
for 15 min. This reaction mixture then washed with water 
(2x30 mL ). Organic layer dried with Na2S04 and evaporated 
to yield crude product which was purified by prep-TLC (Elu-
ent -CH2Cl2:MeOH (8%) to give 162b (0.04 g, 60%) as 
olive green solid. 1HNMR (400MHz, CDC13) o 8.47 (s, lH), 
7.82 (m, 3H), 7.50 (d, 1=6.5 Hz, lH), 7.43 (t, 1=7.5 Hz, 2H), 
0 158.20, 147.25, 146.40, 130.30, 128.60, 127.85, 126.65, 
125.40, 119.65, 113.90, 106.80, 50.20, 49.60, 30.05, 28.95, 
26.00, 25.90. HRMS (FAB) calcd for C19H23N40 2 [M+Ht 
339.1821. found 339.1814. 
1-Pheny ltriazoly lhepty 1-3-hydroxypyridine-2-one 
(159f) 
55 7.34 (t, 1=7.4 Hz, lH), 6.97 (m, lH), 6.66 (m, lH), 4.62 (t, 
1=6.9 Hz, 2H), 4.48 (m, 2H). 13C NMR (100 MHz, CDC13) o 
168.59, 155.22, 148.03, 131.85, 130.17, 128.84, 128.29, 
125.61, 119.84, 113.87, 112.28, 54.99, 46.95, 28.02. HRMS 
(EI) calcd for C16H16N40S [Mt 312.104. found 312.1060. 
Reaction of 158f(0.22 g, 0.50mmol) in anhydrous THF as 60 
described for synthesis of 159b gave 159f (0.13 g, 74%) of 
pure product. 1H NMR (400 MHz, DMSO) o 8.91 (s, lH), 
8.57 (s, lH), 7.82 (d, 1=7.4 Hz, 2H), 7.42 (t, 1=7.6 Hz, 2H), 
7.31(t,1=7.3 Hz, lH), 7.09 (d, 1=6.6 Hz, lH), 6.64 (d, 1=7.0 
Hz, lH), 6.04 (t, 1=6.9 Hz, lH), 4.36 (t, 1=7.0 Hz, 2H), 3.86 65 
(t, 1=7.2 Hz, 2H), 1.83 (m, 2H), 1.61 (m, 2H), 1.26 (m, 6H). 
13C NMR (100 MHz, CDCl3) 0 158.80, 147.89, 147.00, 
l-Phenyltriazolylbutyl-3-hydroxypyridine-2-thione 
(162c) 
Reactionof159c (0.055 g, 0.18 mmol) and P 4S10 (0.051 g, 
0.115 mmol) under neat conditions as described for synthesis 
of162b gave compound 162c (0.032 g, 55%) as a olive green 
solid. o 8.50 (s, lH), 7.81 (m, 3H), 7.36 (m, 4H), 6.94 (d, 
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1=7.6 Hz, lH), 6.62(t,1=6.8 Hz, lH), 4.54 (t, 1=7.6 Hz, 2H), 
4.46 (t, 1=6.4 Hz, 2H), 2.03 (m, 4H). 13C NMR (100 MHz, 
CDC13) o 168.51, 155.08, 147.73, 131.02, 130.36, 128.79, 
128.13, 125.58, 119.91, 113.87, 112.10, 56.96, 49.41, 27.02, 
25.08. HRMS (EI) calcd for C17H18N40S [Mt 326.1201. 5 
found 326.1200. 
128.03, 126.64, 125.61, 119.51, 118.75, 118.29, 59.74, 
50.10, 29.91, 27.99, 25.82, 25.65. HRMS (ESI) calcd for 
C19H23N40S [M+Ht 355.158. found 355.1632. 
1-Pheny ltriazoly lheptyl-3-hydroxypyridine-2-thione 
(162f) 
1-Pheny ltriazoly lpentyl-3-hydroxypyridine-2-thione 
(162d) 
Reaction of 159d (0.025 g, 0.077 mmol) and P4S10 (0.020 
Reactionof159f(0.12 g, 0.532 mmol) andP4S10 (0.076 g, 
0.17 mmol) under neat conditions as described for synthesis 
of162b gave compound 162f(0.054 g, 43%) as a olive green 
10 
semi-solid. 1HNMR(400MHz, DMSO) o 8.55 (m, lH), 7.81 
(d, 1=8.2 Hz, 2H), 7.65 (d, 1=6.2 Hz, lH), 7.42 (m, 2H), 7.30 
(m, lH), 7.02 (m, lH), 6.85 (m, lH), 4.50 (m, 2H), 4.36 (t, 
1=7.l Hz, 2H), 1.85(d,1=7.0Hz, 4H), 1.33 (s, 6H). 13C NMR 
(100 MHz, CDC13) o 147.76, 130.66, 128.76, 130.39, 128.98, 15 128.80, 128.06, 125.97, 125.67, 119.46, 60.10, 50.25, 30.11, 
29.67, 28.33, 26.13, 26.10. HRMS (FAB) calcd for 
C20H25N40S [M+Ht 369.174. found 369.1762. 
g, 0.046 mmol) under neat conditions as described for syn-
thesis of162b gave compound 162d (0.019 g, 73%) as a olive 
green solid. 1 H NMR ( 400 MHz, DMSO) o 8.55 ( d, 1=2.9 Hz, 
2H), 7.83 (t, 1=7.8 Hz, 3H), 7.43 (q, 1=7.4 Hz, 2H), 7.32 (t, 
1=6.6 Hz, lH), 7.08 (m, lH), 6.92 (dd, 1=31.0, 6.8 Hz, lH), 
6.81 (m, lH), 4.51 (m, 2H), 4.41 (t, 1=7.0 Hz, 2H), 1.89 (m, 
4H), 1.32 (m, 2H). 13C NMR (100 MHz, CDC13) o 168.37, 
155.10, 147.66, 131.04, 130.46, 128.75, 128.05, 125.57, 
119.68, 113.69, 111.96, 57.73, 49.73, 29.47, 27.12, 23.04. 20 
HRMS (EI) calcd for C18H20N40S [Mt 340.135. found 
326.1364. 
Example 10 
3rd Generation 3-Hydroxypyridine-2-thione-based 
HDAC Inhibitors 
l-Phenyltriazolylhexyl-3-hydroxypyridine-2-thione 
(162e) 
Reaction of159e (0.18 g, 0.532 mmol) andP 4S10 (0.118 g, 
0.266 mmol) under neat conditions as described for synthesis 
of162b gave compound 162e (0.080 g, 42%) as a olive green 
semi-solid. 1H NMR (400 MHz, CDC13) o 8.57 (s, lH), 7.83 
(d, 1=7.5 Hz, 2H), 7.76 (s, lH), 7.41 (t, 1=7.5 Hz, 2H), 7.32 
(m, 2H), 6.94 (m, lH), 6.72 (m, lH), 4.49 (m, 2H), 4.40 (t, 
1=6.9 Hz, 2H), 1.97 (m, 4H), 1.36 (m, 4H). 13C NMR (100 
MHz, CDC13) o 164.38, 162.90, 147.70, 130.54, 128.76, 
A 3rd generation ofHDAC inhibitors containing 5-carbon 
25 methylene spacers were prepared. The synthetic route to the 
3rd generation compounds was identical to that described for 
the 2nd generation compounds. The new surface cap recogni-
tion cap groups were coupled to ZBG modified linker using 
Cu(I)-catalyzed Huisgen cycloaddition to give intermediates 
30 in good to excellent yields. As described earlier, Lawessons' 
chemistry followed by deprotection with BBr3 resulted in 
desired compounds 166a-166g and 167a-168g. Carbonyl 
derivatives were also synthesized using similar deprotection 
chemistry (Scheme 21). 
Scheme 21. Synthesis of3rd generation 3-HPT based HDACis. 
N3~0Ms 
156d 
s I RY'r~N~o 
N=N u 
165a-165e 
167a-167g 
i 
-
163 
iii 
-
164a-164e 
166a-166g 
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i) 3-methoxypyridine-2-one, K2C03, THF, reflux; ii)R-alkynes, CuI, DIPEA, DMSO:THF; iii) Lawesson's reagent, Toluene, reflux; iv) BBr3m DCM. Compounds 26, 27a-
27 e synthesized by Quaovi Sojdi. Included here to show complete synthetic scheme. 
The 3rd generation compounds in 3-HPT series were tested 
against HDACl, HDAC6 and HDACS using the label-free 
SAMDI mass spectrometry assay as described above. The 
trend in HDAC inhibition activity was very similar to that 15 
observed in the early generation compounds with the thione 
compounds showing superior activity compared to the carbo-
nyl derivatives. For HDACS, the results from this study indi-
cate that substitution on the phenyl ring as cap group is not 
helpful for anti-HDAC activity. Almost all of the cap groups 20 
other than simple phenyl ring failed to improve compound 
potency (compounds 166a-166g; 167a-167g in table 13). 
However, for HDAC6 docking substitution pattern on phenyl 
ring yielded improved potency. In case of methyl substitution, 
para and ortho substitution resulted in more potent drugs than 
meta substitution. This trend was very similar to 1st genera-
tion methyl substituted compounds (comparing compound 
149d-149fand 167a-167e). Out of para (compound 167d) and 
meta (compound 167e) cyano substitution, meta showed 
superior activity compared to para substitution (compound 
167e, IC50=356 nM against HDAC6). In addition, substitu-
tion with electron donating group N,N-dimethylamino and 
electron withdrawing group such as shown in compound 
167 g did not surpass the activity of compound 167 e. In order 
to gain additional insight into binding interactions of 2nd and 
3rd generation of compounds at the enzyme active site, dock-
ing analyses were performed on the most active compounds 
in this series against HDACS. 
TABLE 13 
In vitro HDAC Inhibition of Yd Generation Compounds 
IC nM 
COMPOUNDS HDACl HDAC6 HDAC8 
('y~N~ ~O ~~N/'\___ff 
66% NI 15% 
OH 
166a 
('y~N~ ~S ~~N/'\___ff 
OH 
167a 
('y~N}--{') ~O ~~N· '----< 
OH 
166b 
('y~N~ ~S ~~N· '----< 
OH 
167b 
('y~N}--{') ~O ~~N· )---1 
OH 
166c 
31% 807 ± 207 2533 +/- 823 
88% NI NI 
19% 1100±443 1660+/-416 
NT NI 4% 
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TABLE 13-continued 
In vitro HDAC Inhibition of 3rd Generation Compounds 
IC50 (nM) 
COMPOUNDS HDACl HDAC6 HDAC8 
y.~N:>-p NT 637 ± 160 2402 +!- 263 
S k,.,,N \., j 
OH 
167c 
y.~N:)-0- 70% NI 26% 
0 k,.,,N \., j CN 
OH 
166d 
y.~N:)-0- 33% 905 ± 249 1465 +/- 217 
S k,.,,N \., j CN 
OH 
167d 
y.~N:>-Q 71% NI NI 
0 k,.,,N \., j 
OH CN 
166e 
y.~N:>-Q ND 356 ± 72 2831 +/- 520 
S k,.,,N \., j 
OH CN 
167e 
y.~N:)-0-/ 59% NI 28% 
0 k,.,,N \., j N\ 
OH 
166f 
y.~N:)-0-/ 28% 1006 ± 425 1482 +/- 389 
S k,.,,N \., j N\ 
OH 
167f 
y.~N=>-Q- 71% NI 14% 0 k,.,,N \., j CN 
OH CF3 
166g 
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TABLE 13-continued 
In vitro HDAC Inhibition of 3rd Generation Compounds 
COMPOUNDS 
167g 
SAHA 
SAHA is used for a positive control; 
NI - No significant Inhibition (below 20% Inhibition); 
HDACl 
55% 
38 +/- 2 
% inhibitions of the compounds at 10 µMare given if the IC50 was above 10 µM. 
Docking of 3rd Generation Compounds 
IC nM 
HDAC6 
661±121 
95% 
20 
Compound 162d adopts a docked pose at HDAC8 active 
site which presents the phenyl cap group into a deep, non-
solvent exposed hydrophobic pocket, while the 5-carbon 
methylene spacer optimally fills the connecting the hydro- 25 
phobic pocket to the Zn2 + active site. The ideal spacer length 
of the 5-carbon methylene group facilitates a proper presen-
tation off the 3-HPT ZBG to the active site Zn2+. The deep 
pocket where the phenyl ring orients consists of Tyrl 11, 
Alal 12, Leul 55, Tyrl 54 AA residues. Two tyrosine residues 30 
are within 3 .5 A of the phenyl cap group of compound 162d 
and are ideally suited for pi-stacking interaction. Tyr154 is 
expected to have stronger pi-stacking interaction since plane 
208 
HDAC8 
2258 + !- 1005 
232 ± 19 
showed HDACl selectivity (250 fold). To obtain information 
on the structural basis of the observed disparity in the HDAC 
isoform selectivity, molecular docking analysis was per-
formed on lead compound 149d with two HDAC isoforms. 
However, HDACl docking ofl 49d revealed that there was no 
fruitful interaction of compound 149d at HDACl enzyme 
active site. Repeated docking suggested that the ZBG of 14 9d 
was unable to deeply penetrate (-14 A) the Zn2 active site of 
HDACl. 
Synthetic Procedures 
1-( 4-Tolyl)triazolylpentyl-3-methoxypyridine-2-
thione (165a) 
Reaction of 164a (0.235 g, 0.667 mmol) and Lawesson's 
reagent (0.162 g, 0.40 mmol) in toluene (12 mL) within 12 h 
as described for the synthesis of 147a gave compound 165a 
(0.232 g, 95%) as yellow solid. 1 H NMR ( 400 MHz, CDC13 ) 
o 7.77 (s, lH), 7.73 (d, J=8.2 Hz, 2H), 7.33 (m, lH), 7.25 (dd, 
of its ring is parallel to the phenyl cap group of compound 
162d. However, Tyrl 11 will contribute less to the pi-stacking 35 
interaction because the edge of its phenol ring is oriented 
toward the plane of the cap group 162d. Other AA residues 
such as Leul 15andAlal12 are within3.5 A and contribute to 
the overall hydrophobicity of the pocket into which the phe-
nyl cap group of compound 162d is bound. This might lead to 
lower binding energy conformation and hence better IC50 
value for this 2nd generation compound. 
The docked structures of 162d and six methylene linker 
compound 162e were overlayed. Both compounds bind to the 
same pocket and adopt almost the similar orientation, except 
for slight kinks, at the methylene groups. The major differ-
ence between the docked poses of 162d and 162e is at their 
phenyl cap group which is slightly pushed outside of pi-
stacking interaction with Tyrl 54 in compound 162e and thus 
abolishing this important interaction. This could be the reason 50 
that there is almost 7-fold activity difference between 162d 
and 162e. 
40 J=ll.4, 5.2 Hz, 2H), 6.66 (d, J=7.8 Hz, lH), 6.59 (dd, J=7.8, 6.5 Hz, lH), 4.60 (m, 2H), 4.43(t,1=6.9 Hz, 2H), 3.91(s,3H), 
2.38 (s, 3H), 2.01 (m, 4H), 1.43 (m, 2H); 13C NMR (75 MHz, 
CDC13 ) o 171.03, 158.50, 147.11, 137.37, 131.77, 129.02, 
127.33, 125.03, 119.32, 111.60, 109.78, 56.27, 49.28, 30.48, 
29.05, 26.51, 22.57, 20.82. HRMS (EI) calcd for 
Similarly, compound 167d binds to same pocket as dis-
cussed earlier. Howeverpara-cyano substitution on cap group 
167d causes its phenyl ring to be pushed out of the binding 
pocket seen for compound 162d (Figure 20). Though two 
tyrosine residues are not far away from the phenyl cap group 
(-3.2 A), their orientation is not optimum for pi-stacking 
interaction with the phenyl group of 167d. Moreover, hydro-
phobic interactions with Ala112 and Leul 55 are completely 
lost. However, there is a compensatory pi-stacking interaction 
with Trp141 which may explain the better activity for com-
pound 167 d relative to 162e. 
45 C20H24N4 0S [Mt 368.167. found 368.1667. 
1-(3-Tolyl)triazolylpentyl-3-methoxypyridine-2-
thione (165b) 
Reaction of 164b (0.137 g, 0.389 mmol) and Lawesson's 
reagent (0.094 g, 0.223 mmol) in toluene (10 mL) within 12 
has described for the synthesis of 14 7 a gave compound 165b 
(0.104 g, 73%) as yellow solid. 1H NMR (400 MHz, CDC13 ) 
o 7.78 (s, lH), 7.62 (s, lH), 7.54 (d, J=7.7 Hz, lH), 7.26 (m, 
55 2H), 7.07 (d, J=7.6 Hz, lH), 6.59 (m, lH), 6.52 (dd, J=7.8, 6.5 
Hz, lH), 4.50 (m, 2H), 4.34 (t, J=7.0 Hz, 2H), 3.81 (s, 3H), 
2.32 (s, 3H), 1.90 (m, 4H), 1.33 (m, 2H); 13C NMR (100 
MHz, CDC13 ) o 171.47, 158.81, 147.45, 138.19, 131.83, 
130.21, 128.58, 128.46, 126.03, 122.48, 119.68, 111.72, 
109.80, 56.55, 56.47, 49.50, 29.24, 26.70, 22.77, 21.18. 
60 HRMS (EI) calcd for C20H24N4 0S [Mt 368.1671. found 
368.1682. 
The preference for the HDAC8 isoform over HDACl was 
consistent for almost all of the compounds tested in this 65 
series. This is an important and interesting observation con-
sidering the fact that other aromatic ZBG such as benzamide 
1-(2-Tolyl)triazolylpentyl-3-methoxypyridine-2-
thione (165c) 
Reaction of 164c (0.124 g, 0.351 mmol) and Lawesson's 
reagent (0.085 g, 0.21 mmol) in toluene (10 mL) within 12 h 
US 8,871,728 B2 
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as described for the synthesis of I 4 7 a gave compound I 65c 
(0.093 g, 72%) as yellow solid. 1 H NMR ( 400 MHz, CDC13 ) 
o 7.72 (m, lH), 7.27 (m, 2H), 6.60 (m, lH), 4.57 (m, lH), 4.42 
210 
(t, 1=7.0 Hz, lH), 3.86 (s, lH), 2.44 (s, lH), 1.99 (m, 2H), 1.4I 
(dt, l=I5.2, 7.6 Hz, lH). 13C NMR (100 MHz, CDC13 ) o 5 
I71.8I, I59.04, I46.84, I35.33, I31.86, I30.74, I29.8I, 
I28.68, I27.94, I25.93, I21.86, IIl.78, I09.79, I04.88, 
56.75, 56.6I, 49.60, 29.45, 26.85, 22.97, 21.36. HRMS (EI) 
calcd for C20H24N4 0S [Mt 368.I67. found 368.I662. 10 
7.36 (d, 1=6.5 Hz, lH), 6.68(d,1=7.8 Hz, lH), 6.6I (t, 1=7.2 
Hz, lH), 4.59 (m, 2H), 4.47 (m, 2H), 3.88 (s, 3H), 2.02 (m, 
4H), I.43 (m, 2H); 13C NMR (100 MHz, CDC13 ) o I71.84, 
I59.I4, I44.54, I35.55, I35.22, 133.5I, 133.I8, 131.8I, 
I28.59, I21.86, I20.86, I I5.46, 112.00, I09.97, I08.47, 
77.3I, 76.99, 76.67, 56.69, 49.87, 29.I9, 26.77, 22.77. 
HRMS (EI) calcd for C21 H20N50SF3 [Mt 447.134. found 
447.I341. 
I-( 4-Benzonitrile )triazolylpentyl-3-methoxypyri-
dine-2-thione (I 65d) 
Reaction of I64d (0.2IO g, 0.55I mmol) and Lawesson's 
reagent (O.I33 g, 0.330 mmol) in toluene (I2 mL) within I2 
has described for the synthesis of I 4 7 a gave compound I 65d 
(O.I46 g, 67%) as yellow solid. 1H NMR (400 MHz, CDC13 ) 
o 7.64 (m, 3H), 7.28 (m, lH), 6.73(d,1=8.3 Hz, 2H), 6.6I (d, 
1=7.6 Hz, lH), 6.52 (t, 1=7.I Hz, lH), 4.50 (m, 2H), 4.3I (t, 
1=6.7 Hz, 2H), 3.8I (s, 3H), 2.92 (s, 6H), 1.89 (m, 4H), 1.32 
(m, 2H); 13C NMR (100 MHz, CDC13 ) o I7I.44, I58.8I, 
I49.78, I47.77, I31.9I, I26.37, I I9.05, I I8.34, I I2.52, 
I I 1.73, I09.84, 56.60, 56.49, 49.44, 40.45, 29.29, 26.74, 
22.81. HRMS (EI) calcd for C21 H27N5 0S [Mt 397.I93. 
found 397.I928. 
I -(3-Benzonitrile )triazoly lpenty 1-3-methoxypyri-
dine-2-thione (I 65e) 
I-( 4-Tolyl)triazolylpentyl-3-hydroxypyridine-2-one 
(I66a) 
Reactionof164a (O.IO g, 0.284 mmol) and IM BBr3 (0.34 
mL) in CH2Cl2 (8 mL) within 48 h as described for the 
15 synthesis of I48a gave compound I66a (0.049 g, 52%) as 
light brown solid. 1H NMR (400 MHz, CDC13 ) o 7.7I (m, 
3H), 7.24 (m, 2H), 6.76 (t, 1=6.4 Hz, 2H), 6.I2 (t, 1=7.0 Hz, 
lH), 4.40 (t, 1=6.9 Hz, 2H), 3.96 (t, 1=7.I Hz, 2H), 2.38 (s, 
3H), 2.00 (m, 2H), I.82 (m, 2H), I.39 (m, 2H); 13CNMR(IOO 
20 MHz, DMSO) o I71.80, I46.3I, I37.02, I29.40, I28.08, 
I25.02, I20.79, I I4.36, I05.20, 49.27, 48.22, 29.I 7, 28.0I, 
22.85, 20.82. HRMS (EI) calcd for C19H22N4 0 2 [Mt 
338.I 743. found 338.I 750. 
25 I-(3-Tolyl)triazolylpentyl-3-hydroxypyridine-2-one 
(I66b) 
Reaction of I64e (O.I90 g, 0.523 mmol) and Lawesson's 30 
reagent (O.I30 g, 0.3I4 mmol) in toluene (IO mL) within I2 
has described forthe synthesis of I47a gave compound I65e 
(0.133 g, 67%) as yellow solid. 1H NMR (400 MHz, CDC13 ) 
Reaction of I64b (0.073 g, 0.207 mmol) and IM BBr3 
(0.24 mL) in CH2 Cl2 (8 mL) within 48 has described for the 
synthesis of148a gave compound I66b (52 mg, 74%) as light 
brown solid. 1HNMR (400MHz, CDC13 ) o 7.74 (s, IH), 7.67 
(s, lH), 7.59(d,1=7.7 Hz, lH), 7.30(t,1=7.6 Hz, lH), 7.I4 (d, 
1=7.4 Hz, lH), 6.76(t,1=6.2 Hz, 2H), 6.I2(t,1=7.I Hz, lH), 
4.39 (t, 1=6.9 Hz, 2H), 3.96 (t, 1=7.2 Hz, 2H), 2.39 (s, 3H), 
1.99 (m, 2H), 1.80 (m, 2H), 1.38 (m, 2H). 13C NMR (100 
MHz, CDC13 ) o I58.58, I47.87, I46.52, 138.46, 130.38, 
I28.86, I28.67, I26.75, I26.3I, I22.72, 119.48, 113.6I, 
I06.85, 49.9I, 49.45, 29.65, 28.38, 23.27, 21.38. HRMS (EI) 
calcd for C19H22N4 0 2 [Mt 338.I 74. found 338.I74I. 
o 7.98 (s, lH), 7.84(d,1=8.4 Hz, 2H), 7.56(d,1=8.4 Hz, 2H), 
7.30 (d, 1=6.5 Hz, lH), 6.60 (d, 1=7.0 Hz, lH), 6.52 (dd, 35 
1=7.7, 6.6 Hz, lH), 4.48 (m, 2H), 4.34(t,1=6.9 Hz, 2H), 3.76 
(s, 3H), 1.88 (m, 4H), 1.3I (m, 2H). 13C NMR (100 MHz, 
CDC13 ) o I71.23, I58.70, I45.36, I34.76, 132.30, I31.78, 
I25.68, I21.20, I I8.49, I I 1.83, I I0.73, I09.92, 56.43, 
49.50, 29.0I, 26.56, 22.56. HRMS (EI) calcd for 40 
C20H21N5 0S [Mt 379.I46. found 379.I466. I-(2-Tolyl)triazolylpentyl-3-hydroxypyridine-2-one (I66c) 
I-( 4-(N,N-dimethylaniline) )triazolylpentyl-3-meth-
oxypyridine-2-thione (I 65f) 
Reaction of I64I (O.I45 g, 0.40 mmol) and Lawesson's 
reagent (0.098 g, 0.24I mmol) in toluene (IO mL) within I2 
has described for the synthesis of I 4 7 a gave compound I 65 I 
(O.I49 g, 98%) as yellow solid. 1H NMR (400 MHz, CDC13 ) 
o 8.I2 (t, l=I.4 Hz, lH), 8.06 (m, lH), 7.90 (s, lH), 7.59 (dt, 
1=7.7, I .4 Hz, lH), 7.52(t,1=7.8 Hz, lH), 7.33(dd,1=6.5, I .4 
Hz, lH), 6.67 (dd, 7.9, 1.3 Hz, lH), 6.60 (dd, 1=7.8, 6.5 Hz, 
lH), 4.59 (m, 2H), 4.46 (t, 1=6.9 Hz, 2H), 3.89 (s, 3H), 2.02 
(m, 4H), I .43 (m, 2H); 13C NMR (100 MHz, CDC13 ) o 
I71.30, I58.73, I45,I3, I31.82, I31.7I, I30.97, I29.52, 
I29.44, I28.64, I20.6I, II8.28, II2.49, II1.8I, I09.9I, 
56.44, 49.62, 29.I I, 26.64, 22.68. HRMS (EI) calcd for 
C20H21N5 0S [Mt 379.I46. found 379.I469. 
I-( 4-(3-Trifluoromethyl)-benzonitrile )triazolylpen-
tyl-3-methoxypyridine-2-thione (I 65g) 
Reaction of I64g (0.090 g, 0.2088 mmol) and Lawesson's 
reagent (0.05I g, O.I252 mmol) in toluene (IO mL) within I2 
has described for the synthesis of I 4 7 a gave compound I 65g 
(0.075 g, 8I %) as yellow solid. 1H NMR (400 MHz, CDC13 ) 
o 8.28 (s, lH), 8.I2(d,1=6.7 Hz, 2H), 7.86(d,1=8.I Hz, lH), 
Reactionof164c (0.065 g, O.I8 mmol) and IM BBr3 (0.27 
45 mL) in CH2Cl2 (8 mL) within 48 h as described for the 
synthesis of I 48a gave compound I 66c ( 54 mg, 87%) as light 
brown solid. 1H NMR (400 MHz, dorso) o 8.92 (s, lH), 8.36 
(s, lH), 7.7I (m, lH), 7.25 (m, lH), 7.09 (d, 1=6.8 Hz, lH), 
6.64 (d, 1=6.9 Hz, lH), 6.04 (t, 1=7.0 Hz, lH), 4.39 (t, 1=6.9 
50 Hz, lH), 3.88 (t, 1=7.0 Hz, lH), 2.4I (s, lH), 1.90 (m, lH), 
I .67 (m, lH), I .25 (m, lH). 13C NMR (I 00 MHz, CD30D) o 
I46.28, I35.00, I30.I5, I28.96, I28.2I, I27.72, I25.38, 
I22.09, I06.72, 49.43, 48.98, 29.05, 27.78, 22.69, 20.09. 
HRMS (EI) calcd for C19H22N4 0 2 [Mt 338.I74. found 
55 338.I 741. 
I-( 4-Benzonitrile )triazolylpentyl-3-hydroxypyridine-
2-one (I 66d) 
60 Reaction of I64d (0.075 g, O.I97 mmol) and IM BBr3 
(0.24 mL) in CH2 Cl2 (8 mL) within 48 has described for the 
synthesis of I 48a gave compound I 66d ( 43 mg, 60%) as light 
brown solid. 1 H NMR ( 400 MHz, CDC13 ) o 7 .69 ( d, 1=8.8 Hz, 
2H), 7.6I (s, lH), 6.77 (m, 4H), 6.11 (t, 1=7.I Hz, lH), 4.37 
65 (t, 1=6.9 Hz, 2H), 3.96(t,1=7.2 Hz, 2H), 2.99 (s, 6H), 1.99 (m, 
2H), 1.8I (m, 2H), 1.39 (m, 2H). 13C NMR (100 MHz, 
CDC13 ) o I58.57, I50.35, I48.26, I46.6I, I26.84, I26.6I, 
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I I8.87, I I8.I I, 113.72, I I2.49, I06.86, 49.83, 49.52, 40.46, 
29.70, 28.4I, 23.34. HRMS (EI) calcd for C20H25N5 0 2 [Mt 
367.200. found 367.2007. 
I -(3-Benzonitrile )triazoly lpenty 1-3-hydroxypyridine-
2-one (I 66e) 
Reaction of I64e (0.09 g, 0.25 nnnol) and IM BBr3 (0.30 
mL) in CH2Cl2 (8 mL) within 48 h as described for the 
synthesis of I 48a gave compound I 66e ( 62 mg, 72%) as light 
brown solid. 1HNMR(400MHz,DMSO) 08.93 (s, lH), 8.76 
(s, lH), 8.01 (d, 1=7.7 Hz, 2H), 7.90 (d, 1=8.0 Hz, 2H), 7.09 
(d, 1=6.4 Hz, lH), 6.64 (d, 1=7.I Hz, lH), 6.04 (t, 1=7.0 Hz, 
lH), 4.4I (t, 1=6.5 Hz, 2H), 3.88 (t, 1=6.9 Hz, 2H), 1.89 (m, 
2H), 1.67 (m, 2H), 1.24 (m, 2H). 13C NMR (100 MHz, 
CDC13) o I46.62, I45.80, I34.92, I32.57, I26.69, I25.93, 
I20.88, II8.70, 114.06, IIl.19, I07.06, 50.00, 49.29, 29.43, 
28.28, 23.08. HRMS (EI) calcd for C19H19N50 2 [Mt 
349.I53. found 349.I544. 
I-( 4-(N,N-dimethylaniline ))triazolylpentyl-3-hy-
droxypyridine-2-one (I 66f) 
212 
I-(3-Tolyl)triazolylpentyl-3-hydroxypyridine-2-
thione (I 67b) 
Reactionof165b (O.IO g, 0.27I nnnol) and IMBBr3 (0.33 
5 mL) in CH2Cl2 (8 mL) within 48 h as described for the 
synthesis of I48a gave compound I67b (0.053 g, 56%) as 
olive green solid. 1H NMR (400 MHz, CD30D) o 8.20 (s, 
lH), 7.6I (s, lH), 7.55 (m, 2H), 7.26 (t, 1=7.6 Hz, lH), 7.I2 
(d, 1=7.5 Hz, lH), 6.92 (m, 2H), 4.55 (m, 2H), 4.44 (t, 1=6.7 
10 Hz, 2H), 2.36 (s, 3H), 2.0I (m, 4H), I.4I (m, 2H). 13C NMR 
(100 MHz, CD30D) o I49.29, I40.05, I31.87, 131.78, 
I30.38, I30.20, I27.90, I27.63, I24.13, I22.5I, 5I.40, 
31.07, 30.93, 28.97, 24.49, 22.02. HRMS (EI) calcd for 
C19H22N4 0S [Mt 354.I51. found 354.I523. 15 
I-(2-Tolyl)triazolylpentyl-3-hydroxypyridine-2-
thione (I67c) 
Reaction of I65c (0.072 g, O.I95 nnnol) and IM BBr3 
20 (0.30 mL) in CH2 Cl2 (8 mL) within 48 has described for the 
synthesis of I48a gave compound I67c (0.046 g, 67%) as 
olive green solid. 1H NMR (400 MHz, CD30D) o 7.94 (s, 
lH), 7.6I (m, lH), 7.47 (s, lH), 7.2I (m, lH), 6.97 (m, lH), 
6.76 (m, lH), 4.52 (m, lH), 4.45 (t, 1=6.8 Hz, lH), 2.38 (s, Reaction of I64I (0.078 g, 0.22 nnnol) and IM BBr3 (0.26 
mL) in CH2Cl2 (6 mL) within 48 h as described for the 
synthesis of148a gave compound I66f(48 mg, 64%) as light 
brown solid. 1H NMR (400 MHz, CD30D) o 8.39 (s, lH), 
8.I6 (s, lH), 8.I2 (d, 1=7.5 Hz, lH), 7.68 (d, 1=7.5 Hz, lH), 
7.6I (t, 1=7.6 Hz, lH), 7.04 (m, lH), 6.76 (m, lH), 6.2I (m, 30 
lH), 4.45 (m, 2H), 3.99 (m, 2H), 2.0I (m, 2H), 1.78 (m, 2H), 
25 lH), 2.0I (m, 2H), I .43 (m, lH). 13C NMR (100 MHz, 
CD30D) o I46.74, I35.53, 130.65, I29.46, I28.69, I28.2I, 
I25.88, I22.79, 53.4I, 49.83, 29.42, 27.32, 22.98, 20.55. 
HRMS (EI) calcd for C19H22N4 0S [Mt 354.I51. found 
354.I509. 
I-( 4-Benzonitrile )triazolylpentyl-3-hydroxypyridine-
2-thione (I67d) 
Reaction of I65d (O.IO g, 0.27I nnnol) and IM BBr3 (0.33 
I .33 (m, 2H). 13C NMR (I 00 MHz, CDC13) o I 45 .6 I, I 3 I .97, 
I31.3I, I29.74, I29.65, I29.IO, I20.30, I I8.49, I I2.99, 
I04.90, 50.07, 49.40, 29.52, 28.37, 23.I7. HRMS (EI) calcd 
for C19H19N50 2 [Mt 349.I53. found 349.I539. 
I-( 4-(3-Trifluomethyl)-benzonitrile )triazolylpentyl-
3-hydroxypyridine-2-one (I 66g) 
35 mL) in CH2Cl2 (8 mL) within 48 h as described for the 
synthesis of I48a gave compound I67d (0.053 g, 56%) as 
olive green solid. 1H NMR (400 MHz, DMSO-d6 ) o 8.53 (s, 
lH), 8.27 (s, lH), 7.82 (d, 1=7.I Hz, lH), 7.62 (d, 1=8.8 Hz, 
2H), 7.06(d,1=7.5 Hz, lH), 6.93 (m, lH), 6.77 (m, 2H), 4.52 
Reaction of I64g (0.042 g, 0.097 nnnol) and IM BBr3 
(O.I7 mL) in CH2 Cl2 (6 mL) within 48 has described forthe 
synthesis of148a gave compound I66g (35 mg, 85%) as light 
brown solid. 1 H NMR ( 400 MHz, CDC13) o 8.24 (s, lH), 8. I2 
40 (d, 1=6.9 Hz, 2H), 4.36 (t, 1=7.0 Hz, 2H), 3.2I (s, 6H), 1.88 
(m, 4H), 1.34 (m, 2H). HRMS (EI) calcd for C20H25N50S 
[Mt 383.I 78. found 383.I 776. 
(d, 1=7.9 Hz, lH), 8.00 (s, lH), 7.86 (d, 1=7.9 Hz, lH), 6.75 
(t, 1=5.8 Hz, 2H), 6.I2 (t, 1=7.0 Hz, lH), 4.44 (t, 1=6.9 Hz, 45 
2H), 3.96(t,1=7.I Hz, 2H), 2.02 (m, 2H), 1.8I (m, 2H), 1.37 
(m, 2H). 13C NMR (100 MHz, CDC13) o I58.58, I46.54, 
I44.7I, I35.49, I35.26, I28.57, I26.70, I23.59, I23.54, 
I21.46, I I5.47, 113.82, I08.63, I07.02, 50.I9, 49.3I, 29.45, 
28.30, 23.I2. HRMS (EI) calcd for C20H18N50 2 F3 [Mt 50 
4I7.I41. found 4I7.I425. HRMS (EI) calcd for 
C20H18N5 0 2F3 [Mt 4I 7.I41. found 4I 7.I425. 
I-(3-Benzonitrile )triazolylpentyl-3-hydroxypyridine-
2-thione (I67e) 
Reaction of I 65e (0.095 g, 0.25 nnnol) and IM BBr3 (0.30 
mL) in CH2Cl2 (8 mL) within 48 h as described for the 
synthesis of I48a gave compound I67e (0.055 g, 60%) as 
olive green solid. 1HNMR(400MHz, DMSO) o 8.76 (s, lH), 
8.0I (d, 1=8.I Hz, 2H), 7.87 (m, 2H), 7.65(d,1=6.4 Hz, lH), 
7.00 (m, lH), 6.87 (d, 1=8.2 Hz, lH), 6.70 (m, lH), 4.44 (m, 
4H), 1.89 (m, 4H), 1.3I (m, 2H). 13C NMR (100 MHz, 
CDC13) o I68.23, I55.0I, I45.75, I34.86, I32.56, 131.00, I-( 4-Tolyl)triazolylpentyl-3-hydroxypyridine-2-
thione (I67a) 55 I25.9I, I21.05, I I8.68, I I3.76, 112.04, I I 1.17, 57.64, 
49.8I, 29.3I, 27.06, 22.91. HRMS (EI) calcd for 
C19H19N5 0S [Mt 365.I31. found 365.I3I3. Reaction of I65a (0.075 g, 0.203 mmol) and IM BBr3 (0.24 mL) in CH2 Cl2 (8 mL) within 48 has described forthe 
synthesis of I48a gave compound I67a (0.042 g, 62%) as 
olive green solid. 1H NMR (400 MHz, CD30D) o 8.I8 (s, 60 
lH), 7.66 (d, 1=8.0 Hz, 2H), 7.55 (d, 1=5.7 Hz, lH), 7.20 (d, 
1=7.7 Hz, 2H), 6.97 (d, 1=6.7 Hz, lH), 4.55 (m, 2H), 4.43 (t, 
1=6.7 Hz, 2H), 2.34 (s, 3H), 2.0I (m, 4H), I .39 (t, 1=22.5 Hz, 
2H). 13C NMR (100 MHz, CD30D) 0 I49.25, I39.68, 
I30.93, I29.13, I27.0I, I22.27, 51.4I, 30.95, 24.5I, 21.83. 65 
HRMS (EI) calcd for C19H22N4 0S [Mt 354.I51. found 
354.I5I2. 
I-( 4-(N,N-dimethylaniline )triazolylpentyl-3-hy-
droxypyridine-2-thione (I 67f) 
Reactionof165f(O.I05 g, 0.25 nnnol) and IM BBr3 (0.33 
mL) in CH2Cl2 (8 mL) within 48 h as described for the 
synthesis of I48a gave compound I67I (0.072 g, 66%) as 
olive green solid. 1H NMR (400 MHz, CD30D) o 8.38 (s, 
lH), 8.I5 (s, lH), 8.IO (d, 1=7.9 Hz, lH), 7.63 (m, 3H), 6.95 
(d, 1=7.5 Hz, lH), 6.67 (m, lH), 4.57 (m, 2H), 4.48 (t, 1=7.0 
US 8,871,728 B2 
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Hz, 2H), 2.03 (m, 4H), 1.43 (m, 2H). 13C NMR (100 MHz, 
CD3 0D) ll 145.34, 132.04, 131.14, 129.72, 129.58, 128.63, 
121.75, 112.74, 104.99, 49.79, 29.08, 27.04, 22.73. HRMS 
(EI) calcd for C19H19N5 0S [Mt 365.131. found 365.1310. 
1-( 4-(3-Trifluomethyl)-benzonitrile )triazolylpentyl-
3-hydroxypyridine-2-thione (167g) 
Reactionof165g (0.105 g, 0.25 mmol) and 1MBBr3 (0.33 
mL) in CH2Cl2 (8 mL) within 48 h as described for the 10 
synthesis of 148a gave compound 167g (0.072 g, 66%) as 
olive green solid. 1H NMR (400 MHz, CD30D) ll 8.59 (s, 
214 
Compound 168 
TABLE14 
Anti-cancer activity of selected HDAC inhibitor models. 
IC 
HDACl HDAC6 HDAC8 
(nm) (nm) (nm) DU 145 (µrn) LNCaP (µrn) Jurkat (µrn) 
149g 
149c 
149f 
154a 
162d 
162f 
167e 
167e 
168 
SAHA 
lH), 8.35 (s, lH), 8.21 (d, J=7.8 Hz, lH), 8.00 (t, 1=9.5 Hz, 40 
lH), 7.58 (d, J=6.2 Hz, lH), 6.96 (d, J=7.5 Hz, lH), 6.72 (m, 
lH), 4.57 (m, 4H), 2.04 (m, 4H), 1.42 (m, 2H). 13C NMR (100 
MHz, CD3 0D) ll 146.09, 137.48, 137.24, 134.79, 130.46, 
125.55, 124.87, 123.60, 122.77, 116.84, 109.75, 55.10, 
51.63, 30.84, 28.90, 24.47. HRMS (EI) calcd for 45 
C19H19N5 0S [Mt 365.131. found 365.1310. HRMS (EI) 
calcd for C20H13N50S [Mt 433.1184. found 433.1189. 
NI 
NI 
NI 
NI 
NI 
NI 
NI 
NI 
NI 
681 ± 110 3675 ± 1201 NI NI NI 
NI 2858 ± 944 22.84 ± 3.8 16.23±1.11 10.62 ± 0.97 
>20 
372 ± 35 1907 ± 771 30.0 ± 5.85 14.65 ± 0.84 8.95 ± 0.69 
>20 
306 ± 69 3105 ± 1649 13.59 ± 2.91 7.75 ± 0.73 3.19 ± 0.3 
41% 1570 ± 1067 24.02 ± 7.47 13.11±1.51 4.68 ± 0.34 
>20 
911±173 917±139 9.33 ± 0.96 5.43 ± 0.47 3.27 ± 0.60 
955 ± 150 1377 ± 205 17.72 ± 3.28 10.95 ± 1.92 9.04 ± 1.31 
637 ± 160 2402 ± 263 11.08 ± 2.38 4.95 ± 0.43 5.18 ± 1.18 
356 ± 72 2831±520 5.03 ± 1.13 3.49 ± 0.34 3.44 ± 0.57 
534 ± 185 5470 ± 1603 16.07 ± 2.24 7.80 ± 0.55 6.55 ± 0.91 
2.49 ± 0.2 2.31 ± 0.74 1.49 ± 0.10 
Example 12 
Synthesis of Macrolide HDAC Inhibitors on a 
Multi-Gram Scale 
Synthetic strategies which permit the synthesis of mac-
Example 11 
50 rolide HDAC inhibitors one a multi-gram scale were also 
developed (Scheme 22). Clarithromycin or azithromycin can 
be N-demethylated to afford des-N-methyl clarithromycin or 
azithromycin (A). Subsequent alkylation of A with 4-ethy-
Anti-Cancer Activity of Selected 
3-Hydroxypyridine-2-thione-based HDAC Inhibitors 
55 nylbenzyl methanesulfonate afforded the modified 4'-ethy-
ny lbenzy lclarithromycin or 4'-ethyny lbenzylazithromycin 
(B). Copper (I) catalyzed cycloaddition of B containing an 
azithromycin macrolide with a protected azidohydoxamate 
60 
analog (route A), afforded the 1,2,3-triazole linked deriva-Selected HDAC model inhibitors, including compound 1.68 (below), were screened for activity against three cancer 
cell lines: DU 145 (androgen independent prostate cancer 
known to be responsive to HDAC inhibitors), LNCaP ( andro-
gen dependent prostate cancer, sensitive to HDAC6 activity), 
and Jurkat (T cell leukemia overexpressing HDAC8). The 
IC50 values forthe selected compounds are shown in Table 14 65 
below. When calculated IC50 was greater than 20 µM (highest 
concentration tested), it is reported as >20 µM. 
tives. Subsequent deprotection with CsF gave the desired 
azithromycin product (C) in good yield. Copper (I) catalyzed 
cycloaddition of B containing a clarithromycin macrolide 
with an unprotected azidohydoxamate analog (route 13), 
afforded the 1,2,3-triazole linked clarithromycin product (D) 
in good yield. The yields for each step are shown in Table 15. 
Compound 
A (Azithromycin or 
Clarithromycin) 
B (Azithromycin) 
B (Clarithromycin) 
C (Azithromyoin) 
D (Clarithromycin) 
Azithromycin 
or 
Clarithromycin 
Starting 
material 
215 
TABLE 15 
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To improve the efficiency of the multi-gram synthesis, 
methods of purifying B which obviate the need for chroma-
tography were developed. 
scale Yield Comments 
25 g 
10 g 
10 g 
5g 
5g 
55% Purified by crystallization 
(4:1 acetone-NH4 0H) 
60% Condition: K2C03 , CH3CN, 
soc C., 2 h; purified by pH 
selective (acetate buffer) extraction 
60% Condition: Hiinig's base, DMSO, 
soc C., 2 h; purified by pH 
selective (acetate buffer) extraction 
followed by crystallization 
(4:1 hexane-dichloromethane) 
SO% Purified by trituration 
(2: 1 hexane-dichloromethane) 
SO% Purified by trituration 
(2: 1 hexane-dichloromethane) 
Methods for purifying compound A containing an azithro-
mycin macrolide are shown in Scheme 23.5 g of crude mate-
rial were dissolved in 70 mL of MeOH. 70 mL of acetate 
10 buffer (0.75 M, pH 5.5) was added, forming a colorless sus-
pension. 70 mL of methanol was added, forming a clear 
solution. The solution was extracted with mixtures ofhexanes 
and ethyl acetate, and organics were discarded. 50% aqueous 
15 
NH4 0 H was added to the aqueous phase, raising the pH of the 
solution to 8.5. The solution was extracted with hexanes and 
mixtures ofhexanes and ethyl acetate, and the organic phases 
were collected and dried in vacu to obtain B. 
Scheme 22. 
~ MzO~ 
MeOH, H10, 50° C., 10 h conditions 
B 
.,,,,O=R 
A 
0 
N3~NHOIEDMS 
(i) Cul, Hunig's base 
THF, DMSO, rt, 12 h 
(ii) CsF, MeOH, rt, 2 h 
0 
N3 II ~NHOH 
Cul, Hunig1s base 
THF, DMSO, rt, 12 h 
C (n ~ 5 or 6) 
D (n ~ 5 or 6) 
-N "'""" ··"'o~ 
' 
. 
' 
. 0 
,• 
__ $ 
Azithromycin 
0 
..... 0 ··., 
'OH I 
Clarithromycin 
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Scheme 23. Purification of compound B (Azithromycin). 
30% EtOAc-Hexane (2 x 200 rnL) 
40% EtOAc-Hexane (1x200 rnL) 
20% EtOAc~~~~:~~~ x 200 rnL) }-
70 mL ofMeOH 70 mL of acetate buffer TLC checked; non polar impurities 
(0.75M, pH 5.5) 70 mL ofMeOH in the organic phase 
i I I t aqueous phase 
5 g (crude) -- Methanolic solution _i_.. while suspension _i_.. Clear solution _l_. (containd compound 
including polar impurities) 
Discarded 
(only non-polar 
impurities) 
combined and concentrated 
in vacuo 
-{ 
Extraction: 
Hexane (2 x 200 mL) 
5% EtOAc-Hexane (2 x 200 mL) 
10% EtOAc-Hexane (2 x 200 mL) 
TLC checked; pure product 
I- 50% aqueous NJLiOH solution was added; 
1 
,HwMra;oo .. IDRO 
Methods for purifying compound B containing a clarithro-
mycin macrolide are shown in Scheme 24. 4 g of crude 25 
material were dissolved in 70 mL ofMeOH. 15 mL of acetate 
buffer (0.75 M, pH 5.5) was added, forming a colorless sus-
pension. 50 mL of methanol was added, forming a clear 
solution. The solution was extracted with mixtures ofhexanes 
and ethyl acetate, and the organic phases were collected and 30 
dried in vacuo. B was then purified by crystallization from a 
4:1 mixture ofhexanes:dichloromethane. 
aqueous phase 
(discarded; only polar impurities) 
Scheme 24. Purification of compound B (Clarithromycin). 
50 rnL ofMeOH 
15 rnL of acetate buffer 
(0.75 M, pH 5.5) 50mLofMeOH 
4 g (crude) _l Methanolic solution _l while suspension _l Clear solution T aqueous phase (discarded; contains only polar impurities) 
Crystallized from 4:1 Hexane-DCM 
(nonpolar impurities in the filtrate) 
We claim: 
--
1. A compound of Formula I or II: 
combined and concentrates 
in vacuo 
D-A-B-ZBG 
R13Q. R~-l 
50 
55 
60 
Extraction: 
30% EtOAc-Hexane (2 x 200 mL) 
35% EtOAc-Hexane (4 x 200 mL) 
TLC checked; compound including 
non-polar impurities in the 
organic phase 
-continued 
R14 
R13C!;_ N-R16 
rnc-R-A-D\ ;°J---\_R,, 
E-M \-{_ 
R1s 
wherein M represents a macrolide subunit, 
II 
/0 R1s 
M 
E is a C1_6 group, optionally containing one or more het-
eroatoms, wherein the carbon atoms and/or heteroatoms 
are in a linear and/or cyclic arrangement, 
65 
R1s 
D is a substituted or unsubstituted alkyl, substituted or 
unsubstituted heteroalkyl, substituted or unsubstituted 
aryl, substituted or unsubstituted heteroaryl group, 
US 8,871,728 B2 
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A is a linking group connected to D, 
B is an alkyl, heteroalkyl, alkylaryl or alkylheteroaryl 
spacer group, 
ZBG is a Zinc Binding Group comprising a heterocyclic 
moiety, 
R13 is selected from hydrogen, a substituted or unsubsti-
tuted C1_6 alkyl group, a substituted or unsubstituted 
c2-6 alkenyl group, a substituted or unsubstituted c2-6 
alkynyl group, a substituted or unsubstituted C1 _6 
alkanoate group, a substituted or unsubstituted C2 _6 car-
10 
bamate group, a substituted or unsubstituted C2 _6 car-
bonate group, a substituted or unsubstituted C2 _6 car-
bamate group, or a substituted or unsubstituted C2 _6 
thiocarbamate group, 15 
R14 and R16 is selected from hydrogen, hydroxyl, a substi-
tuted or unsubstituted C1_6 alkyl group, a substituted or 
unsubstituted C2 _6 alkenyl group, a substituted or unsub-
stituted C2 _6 alkynyl group, a substituted or unsubsti-
tuted C1_6 alkanoate group, a substituted or unsubsti- 20 
tuted C2 _6 carbamate group, a substituted or 
unsubstituted C2 _6 carbonate group, a substituted or 
unsubstituted C2 _6 carbamate group, or a substituted or 
unsubstituted c2-6 thiocarbamate group, 
R1s is hydrogen or -OR17, 
R1 7 is selected from a group consisting of hydrogen, a 
substituted or unsubstituted C1_6 alkyl group, a substi-
tuted or unsubstituted C2 _6 alkenyl group, a substituted 
25 
or unsubstituted C2 _6 alkynyl group, a substituted or 
unsubstituted C1_6 alkanoate group, a substituted or 
30 
unsubstituted C2 _6 carbamate group, a substituted or 
unsubstituted C2 _6 carbonate group, a substituted or 
unsubstituted C2 _6 carbamate group, or a substituted or 
unsubstituted c2-6 thiocarbamate group. 35 
2. The compound of claim 1, wherein the macrolide sub-
unit is a multi-member lactonic ring structure. 
3. The compound of claim 2, wherein the macrolide sub-
unit has the structure: 
R,;0·· :, ,,,, .. , 
I 
R1 0 
0 
R 
wherein 
~ 
I 
0 
40 
45 
50 
Wis selected from --C(O)-, --C( NO Ru)-, -CH 55 
(---ORu)-, -NRuCH2-, --CH2NRu-, -CH 
(NRuRu)-, -C( NNRuRu)-, -NRuC 
(0)-, -C(O)NRu-, and -C(=NRu)-; 
R is selected from the group consisting of H and C1 _6 
alkyl; 60 
R1 is selected from the group H, halogen, -NRu Rw 
NRuC(O)R1 u ---OR1 u ---OC(O)R1 u ---OC(O) 
ORw ---OC(O)NRuRw -OC(O)C1_6 alcyl-Rw 
-OC(O)C1_6 alkyl-R12, ---OC(O)OC1 _6 alkyl-Rw 
-OC(O)NRuC1_6 alkyl-R12, C1_6 alkyl, C1 _6 alk- 65 
enyl, C1 _6 alkynyl, optionally is substituted with one 
or more R12 groups; 
220 
R2 isH; 
R3 is selected from H, ---ORw -OC1_6 alkyl-Rw 
-OC(O)Ru, -OC(O)C1 _6 alkyl-R12, ---OC(O) 
OR1 u ---OC(O)OC1 _6 alkyl-Rw -OC(O)NRuRu, 
-OC(O)NRuC1_6 alkyl-R12; alternatively, R3 is a 
pyran ring which can be substituted as defined above 
in Formulae I and II; 
R4 is selected from H, Rw --C(O)Rw -C(O)ORw 
-C(O)NRuRu, -C1_6 alkyl-T-Ru, -C2 _6 alkenyl-T-
Rw and-C2 _6 alkynyl-T-Ru; alternatively R3 and R4 
taken together form 
T is selected from --C(O)-, --C(O)O-, --C(O) 
NRu-, -C(=NRu)-, 
-C(=NRu)O-, -C(=NRu)NRu-, g) ---OC(O)-, 
---OC(O)O-, -OC(O)NRu-, 
-NRuC(O)-, -NRuC(O)O-, -NRuC(O)NRu-, 
-NRu C( NRu)NRu-, and -S(O)P -, wherein p 
0-2; 
Rs is selected from Ru, ---OR1 u -NRuR1 u 
-OC1_6 alkyl-R12, --C(O)R1 u --C(O)C1 _6 alkyl-Rw 
---OC(O)R1 u -OC(O)G1_6 alkyl-R12, -OC(O)ORu, 
---OC(O)OC1 _6 alkyl-R.w ---OC(O)NR11R1 u -DC 
(O)NRuC1_6 alkyl-R12, -C(O)C2 _6 alkenyl-Rw and 
--C(O)C2 _6 alkynyl-R12 ; 
alternatively, R4 and Rs taken together with the atoms to 
which they are bonded, form: 
wherein, Q is CH or N, and R23 is ---ORu or Ru; 
R6 is selectedfrom-0Ru,-C1_6 alkoxy-Rw--C(O) 
Rw ---OC(O)Rw ---OC(O)ORw ---OC(O) 
NRuR1 u -NRuRu; 
alternatively, Rs and R6 taken together with the atoms to 
which they are attached form a 5-membered ring by 
attachment to each other through a linker selected 
from -OC(R12) 20-, -OC(O)O-, ---OC(O) 
NRu-, d)-NRuC(O)O-, 
-OC(O)NORu-, -NORuC(O)O-, ---OC(O) 
NNRu Ru-, -NNRu Ru C(O)O-, 
-OC(O)C(R12) 2-, -C(R12) 2C(O)O-, -OC(S)O-, 
---OC(S)NRu-, -NRuC(S)O-, n) 
-OC(S)NORu-, -NORuC(S)O-, ---OC(S) 
NNRu Ru-, -NNRu Ru C(S)O-, 
-OC(S)C(R12) 2-, -C(R12) 2 C(S)O-; 
US 8,871,728 B2 
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alternatively, W, R5 , and R6 taken together with the 
atoms to which they are attached form: 
wherein J is selected from the group consisting ofO, S, and 
NR11 ; 
10 
15 
R6 • is selected from H, unsubstituted or substituted C1_4 
alkyl, C2 _4 alkenyl, which can be further substituted 
with C1_2 alkyl or one or more halogens, C2 _4 alkynyl, 
20 
which can be further substituted with C1 _2 alkyl or one 
or more halogens, aryl or heteroaryl, which can be 
further substituted with C1 _2 alkyl or one or more 
halogens, --C(O)H, -COOH, -CN, -COOR11 , 25 
-C(O)NR11 R11 , -C(O)R11 , --C(O)SR11 ; 
alternatively R6 and R6 • taken together with the atom to 
which they are attached to form an epoxide, a carbo-
nyl, an olefin, or a substituted olefin, or a C3 -C7 car-
bocyclic, carbonate, or carbamate, wherein the nitro- 30 
gen of the carbamate can be further substituted with a 
C1 -C6 alkyl; 
R7 is selected from C1 _6 alkyl, C2 _6 alkenyl, and C2 _6 
alkynyl, optionally is substituted with one or more 
R12 groups; 35 
R11 , for each occurrence, is selected from H, C1_6 alkyl, 
c2-6 alkenyl, c2-6 alkynyl, c6-10 saturated, unsatur-
ated, or aromatic carbocycle, 3-12 membered satu-
rated, unsaturated, or aromatic heterocycle containing 
one or more heteroatoms selected from nitrogen, oxy- 40 
gen, and sulfur, -C(O)-C1_6 alkyl, --C(O)--C2 _6 
alkenyl, --C(O)-C2 _6 alkynyl, -C(O)--C6 _10 satu-
rated, unsaturated or aromatic carbocycle, -C(0)-3-
12 membered saturated, unsaturated, or aromatic het-
erocycle containing one or more heteroatoms selected 45 
from nitrogen, oxygen, and sulfur, --C(O)O-C1 _6 
ally!, --C(O)O--C2 _6 alkenyl, --C(O)O-C2 _6 alky-
nyl, --C(O)O-C6 _10 saturated, unsaturated, or aro-
matic carbocycle, --C(0)0-3-12 membered satu-
rated, unsaturated, or aromatic heterocycle containing 50 
one or more heteroatoms selected from the group 
consisting of nitrogen, oxygen, and sulfur, and 
-C(O)NR13R13 , optionally is substituted with one or 
more R12 groups; and 
R12 is selected from R14, C1_8 alkyl, C2 _8 alkenyl, C2 _8 55 
alkynyl, C3 _12 saturated, unsaturated, or aromatic car-
bocycle, 3-12 membered saturated, unsaturated, or 
aromatic heterocycle containing one or more heteroa-
toms selected from nitrogen, oxygen, and sulfur, 
optionally substituted with one or more substituents. 60 
4. The compound of claim 1, wherein Dis a phenyl, bi phe-
nyl, or naphthyl group. 
5. The compound of claim 1, wherein A is an amide 
-0-, or 1,2,3-triazolyl group. ' 
222 
6. The compound claim 1, wherein B is an alkyl group 
having from 4-9 carbon atoms . 
. 7. The compo~d claim 1, wherein the zinc binding group 
1s 3-hydroxypyndme-2-thione. 
8. The compound claim 1, wherein the compound is 
defined by the following formula 
wherein R is: 
R14 ~ ;°x:,, 
M \-{_ 
R15 or 
R14 /( ;°x::: 
E-M \-{_ 
R1s 
and mis an integer from 1-12 inclusive. 
9. The compound of claim 8, wherein m is an integer from 
5-9 inclusive. 
10. A pharmaceutical composition comprising an effective 
amount of the compound of claim 1 in combination with a 
pharmaceutically acceptable diluent, excipient, or carrier. 
11. The composition of claim 10, wherein the composition 
is formulated for enteral or parenteral administration. 
12. The composition of claim 10, wherein the composition 
is formulated for immediate release, modified release, and 
combinations thereof. 
13. The composition of claim 12, wherein the formulation 
is selected from the group consisting of delayed release, 
extended release, pulsatile release, and combinations thereof. 
14. A method of treating a disease or disorder in a human or 
animal subject in need thereof comprising administering an 
effective amount of a compound claim 1 to the subject, 
wherein the disease or disorder is selected from the group 
consisting of cancer, inflammation, and parasitic infections. 
15. The method of claim 14, wherein the disease or disor-
der to be treated is cancer. 
16. The method of claim 15, wherein the cancer is selected 
from the group consisting of lung cancer, myeloma, leuke-
mia, lymphoma, breast cancer, prostate cancer, pancreatic 
cancer, cervical cancer, ovarian cancer, and liver cancer. 
17. The method of claim 14, wherein the parasitic infection 
is. se.lected from the group consisting of malaria and leishma-
mas1s. 
* * * * * 
